Towards Uncovering the Role of Pre-fibrillar Oligomers of á-Synuclein in the Pathogenesis of Parkinson's Disease by Gajula Balija, Madhu Babu
 
 
 
 
 
Towards Uncovering the Role of Pre-fibrillar 
Oligomers of α-Synuclein in the Pathogenesis of 
Parkinson’s Disease 
 
 
 
 
 
PhD Thesis 
 
 
in partial fulfillment of the requirements 
for the degree of “Doctor of Philosophy (PhD)” 
in the Molecular Biology Program 
at the Georg August University Goettingen, 
Faculty of Biology 
 
 
 
 
 
submitted by 
Madhu Babu Gajula Balija 
 
 
born in 
Kodumur, India 
 
April 2010 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I hereby declare that the PhD thesis entitled, “Towards Uncovering the Role of 
Pre-fibrillar Oligomers of α-Synuclein in the Pathogenesis of Parkinson’s 
Disease,” has been written independently and with no other sources and aids than 
quoted. 
 
 
 
 
Madhu Babu Gajula Balija  
 
 
 
 
 iv 
 
 
 
 v 
 
 
 
 
 
 
Dedicated to 
 
 
 
My wonderful parents… 
for their efforts to set me on my path. 
for showing me the real value of education in life by themselves having fated to 
live practically without any formal education.  
 
My remarkable teachers… 
for instilling the right approach towards knowledge and learning. 
for their efforts to infuse right values into life. 
 
The IMPRS Molecular Biology/the Max Planck Institute… 
for nurturing my passion for science. 
for the transformational learning experience.  
 
 
 
 
 
 
 
 
 
 vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
 
 
Contents  
 
Contents .................................................................................................................. vii 
List of Figures.........................................................................................................xi 
List of Tables.........................................................................................................xiii 
Abbreviations ......................................................................................................... xv 
Abstract ..................................................................................................................xvii 
Acknowledgements.......................................................................................... xix 
1. Introduction.......................................................................................................1 
1.1 Parkinson’s disease ................................................................................................................... 2 
1.2 Lewy bodies .................................................................................................................................. 3 
1.3 α‐Synuclein structure and function.................................................................................... 4 
1.4 Misfolding and aggregation of α‐Synuclein .................................................................... 6 
1.5 Soluble pre‐fibrillar oligomers in neurodegeneration—revisiting the amyloid 
hypothesis...........................................................................................................................................10 
1.6 Pathogenicity of pre‐fibrillar soluble oligomers.........................................................12 
1.7 Drosophila model for Parkinson’s disease.....................................................................14 
1.8 Understanding motor and non‐motor symptoms of PD in the Drosophila 
model.....................................................................................................................................................17 
1.9 Aims of this study.....................................................................................................................18 
2. Materials and Methods.............................................................................. 21 
2.1 Molecular Biology.....................................................................................................................21 
2.1.1 Polymerase Chain Reaction (PCR) .............................................................. 21 
2.1.2 DNA Sequencing........................................................................................... 21 
2.1.3 Restriction digest of DNA ............................................................................. 21 
2.1.4 Sample preparation of single fly PCR .......................................................... 22 
 
 viii 
2.1.5 DNA extraction from agarose gels ............................................................... 22 
2.1.6 Dephosphorylation of vector DNA ............................................................... 22 
2.1.7 DNA ligation................................................................................................. 22 
2.1.8 Transformation of bacterial cells ................................................................. 22 
2.1.9 Preparation of plasmid DNA........................................................................ 23 
2.1.10 DNA preparation for embryo injections ..................................................... 23 
2.1.11 Preparation of fly head extracts ................................................................. 23 
2.1.12 Polyacrylamide Gel Electrophoresis (PAGE) ............................................ 24 
2.1.13 Immunoblotting........................................................................................... 24 
2.1.14 Dot blotting................................................................................................. 25 
2.2 Fly Techniques...........................................................................................................................25 
2.2.1 Maintenance of flies...................................................................................... 25 
2.2.2 Generation of stable transgenic fly lines ...................................................... 25 
2.2.3 Ectopic gene expression via the UAS/GAL4 system..................................... 26 
2.2.4 Antibody (Ab) staining of adult fly brains .................................................... 26 
2.2.5 Dissection of larval NMJs (Neuromuscular Junctions) ............................... 27 
2.2.6 Immunocytochemical staining of NMJs........................................................ 27 
2.2.7 Confocal microscopy .................................................................................... 27 
2.3 Behavioral Assays ....................................................................................................................30 
2.3.1 Climbing assay ............................................................................................. 30 
2.3.2 Longevity assay............................................................................................. 30 
2.3.3 Analysis of circadian behaviour ................................................................... 30 
2.3.4 Sleep assays .................................................................................................. 31 
3. Results .................................................................................................................... 33 
3.1 Structure‐based rational design of the α‐synuclein variants................................33 
3.2 TP‐αS and A56P‐αS show increased propensity to form oligomers and 
delayed fibril‐formation kinetics ..............................................................................................36 
3.3 Generating the Drosophila model for Parkinson’s disease.....................................38 
3.4 Pre‐fibrillar oligomer‐enriched structural variants of αS cause motor deficits
..................................................................................................................................................................40 
3.5 Pre‐fibrillar oligomer‐enriched αS structural variants reduce longevity .......42 
3.6 Expression of pre‐fibrillar structural αS variants causes age‐dependent 
degeneration of dopaminergic (DA) neurons......................................................................44 
 
 ix 
3.6.1 No degeneration of DA neurons in young flies expressing αS variants....... 44 
3.6.2 Degeneration of DA neurons in old flies expressing αS variants ................ 46 
3.7 Dopamine dependent behavioral deficits in flies expressing αS variants.......48 
3.8 Sleep abnormalities in PD flies expressing αS variants...........................................48 
3.9 Abnormalities in circadian locomotor activity behavior of flies expressing an 
oligomer‐forming αS variant ......................................................................................................52 
3.10 Circadian defects in response to TP‐αS expression can be mimicked by DA 
neuron inactivation.........................................................................................................................61 
3.11 Defective localization of neurotoxic αS variants to the synaptic terminals in 
vivo .........................................................................................................................................................64 
4. Discussion ........................................................................................................... 67 
4.1 Accumulation of αS has a toxic gain‐of function........................................................67 
4.2 Soluble oligomers of α‐synuclein are the likely culprits in PD pathogenesis 68 
4.3 Formation of more pre‐fibrillar oligomers by the TP‐αS and A56P‐αS 
variants.................................................................................................................................................71 
4.4 An improved Drosophila PD model to study the pathogenicity of oligomer‐
forming αS variants .......................................................................................................................73 
4.5 Motor deficits and reduced longevity: human PD‐like features in the flies 
expressing pre‐fibrillar oligomer‐forming αS variants..................................................75 
4.6 Degeneration of DA neurons in the flies expressing pre‐fibrillar oligomer‐
forming αS variants .......................................................................................................................76 
4.7 Non‐motor deficits in PD flies expressing pre‐fibrillar oligomer forming αS 
variants.................................................................................................................................................77 
4.8 Sleep abnormalities in the PD flies ...................................................................................78 
4.9 Circadian dysfunction in the flies expressing most toxic oligomer‐forming 
TP‐αS....................................................................................................................................................80 
4.10 Synucleinopathies are synaptopathies: defective localization of the 
neurotoxic αS variants at the synaptic terminals of larval NMJs...............................82 
4.11 Conclusion ................................................................................................................................84 
 
 
 x 
5. Summary and Outlook................................................................................. 87 
A. Appendix ................................................................................................................ 93 
Algorithms used for the sleep analysis in Drosophila ......................................................93 
Script 1................................................................................................................................................93 
Script 2................................................................................................................................................99 
Script 3.............................................................................................................................................103 
Script 4.............................................................................................................................................107 
Bibliography .........................................................................................................111 
Curriculum Vitae...............................................................................................127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
 
 
 
List of Figures 
Figure 1: Lewy bodies in the human PD brain contain amyloid fibrils of αS _________ 3 
Figure 2: Domain comparisons of the Synuclein protein family ___________________ 5 
Figure 3: Domain structure of the αS and human PD related missense mutations_____ 6 
Figure 4: Amyloid aggregates of misfolded proteins in the neurodegenerative diseases 7 
Figure 5: Schematic representation of the general mechanism of aggregate formation _ 9 
Figure 6: Factors promoting the formation of pre-fibrillar oligomers may cause early-
onset of the disease _____________________________________________________ 11 
Figure 7: Schematic depiction of the potential pathogenic mechanisms in PD _______ 13 
Figure 8: α-Synuclein variants with reduced fibrillation propensity and impaired β-
structure form more on-pathway pre-fibrillar oligomers ________________________ 34 
Figure 9: Illustration of the summary of results based on in vitro experiments with 
structure based design variants of the αS ____________________________________ 37 
Figure 10: Generating the Drosophila model for Parkinson’s disease by using φ-C31 
based site-specific recombination method____________________________________ 39 
Figure 11: Drosophila expressing pre-fibrillar oligomer enriched α-Synuclein variants 
show motor deficits in the climbing assay____________________________________ 41 
Figure 12: Longevity of flies expressing different variants of αS and LacZ _________ 43 
Figure 13: Dopaminergic (DA) neurons in the young flies expressing different variants of 
αS and LacZ __________________________________________________________ 45 
Figure 14: Age dependent degeneration of DA neurons in the flies expressing different 
variants of αS _________________________________________________________ 46 
Figure 15: Flow chart depicting the sleep assay and analysis in Drosophila ________ 49 
 
 xii 
Figure 16: Dopamine dependent sleep deficits in the flies expressing different variants of 
αS___________________________________________________________________ 51 
Figure 17:  Schematic representation of a typical circadian experiment____________ 53 
Figure 18: Properties of rhythmic data _____________________________________ 55 
Figure 19: Circadian locomotor activity profiles of young Drosophila expressing WT-αS 
and TP-αS ____________________________________________________________ 56 
Figure 20: Circadian locomotor activity profiles of old Drosophila expressing WT-αS 
and TP-αS ____________________________________________________________ 57 
Figure 21: Age dependent circadian defects in Drosophila expressing TP-αS in the DA 
neurons ______________________________________________________________ 59 
Figure 22: Schematic representation of inactivation/attenuation of the Dopaminergic 
(DA) neurons __________________________________________________________ 61 
Figure 23: Circadian defects caused by TP-αS mimic the effects of DA neuron 
inactivation by using genetic methods_______________________________________ 62 
Figure 24: Defective localization of αS variants to the synaptic terminals __________ 65 
Figure 25: Caricatured representation of the conclusive summary________________ 85 
Figure 26: Circadian locomotor activity profiles of old Drosophila expressing WT-αS 
and A53T-αS _________________________________________________________ 108 
 
 
 
 
 
 
 
 xiii 
 
 
 
List of Tables 
 
 
Table 2.1: List of primary antibodies used in this study................................................... 28 
Table 2.2: List of secondary antibodies used in this study ............................................... 28 
Table 2.3: List of fly stocks used and generated in this study .......................................... 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
 
 
 
 
 
 
 
 xv 
 
 
 
Abbreviations 
 
Ab   Antibody 
AD   Alzheimer’s Disease 
ALS    Amyotrophic Lateral Sclerosis 
ANOVA  Analysis of Variance 
attB   Attachment site B 
attP   Attachment site P 
AWK   Programming language called AWK 
Aβ   Amyloid-β 
BRP   Bruchpilot 
cAMP   cyclic Adenosine Monophosphate 
CNS   Central Nervous System 
DA   Dopamine 
DA neurons  Dopaminergic neurons 
DAM   Drosophila Activity Monitors  
DD   Dark-Dark 
Ddc-Gal4  Dopamine decarboxylase-Gal4 
DL   Dorsolateral 
DM   Dorsomedial 
DNA   Deoxyribonucleic Acid 
EGFR   Epidermal Growth Factor Receptor 
EJC   Excitatory Junctional Currents 
EKO   Electrical Knockout 
ER   Endoplasmic Reticulum 
hr   Hour 
HRP   Horse Radish Peroxidase 
 
 xvi 
lacZ   Gene that encodes β-D-galactosidase 
LB    Luria Bertani broth 
LBs   Lewy Bodies   
LD   Light-Dark 
LED   Light Emitting Diode 
MB   Mushroom Body 
mEJC   miniature Excitatory Junctional Currents 
NAC   Non-Aβ Component 
NaChBac  Bacterial Sodium Channel 
NMJ   Neuromuscular Junctions 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PD   Parkinson’s Disease 
Phi-C31  Bacteriophage Phi-C31 
PPR   Paired Pulse Ratio 
SDS   Sodiumdodecyl Sulfate 
SEM   Standard Error Mean 
SNpc   Substantia Nigra pars compacta 
SUV   Small Unilamellar Vesicle 
TH   Tyrosine Hydroxylase 
TH-Gal4  Tyrosine Hydroxylase-Gal4 
ThT   Thioflavin T 
TP-αS   A30P/A56P/A76P/α-Synuclein 
UAS   Upstream Activating Sequence 
UPR   Unfolded Protein Response 
WT-αS  Wildtype-α-Synuclein (human) 
αS   α-Synuclein 
µg   Microgram 
µl   Microlitre 
 
 xvii 
 
 
 
Abstract 
 
Parkinson’s disease (PD) is a progressive neuropathological disorder that is 
characterized by the presence of intra-cytoplasmic inclusions called Lewy Bodies 
(LBs). LBs represent insoluble protein aggregates with α-Synuclein (αS) as a 
major component. LBs also mark lesions found in a range of related disorders, 
collectively referred to as synucleinopathies. Recent studies suggest that 
pathogenesis could result from small pre-fibrillar intermediates of the aggregation 
pathway, i.e. soluble oligomers of misfolded α-Synuclein. So, it is not decided yet 
whether the soluble oligomers or the final products of the αS aggregation (i.e. the 
αS fibrils) are cause of the disease, meaning that the nature of pathogenic αS 
species is still unresolved.  
To understand the nature of pathogenic αS species and to investigate 
whether accumulation of soluble pre-fibrillar oligomers of αS is responsible for 
the increased neurotoxicity in PD, I have used rationally designed structural 
variants of αS with different aggregation properties and tested their biological 
properties in Drosophila melanogaster, which lacks an αS gene in the wild type 
genome. Two of the designed variants, TP-αS and A56P-αS, have a remarkably 
decreased propensity to aggregate, and they form more pre-fibrillar soluble 
oligomeric species in aggregation assays in vitro. In order to examine their 
biological effects in vivo, I have employed Drosophila as a tool to explore 
possible PD-like effects of the αS mutants. The αS mutant genes were inserted 
into the Drosophila genome. To avoid possible “position effects” affecting the 
expression of the individual transgenes, I used the phiC31 site-specific integration 
system. The site specific genomic integration of the αS gene and the different αS 
mutants permit to directly compare the effects of the different αS variants on 
 
 xviii 
various biological parameters such as longevity, climbing (negative geotactic and 
phototactic responses), sleep behavior and circadian rhythmicity that were used as 
sensitive readouts for neurotoxicity in response to αS activity expressed 
specifically in the Dopaminergic (DA) neurons. The results show that the TP-αS 
and A56P-αS mutants caused increased neurotoxicity as compared to wild type 
αS or expression of the bacterial lacZ gene serving as controls. 
Immunohistochemistry on adult fly brains confirm that neurotoxicity as revealed 
by the behavior tests correlates well with the degeneration of DA neurons in 
response to the expression of the αS variants. The data show that the pre-fibrillar 
oligomer-forming TP-αS mutant is most toxic among the αS variants. The results 
are consistent with the conclusion that pre-fibrillar oligomers of αS are highly 
toxic pathogenic species in the neurodegeneration process associated with PD. 
Aside from supporting the hypothesis that the pre-fibrillar status of αS is already 
toxic for neurons, the Drosophila system presented here delivers a novel 
experimental system in which the non-motor aspects of PD, the mechanism of 
cellular action and likely even the efficacy of lead compounds leading to 
therapeutic drugs can be addressed.  
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1 
Introduction 
 
Brain is a highly complex organ made up of extremely intricate and 
enigmatic neuronal circuits that govern crucial functions of the organism. Integrity 
and functions of the neuronal circuits are controlled by the health and wellbeing of 
neurons that constitute them. The neuronal cellular machineries are often 
subjected to malfunction and dysregulation because of the genetic and sporadic 
perturbations that will eventually lead to neurodegeneration. Progressive neuronal 
loss and neurological impairment are hallmarks of the neurodegenerative 
disorders. Prevalence of neurodegenerative disorders is especially high in the 
countries with more life expectancy and demographically aging population, as age 
is one of the risk factor associated with neurodegeneration (Forman et al., 2004; 
Outeiro et al., 2007). A wide variety of neurodegenerative disorders are clinically 
and neuropathologically characterized and they are linked to the formation of 
intracellular and extracellular fibrillar aggregates of misfolded proteins. Such 
diseases include Alzheimer’s, Parkinson’s, Huntington’s, and dementia with Lewy 
bodies, Spinocerebellar ataxia, and Multiple systems atrophy etc.) (Chiti and 
Dobson, 2006). Here, I focus mainly on the α-Synuclein (αS) aggregation and its 
relation to pathogenesis in Parkinson’s disease (PD) as well as other 
synucleinopathies.  
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1.1 Parkinson’s disease  
PD is the second most common neurodegenerative disease in Europe with an 
incidence of more than one patient per thousand inhabitants. People are diagnosed 
usually in their 40ies, but disease is more prevalent with the more than 60 years 
old people with no difference in gender (http://www.europarkinson.net).  
Nearly 200 years ago, James Parkinson initially described PD as ‘shaking 
palsy’ in his monograph An Essay on the Shaking Palsy (see Factor, 2002). Later, 
in recognition of this remarkable work, the French neurologist Charcot referred to 
‘shaking palsy’ as Parkinson’s disease. However, even long before these 
descriptions, there were accounts of a clinical syndrome consisting of tremor and 
akinesia described in Indian medical (Ayurvedic) texts written more than 3000 
years ago (reviewed in Katzenschlager et al., 2004; Manyam, 1990). This 
syndrome, termed Kampavata in Sanskrit, was treated with natural products from 
Mucuna pruriens, a plant later now known to contain levodopa (L-dopa). 
Incidentally, L-dopa is a drug that was used from the mid-20th century onwards 
for the treatment of PD symptoms and its use has revolutionized the PD therapy 
(Lee and Trojanowski, 2006).  
There has been an unprecedented development in understanding of the 
Parkinson’s and other neurodegenerative disorders in the past two decades 
(reviewed in Lee and Trojanowski, 2006) . By now, important clinical features of 
the PD include chronic and progressive neurodegeneration characterized by severe 
motor symptoms such as bradykinesia (slowness in initiating voluntary 
movements), resting tremor, rigidity (increased resistance to passive movement) 
and postural instability (balance difficulties). In addition, many non-motor 
symptoms like sleep-disorders, autonomic disturbances, cognitive dysfunction and 
depression are common among the PD patients. In neuropathological terms, the 
key defining features of PD are the loss of the dopaminergic (DA) neurons in the 
Substantia Nigra pars Compacta (SNpc) and the presence of intracytoplasmic 
inclusions called Lewy bodies (LBs) or Lewy body containing neurites, termed 
Lewy neurites (Factor, 2002; Moore et al., 2005; Shults, 2006). 
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1.2 Lewy bodies 
LBs are the common neuropathological lesions found in PD and a group of 
related neurodegenerative disorders called synucleinopathies (Figure 1). LBs 
found in synucleinopathies such as PD, dementia with Lewy bodies, and Multiple 
systems atrophy as well as a number of other neurodegenerative disorders contain 
the insoluble fibrillar aggregates of αS (reviewed in Shults, 2006; Spillantini et 
al., 1997). αS is the major protein component of LBs (Shults, 2006), which is an 
abundant neuronal protein expressed in the central nervous system (CNS). Though 
LBs are an idiosyncratic feature of the synucleinopathies including autosomal 
dominant familial PD, there are very few exceptional neurodegenerative diseases 
which don’t show the formation of LBs. Few examples in this category are: 
Autosomal recessive juvenile parkinsonism (ARJP, a juvenile-onset form of PD) 
(Kitada et al., 1998), Gerstmann-Straussler syndrome (a genetic prion disease; 
(Hsiao and Prusiner, 1991) and sporadic ALS (Amyotrophic lateral sclerosis) 
(Rosen, 1978). 
With the growing list of neurodegenerative diseases, experimental evidence 
drawn primarily from the disciplines of neuropathology, genetics and biophysics 
strongly supports hypothesis that protein aggregation triggers the cascade of 
events that finally result in neurodegeneration and disease (Hardy and Selkoe, 
2002).  
 
(on the next page) 
Figure 1: Lewy bodies in the human PD brain contain amyloid fibrils of αS 
Human brain (left panel) picture showing the regions of brain involved in Dopamine 
signaling and affected in PD. Lewy body (intracytoplasmic neuronal inclusions) found in 
the human PD brains (middle panel)(Spillantini et al., 1997). Electron micrographs of the 
amyloid fibrils of αS (right panel) found in Lewy bodies and in vitro preparations 
(Goedert, 2001).  
Introduction 
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1.3 α-Synuclein structure and function 
α-Synuclein is an abundantly expressed protein in the CNS (Iwai et al., 1995). It 
belongs to a highly conserved family of proteins consisting of α-, β-, and γ-
synuclein (Figure 2) (Clayton and George, 1998). αS consists of 140 amino acid 
residues and is the longest synuclein polypeptide. It is encoded by the five of the 
seven exon containing αS gene (Goedert, 2001). αS was first cloned from 
Torpedo californicum (Maroteaux et al., 1988) and later identified in humans as 
the non-Aβ component (NAC) of Alzheimer’s disease amyloid precursor NACP 
(Ueda et al., 1993). αS is a major component of the LBs.  
In aqueous solution, monomeric αS is highly flexible and belongs to the 
class of intrinsically disordered proteins, with transient long-range interactions 
stabilizing a closed conformation (Bertoncini et al., 2005; Dedmon et al., 2005). 
Structurally, the αS protein is divided into three parts: (i) amphiphatic N-terminal 
region, (ii) the non-Aβ component (NAC) region and (iii) the acidic C-terminal 
region (Figure 2). The N-terminal region is composed almost entirely of six 
variants of a degenerate 11-amino acid consensus motif with slight variations of 
the sequence KTKEGV (Figure 3). The 11-mer repeats comprise an 
apolipoprotein-like-A2 helix, which mediates binding to phospholipids vesicles. 
These 11-mer repeats are highly conserved among the α-, β-, and γ-synuclein. The 
central regions of the synucleins contain two of the 11-mer repeats and the 
hydrophobic NAC portion spanning 71-82 amino acid residues. The NAC region 
has a crucial role in fibrillation and thus, αS lacking this region doesn’t fibrillate 
Substantia 
Nigra
Nigra-straital
 Neurons
Striatum
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(Shults, 2006). The C-terminus of αS is not conserved among the synucleins. It 
has the preponderance of acidic amino acid residues and is subjected to many 
posttranslational modifications (Goedert, 2001).  
 
Figure 2: Domain comparisons of the Synuclein protein family  
Primary sequences of the α-, β-, γ-synucleins are highly conserved. Their sequences can 
be divided into three regions. Highly conserved amphiphatic N-terminal region (green), 
hydrophobic NAC region (red), and less conserved acidic C-terminal region (blue). The 
extra eleven amino acid residues present in the NAC region of α-synuclein (hatched box 
within the red region) bestow it the unique property of aggregation among its family 
members.  
The precise cellular function of the αS is still enigmatic. However, many 
studies implicate a potential role of αS in synaptic function. αS is a presynaptic 
protein (George et al., 1995; Iwai et al., 1995) that is highly expressed in the 
central nervous system. αS is enriched in synaptosomal preparations, but not 
found in purified fractions containing the synaptic vesicles (Kahle et al., 2000). 
These findings support a possible role of αS in the synaptic function and hints that 
it might be a visiting protein of the synaptic vesicles (Takamori et al., 2006). αS is 
not necessary for the normal development as αS knockout mice were viable and 
fertile, and had normal brain architecture, particularly of the nigrostriatal DA 
system (Abeliovich et al., 2000).  Nevertheless, αS is shown to have a cooperative 
function together with the cystein-string-protease-α (CSPα) in preventing 
neurodegeneration (Chandra et al., 2005), and some regulatory function on the 
reserve or resting pool of presynaptic vesicles (Cabin et al., 2002; Chandra et al., 
Amphiphatic N-terminal Region Acidic C-terminal RegionNAC Region
!-synuclein
1 14060 72 84 95
"-synuclein
1 134
#-synuclein
1 127
1 14060 72 84 95
Amphiphatic N-terminal Region Acidic C-terminal RegionNAC Region
!-Synuclein
Monomer
A30P A56P A76P
A30P A56P A76P
!-Synuclein
Fibril
!-Synuclein
Fibril
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2004). Lack of known defined function in a specific biological pathway makes it 
formidably difficult to understand the role of αS in pathophysiology and 
neurodegeneration of Parkinson’s disease and other synucleinopathies.  
 
Figure 3: Domain structure of the αS and human PD related missense mutations 
The N-terminal region of αS has imperfect 11-mer repeats with KTKEGV hexamer 
motif. The acidic C-terminal region (blue) is susceptible to many posttranslational 
modifications and it is known to inhibit aggregation. Point mutations in the αS, A30P-αS, 
E46K-αS, and A53T-αS (black arrows) are known to cause dominant familial PD in 
humans.  
1.4 Misfolding and aggregation of α-Synuclein  
Proteins are dynamic entities continuously engaged in the process of folding 
and unfolding/partial unfolding in response to the demands set by cellular 
environments. In doing so, proteins tend to misfold and adopt alternative 
conformations that are completely non-physiological (Dobson, 2003). Natively 
unfolded proteins like αS have a high tendency to misfold. If cellular surveillance 
mechanisms are overridden by the factors that promote misfolding, it will either 
result in proteins with compromised function or aggregated proteins (Chiti and 
Dobson, 2006; Selkoe, 2003). Aggregates are formed when proteins with 
misfolded conformations come together and stabilize themselves with more 
intermolecular interactions (Figure 4 shows some aggregates formed by the 
misfolded proteins in different neurodegenerative disorders). Aggregation is 
favored because the energy minima of aggregates/aggregation-intermediates 
resulting from inter-molecular interactions between misfolded conformations are 
less than that of the native protein stabilized by intra-molecular interactions 
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Monomer
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(Dobson, 2003). The misfolded conformations in aggregation pathway may 
further seed or nucleate the process of aggregation, thereby promoting the 
formation of more pre-fibrillar intermediates, which finally result in the 
neurological and systemic diseases (reviewed in Lashuel and Lansbury, 2006; 
Selkoe, 2003; Soto, 2003). For this reason, the neurodegenerative diseases like 
Parkinson’s, Alzheimer’s, and Huntington’s are often called protein 
conformational disorders.  
 
Figure 4: Amyloid aggregates of misfolded proteins in the neurodegenerative 
diseases 
Amyloid plaques (white arrows) in different neurodegenerative disorders have fibrillary 
deposits of misfolded proteins. In spite of different protein compositions, the 
ultrastructure of these deposits is similar and composed mainly of a network of protein 
fibrils (electron micrograph of fibrils in the centre). Cellular localization of these 
aggregates varies in different neurodegenerative diseases: extracellular amyloid plaques 
and intracellular neurofibrillar tangles (yellow arrows) in Alzheimer’s disease, 
intracytoplasmic aggregates in Parkinson’s disease and Amyotrophic lateral sclerosis, 
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intranuclear inclusions in Huntington’s disease, and extracellular prion amyloid plaques 
in Spongiform encephalopathy and Creuzfeldt Jacob disease. Adapted figure from Soto, 
2003.  
αS has little or no detectable secondary structure in its native form in 
solution and hence, it is referred to as natively unstructured (Bernado et al., 2005; 
Cookson, 2005; Ulmer et al., 2005). αS with its natively unfolded structure and 
hydrophobic NAC region has a high propensity to misfold into the conformations 
that have a higher tendency to aggregate. The process of misfolding and 
aggregation is aggravated in PD and other synucleinopathies either by the 
missense mutations in αS gene or by sporadic factors (reviewed in Lansbury and 
Lashuel, 2006; Moore et al., 2005). Generally, the genetic perturbations in αS 
gene or familial forms of PD have early-onset and greater severity than the 
sporadic cases and they are also associated with a greater load of protein 
aggregates (Hardy and Selkoe, 2002). Recently, point mutations discovered in the 
αS gene as shown in Figure 3 (A53T-αS in Greek kindred; A30P-αS in German 
kindred; and E46K-αS in Spanish kindred) and triplication of the αS locus (in 
Iowa kindred) (Kruger et al., 1998; Polymeropoulos et al., 1997; Singleton et al., 
2003) alter the fibrillation propensity of αS that subsequently results in the 
autosomal dominant PD. In addition, recent genome-wide association studies have 
unequivocally revealed that SNP (single nucleotide polymorphism) variations 
within the αS and LRRK2 (leucine-rich repeat kinase 2) gene loci contribute to 
the etiology of sporadic PD (Simon-Sanchez et al., 2009). 
High-resolution three-dimensional structures of the fibrils of αS and other 
proteins involved in neurodegeneration commonly have a canonical ‘cross-β’ 
structure, the structural fingerprint of amyloid fibrils. The β strands from 
individual misfolded protein monomers are arranged perpendicular to the axis of 
cross-β structure and stabilize it by the inter- and intra-molecular interactions 
(Antzutkin et al., 2000; Balbach et al., 2002; Heise et al., 2005; Petkova et al., 
2002). Fibrils formed by same protein or peptide can exhibit conformational 
polymorphism (Chiti and Dobson, 2006; Heise et al., 2005; Vilar et al., 2008). 
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Nevertheless, it is worth noticing here that the proteins with completely different 
primary sequence can fold into the same three-dimensional structure in their 
aggregated form (Figure 5).  
 
 
Figure 5: Schematic representation of the general mechanism of aggregate 
formation 
Unfolded or partially unfolded proteins associate with each other to form small, soluble 
pre-fibrillar oligomers that undergo further assembly into protofibrils or protofilaments 
(a) and then mature fibrils (b, top electron microscope images). The fibrils often 
accumulate in plaques or other structures such as the Lewy bodies associated with 
Parkinson’s disease (c, electron microscope image on right). Some of the early aggregates 
seem to be amorphous or micellar in nature, although other soluble pre-fibrillar oligomers 
form ring-shaped species with diameters of approximately 10 nm (d, electron microscope 
image). Adapted figure from Dobson, 2003. 
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1.5 Soluble pre-fibrillar oligomers in neurodegeneration –
revisiting the amyloid hypothesis 
The recent decade of research on neurodegenerative diseases has resulted in 
shaping the “amyloid hypothesis” to define a precise relationship between protein 
aggregation and neurodegeneration. The amyloid hypothesis postulates that 
aggregation of proteins (for example, αS) triggers a cascade of events that would 
finally result in the neurodegeneration and disease (Hardy and Selkoe, 2002). In 
addition, factors that promote increased expression and decreased degradation of 
aggregate-prone proteins (like αS) are sufficient to cause neurodegeneration 
(Barrachina et al., 2006; Lansbury and Brice, 2002; Leroy et al., 1998). This 
hypothesis has drawn evidence and support mainly from three disciplines: 
neuropathology, genetics, and biophysics. It has withstood concerted efforts to 
disprove it and evolved along with the new scientific developments in 
understanding of the in vitro aggregation and in vivo neuropathological studies.  
There is indeed an existing correlation between the presence of LBs 
containing aggregated proteins in the brain and the neurodegenerative disorders. 
But the finding that amyloid plaques are also found throughout the cortex of many 
cognitively normal 70-year-old people has confounded the interpretation of 
relationship between the protein aggregation and neurological disease (Dickson et 
al., 1992). Though available evidence strongly suggests formation of fibrillar 
aggregates as an epiphenomenon of the disease, logical interpretation based on 
recent in vitro and in vivo studies predicts that pre-fibrillar intermediates in the 
aggregation pathway could be the apparent toxic species involved in 
neurodegeneration (Conway et al., 2000; Hartley et al., 1999; Lansbury and 
Lashuel, 2006; Rochet et al., 2000; Volles and Lansbury, 2002; Walsh et al., 
2002). Based on this interpretation, it is conceivable that genetic and sporadic 
factors that promote/accelerate formation of pre-fibrillar oligomers or aggregation 
intermediates may not only result in early-onset of the disease but also increase 
the formation of fibrillar aggregates (Figure 6).  
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Figure 6: Factors promoting the formation of pre-fibrillar oligomers may cause 
early-onset of the disease  
A number of factors have been proposed to trigger protein oligomerization and disease. 
Whether pre-fibrillar aggregates are the cause of disease is still uncertain, but 
circumstantial evidence supports a pathogenic role for these structures. Adapted figure 
from Lansbury and Lashuel, 2006. 
 
In contrast to the unusual stability of fibrillar structures, diffusible pre-
fibrillar oligomers are not stable and are proven to be very difficult to extract and 
characterize from the brains (reviewed in Lansbury and Lashuel, 2006). Besides 
this, the path towards ascertaining the role of soluble pre-fibrillar oligomers in 
neurodegeneration is compounded by the dynamic nature of protein aggregation 
and the technical challenges of advanced imaging methods for correlating disease 
progression in vivo to the protein aggregation in vitro.   
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1.6 Pathogenicity of pre-fibrillar soluble oligomers 
The above-mentioned paradigm shift of focus towards pre-fibrillar oligomers 
in understanding the nature and mechanisms of pathogenesis involved in 
neurodegenerative disorders has spurred numerous new scientific studies. Despite 
tremendous progress, there is by now still no conclusive evidence that pinpoints 
the nature of toxic species in the aggregation pathway. However, there are some 
common structural and functional features shared by pre-fibrillar oligomers of 
different amyloid proteins that could be useful to decipher the possible 
mechanisms involved in toxicity (reviewed in Lashuel and Lansbury, 2006).  
Soluble pre-fibrillar oligomers of misfolded proteins can diffuse and 
interfere with many neuronal functions. They can adversely affect synaptic 
physiology, structure and function, thereby changing the overall plasticity and 
integrity of individual neurons and neuronal networks. Studies done on the soluble 
Aβ-42 oligomers formed by the Amyloid-β (Aβ) and polyglutamine-rich 
Huntingtin oligomers have demonstrated that oligomerization of misfolded 
protein is harbinger of the cascade of events that finally result in dementia and 
cognitive dysfunction (reviewed in Haass and Selkoe, 2007). In addition, the pre-
fibrillar oligomers formed by amyloid proteins like αS (PD and diffuse Lewy 
body disease), Aβ (Alzheimer’s disease), Superoxide dismutase-I (Amyotrophic 
lateral sclerosis), Prion protein (Creutzfeldt-Jakob disease, bovine spongiform 
encephalopathy), and Huntingtin (Huntington’s disease) are shown to form pore-
like structures (Lashuel and Lansbury, 2006). The pore-like structures formed by 
amyloid oligomers of pathogenic proteins are shown to affect the integrity of lipid 
membrane. Thus it is hypothesized that they may impair the functions of neuronal, 
mitochondrial membranes and dopamine vesicles (see Figure 7). 
In addition, pre-fibrillar oligomers can also promote their own accumulation 
by inhibiting proteasomal activity (Figure 7; Lashuel and Lansbury, 2006). 
Experimental support for the hypothetic scheme outlined in the Figure 7 comes 
mainly from in vitro studies and the studies done in cell culture models (Ding et 
al., 2002; Gosavi et al., 2002; Leroy et al., 1998; Rubinsztein, 2006; Sharon et al., 
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2003a; Sharon et al., 2003b). Pre-fibrillar oligomers of wild type/WT-αS and 
three familial PD αS mutants, A30P-αS, A53T-αS, and E46K-αS, form annular 
and tubular structures akin to protein channels or pores (Kim et al., 2009; Lashuel 
and Lansbury, 2006). However, in vivo pathogenicity of the soluble pre-fibrillar 
oligomers of αS has not been tested in any animal model system. 
Considering these important developments, it is very challenging to correlate 
the in vitro pre-fibrillar oligomer formation and their in vivo biological 
significance in PD pathogenesis.  Major impediments to address this problem are 
the dynamic nature of protein aggregation process and the extremely transient and 
labile properties of the pre-fibrillar oligomeric intermediates. As soon as the 
concentration of so-called ‘on-pathway’ oligomeric intermediates reaches certain 
threshold, they are rapidly converted into fibrils (Kim et al., 2009). Contrary to the 
on-pathway amyloid αS oligomers, off-pathway oligomers don’t seed the 
fibrillation of WT-αS and they are found to be innocuous. This additional on/off-
pathway feature of aggregation intermediates further complicates the design of 
experiments to resolve the identity of pathogenic species in the PD pathogenesis.  
(on the next page) 
Figure 7: Schematic depiction of the potential pathogenic mechanisms in PD 
Several factors have been shown to play a role in initiating and/or accelerating αS 
aggregation, consequently promoting the pre-fibrillar oligomer formation. Factors such as 
increased expression, missense mutations, oxidative stress induced modifications such as 
cross-linking, and phosphorylation at S129 influence the aggregation of αS to promote 
formation of pre-fibrillary oligomers (Chen and Feany, 2005; Chen et al., 2009; Fujiwara 
et al., 2002; Smith et al., 2005). In addition, pre-fibrillar oligomers can promote their 
accumulation by inhibiting the proteasome. Pore-like structures formed by amyloid 
oligomers can affect the membranes of mitochondria and DA vesicles leading to release 
of reactive oxygen species (ROS) and other pro-apoptotic factors (Abou-Sleiman et al., 
2006). In addition, proteins that have a role in regulating the αS levels are known to be 
the risk factors for PD (for example, neuronal UCH-L1 (Ubiquitin C-terminal hydrolase-
1), and Parkin (E3-ubiquitin ligase)) (Barrachina et al., 2006; Leroy et al., 1998). Taken 
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together, experimental evidence generated from the above studies suggests possible role 
of soluble pre-fibrillar oligomers of αS in PD pathogenesis. 
 
 
 
1.7 Drosophila model for Parkinson’s disease 
The fly Drosophila melanogaster, below referred to simply as Drosophila or 
“fly”, has enabled significant advances in neurodegenerative research, notably in 
the identification of genes that are required to maintain structural integrity of the 
brain. Gene discovery is quick and straightforward in flies. Furthermore, the 
central nervous system of invertebrates and vertebrates share a common 
evolutionary origin, and the fly has been used successfully for the genetic analysis 
of complex behaviors ranging from sleep to learning and memory to aggression. 
Of the human protein sequences associated with disease in the Online Mendelian 
Inheritance (OMIM) database, 74% have highly related sequences in the fly 
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genome (http://superfly.ucsd.edu/homophila/; Chien et al., 2002). Moreover, a 
number of dominantly inherited human neurodegenerative diseases, such as those 
caused by polyglutamine repeat expansions, have been successfully modeled in 
Drosophila by transgenic expression of human disease genes (reviewed in Lessing 
and Bonini, 2009). 
Drosophila contains no endogenous αS or αS-like genes in its genome 
(Auluck and Bonini, 2002; Feany and Bender, 2000). Feany and Bender 
developed the first Dorosophila PD model by introducing human αS gene into the 
wildtype fly genome (“humanized flies”). In their study, pan-neuronal 
overexpression of human wildtype (WT-αS) and mutant αS (A53T-αS, A30P-αS) 
using the UAS/Gal4 bipartite system (Section 2.2.3) has resulted in the human 
PD-like features in flies (Feany and Bender, 2000). This initial study spearheaded 
a flurry of investigations further on addressing various aspects of the 
neurodegeneration in PD. αS expressed in Drosophila has been shown to undergo 
the similar posttranslational modifications (for example, S129 and Y125 
phosphorylation) and processing as observed in human (Chen and Feany, 2005; 
Chen et al., 2009). Humanized Drosophila expressing αS mutants also show 
motor deficits in the climbing assay, reduced lifespan in survival assay, and 
degeneration of dopaminergic neurons in an age dependent manner (Feany and 
Bender, 2000).  
Climbing (= negative geotaxis) is the most commonly assayed behavior with 
respect to fly neurodegeneration. It is used for three reasons: (i) as a test of 
mobility, (ii) it can reflect ataxia that is common in human degenerative diseases, 
and (iii) a large number of flies can be tested at once. Generally, all 
neurodegenerative mutants have a shortened lifespan; therefore a straightforward 
first look at a mutant can be obtained with a survival curve. Also, the assay is also 
easy to perform and the observed behavioral deficit correlates well with the 
human disease. Drosophila also has easily identifiable and countable dorsomedial 
(DM) and dorsolateral (DL) clusters of the dopaminergic (DA) neurons in the 
adult brain, which can be immunostained with tyrosine hydroxylase antibody 
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(Periquet et al., 2007). The DM and DL clusters are also known to be sensitive to 
the αS-mediated toxicity (Periquet et al., 2007; Sang et al., 2007). Though 
significant loss of the DA neurons in the Substantia Nigra is a common clinical 
feature in human PD, neurodegeneration is not restricted to the DA neurons but 
extends to other regions of brain as the disease progresses (Farrer, 2006).  
The Drosophila model also provides a clean genetic background, as it 
doesn’t have endogenous αS in its wildtype genome. This experimental situation 
allows then investigating the dominant-gain of toxic functions of the human αS 
mutations in comparison with the effect of wildtype-αS expression in the fly. 
Fundamental biological pathways in flies, such as signaling, metabolism, innate 
immunity, learning and memory, sleep as well as circadian rhythms, share 
significant similarity to the mammalian pathways (Hendricks and Sehgal, 2004).  
As a result, the use of Drosophila as a model system also helps to understand the 
mechanisms responsible for PD pathogenesis. And of course, amenability and 
ease of Drosophila genetics further makes it a best system to screen for the 
candidate genes modifying αS toxicity. In fact, Drosophila is so far is one of the 
PD model organism that has shown significant and consistent similarity to the 
human PD phenotype (reviewed in Farrer, 2006; Maries et al., 2003). 
As mentioned in the previous sections, a million dollar question that still 
remains to be answered in the emerging field of PD pathogenesis is the precise 
identity and nature of pathogenic species in the aggregation pathway of αS. First 
step towards answering this question involves finding an animal model system 
that can reliably translate the pattern of observations made from in vitro 
aggregation experiments into the in vivo toxicity readout. We can then use that 
model system to correlate the in vitro aggregation properties of αS variants (for 
e.g. αS variants that form more pre-fibrillar oligomers and no fibrils) to the in vivo 
neurotoxicity. In the current study, I have generated an improved Drosophila PD 
model using the Phi-C31 site-specific integration system (Sections 2.2.2; 3.3) to 
correlate the in vitro pre-fibrillar oligomer formation of αS to the in vivo 
neurotoxicity. The advantage of this system is that transgenes can be inserted into 
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the same chromosomal location of the flies. This way, possible ‘position effects’ 
resulting from the αS gene insertion into different locations of the fly genome is 
circumvented. The site-specific integration of the αS gene consequently allows us 
to directly compare the toxicity of different αS variants in vivo because of the 
similar expression levels of the inserted transgenes.  
1.8 Understanding motor and non-motor symptoms of PD in 
the Drosophila model 
In most PD animal models including Drosophila, studying motor 
dysfunction is the main focus to understand PD pathogenesis. Since motor 
symptoms are considered to arise as a direct result of the loss of DA neurons in 
brain which is easy to observe and score. Partly it is also because of the popularity 
of Parkinson’s disease as a movement disorder. As already outlined above, the 
climbing assay is the most commonly used tool to check the mobility and motor 
integrity of PD (Lessing and Bonini, 2009). Here, I present a new PD Drosophila 
model with which I have tested both the negative geotaxis and positive phototaxis 
in a specially devised climbing assay apparatus (Sections 2.3.1; 3.4) and I have 
also monitored the fly locomotor activity using the Drosophila Activity Monitors 
(Sections 2.3.3; 3.9).  
Strikingly, understanding non-motor symptoms like sleep disorders, 
circadian changes, and cognitive dysfunction are not given much emphasis in the 
animal models generally used, as they are relatively tough and intricate to study. 
But the quality of life in human PD patients is severely affected by these non-
motor symptoms. Improving non-motor symptoms like sleep will not only 
increase the quality of life of patients but also helps them to recover from 
circadian and cognitive dysfunction (Pallier et al., 2007; Reddy and O'Neill, 
2010). Conserved cardinal features of sleep and circadian pathways in Drosophila 
(reviewed in Colwell, 2007; Hendricks and Sehgal, 2004) make it an 
indispensable and invaluable system to both understand and improve non-motor 
symptoms in PD pathogenesis. With the help of the newly generated Drosophila 
PD model system presented here, which uses site-specific recombination events to 
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insert mutant αS variants into the same location of the fly genome (Sections 2.2.2; 
3.3), I have pioneered to study both the motor and non-motor symptoms such as 
sleep and circadian rhythms in order to correlate in vitro pre-fibrillar oligomer 
formation with the in vivo neurotoxicity of distinct αS variants in PD 
pathogenesis.  
1.9 Aims of this study 
Considering recent developments in the field of PD pathogenesis when I 
have started this work, my aim was to investigate and ascertain the nature and 
identity of pathogenic species in the aggregation pathway of αS. In my notion, 
results from this huge scientific stride would help to resolve a longstanding debate 
in the field of PD pathogenesis, and funnel the focus of concerted efforts in a 
specific direction to understand the mechanisms of PD pathogenesis. I have 
planned to undertake a reverse genetics approach to investigate this problem in a 
systematic fashion. Initially, we need to resolve the question of whether the pre-
fibrillar oligomers or the fibrils of αS are potent pathogenic species in aggregation 
pathway of αS. Since there has been accumulating evidence that pre-fibrillar 
oligomers are the potential pathogenic species in the neurodegenerative diseases, 
like in Alzheimer’s and Huntington’s disease, my primary goal was to test 
whether this paradigm also holds true for the Parkinson’s disease.  
My strategy to achieve this goal involved the rational design of different αS 
variants based on structural information and testing their aggregation properties in 
vitro. This part of the work was performed in collaboration with Christian 
Griesinger’s and Markus Zweckstetter’s lab. After generating and characterizing 
different αS variants that can form more pre-fibrillar oligomers and less or even 
no fibrils, our idea was to correlate the in vitro soluble pre-fibrillar oligomer 
formation to the in vivo neurotoxicity in different model systems including C. 
elegans, Drosophila and mammalian neurons. My specific aim was to generate a 
Drosophila model for PD in order to critically test whether the in vitro pre-
fibrillar oligomer formation can be correlated with in vivo toxicity of different αS 
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variants that were generated by the rational design. By using Drosophila as a 
model for PD, I also performed studies concerned with both non-motor and motor 
symptoms of human PD (Section 1.8). The study was designed to better 
understand PD pathogenesis as a starting point for devising novel therapeutic 
interventions.  
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“The true method of knowledge is experiment.” 
 
(William Blake) 
 
 
 
 
 
2 
Materials and Methods 
2.1 Molecular Biology 
2.1.1 Polymerase Chain Reaction (PCR) 
PCR was used to amplify or mutate DNA fragments. It was carried out according 
to a standard protocol (Ausubel, 1999). Annealing temperatures and extension 
times were adjusted to fit the respective primer melting temperature and the length 
of the expected PCR product. The typical protocol involved 30-35 cycles (at 
annealing temperature 550C and extension time 1min 30sec) in a PTC-200 DNA 
Engine Cycler (Biorad, Hercules, USA). 
2.1.2 DNA Sequencing 
DNA sequencing was performed by the MWG Company (Ebersberg, 
Germany). DNA and primers were added according to the instructions given by 
the company on how to prepare a sample for the sequencing reaction. 
2.1.3 Restriction digest of DNA 
Restriction endonucleases (New England Biolabs, Ipswich, USA or Fermentas 
Burlington, Canada) were used according to the manufacturer’s instructions. For 
cloning, PCR-products or preparative amounts of plasmid DNA (10-20 µg) were 
incubated overnight with 10-folds excess of enzyme.  
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2.1.4 Sample preparation of single fly PCR 
Single adult flies were homogenized on ice in 50 µl squashing buffer (10 mM 
Tris-HCl pH 8.2, 1mM EDTA, 25 mM NaCl, 200 µg/ml proteinase K). The 
homogenate was incubated at 37°C for 30 min and proteinase K activity quenched 
by subsequent heat treatment (95°C for 2 min). After sedimentation by a short 
centrifugation step, the supernatant was then directly used for PCR. 
2.1.5 DNA extraction from agarose gels 
Ethidium Bromide stained DNA was excised from the agarose gel using a clean 
scalpel and extracted using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, 
Germany) as described by the manufacturer.  
2.1.6 Dephosphorylation of vector DNA 
In order to minimize self-ligation of vector DNA, the 5’ phosphate group was 
removed by Alkaline Phosphatase treatment. Restricted vector DNA was 
incubated for 30 min with 1µl of Shrimp Alkaline Phosphatase (SAP, USB, 
Staufen, Germany) and the appropriate volume of dephosphorylation buffer 
(USB) as outlined by the manufacturer. Dephosphorylated DNA was subsequently 
purified using the QIAspin Nucleotide Removal Kit (Qiagen, Hilden, Germany) 
according to the provided manual. 
2.1.7 DNA ligation 
Ligation was performed with T4 DNA ligase (Fermentas, Burlington, Canada). A 
total of 100ng of DNA (molar ratio of insert to host vector DNA of 3:1) was 
incubated with 1 µl T4 ligase in 10µl reaction volume (overnight, 18°C) as 
recommended by the manufacturer. 
2.1.8 Transformation of bacterial cells 
Escherichia coli DH5α or Top10 cells were obtained from Invitrogen (Karlsruhe, 
Germany). Chemically competent cells were prepared according to a standard 
protocol (Inoue et al., 1990). For transformation of cells by DNA present in the 
ligation reactions, an aliquot of chemically competent cells was added to 
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approximately 100 ng of plasmid DNA followed by 30 min incubation on ice. 
Cells were then heat shocked in a water bath at (42°C, 45 s) and immediately 
transferred back on to ice. After 2 min on ice, Luria-Bertani (LB) medium 
(Invitrogen, Karlsruhe, Germany) was added, and the cells were allowed to 
recover for 30 min at 37°C. The cells were distributed on LB agar plates 
containing antibiotics and incubated overnight at 37°C. 
2.1.9 Preparation of plasmid DNA 
Plasmid DNA was purified using the QIAGEN Mini or Maxi Kits (QIAGEN, 
Hilden, Germany) following the manufacturer’s protocol 
2.1.10 DNA preparation for embryo injections 
Targeting plasmid construct containing attB site and the vector DNA elements 
were cloned and purified using the Quiagen Midi-prep DNA kit (Qiagen, Hilden, 
Germany) and the protocol provided by the manufacturer. Purified DNA was 
diluted with water to a final concentration of 200 ng/µl. DNA of the targeting 
construct (i.e. the “transgene”) was injected into the embryos which were 
homozygous for both a attP landing site in a defined position of the genome and 
the germline specific Phi-C31 integrase provided by an integrated transgene 
(Bischof et al., 2007).  
For details see http://flyc31.frontiers-in-genetics.org/sequences_and_vectors.php  
2.1.11 Preparation of fly head extracts 
Flies (wildtype or mutants) were frozen and approximately 50µl of fly heads of 
the different genotypes were separated and collected. Heads were homogenized in 
three volumes of the ice-cold Head Extraction Buffer (containing 100mM KCl, 
20mM   Hepes, 5% Glycerol, 10mM EDTA, 0.1% Trition X-100, 1mM DTT, 
Sigma cocktail protease inhibitor, PH - 7.5) as described (Nawathean and 
Rosbash, 2004). The homogenate was subsequently centrifuged for 5 min to 
obtain the supernatant. After removal of the supernatant, protein concentration 
was determined using BCA (Bicinchoninic Acid) method using BCA Protein 
Assay Kit (Pierce Biotechnology, Rockford, USA) according the manufacturer’s 
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manual. For comparison, ~50µg of total protein extracts was mixed with the 2X 
SDS sample buffer and proteins were subsequently separated by SDS PAGE (see 
Section 2.1.12).  
2.1.12 Polyacrylamide Gel Electrophoresis (PAGE) 
Samples were separated in a 15% denaturing Tris/Tricine SDS polyacrylamide gel 
electrophoresis system, as described (Schagger and von Jagow, 1987). The 
separation gel contained 15% bis-acrylamide (Rotiphorese Gel 30, Roth GmbH, 
Karlsruhe, Germany), 1 M Tris (pH 8.45), 0.1% SDS, 10% glycerol; the stacking 
gel contained 4% bis-acrylamide 1 M Tris (pH 8.45), 0.1% SDS. Ammonium 
persulfate and TEMED (N, N, N’, N’-Tetramethylethylene-diamine) were added 
for polymerization and cross-linking of the bis-acrylamide. Before loading the 
protein samples onto the gel, they were boiled for 5min. 5 µl PageRuler prestained 
protein ladder solution (Fermentas, Burlington, Canada) was used for each gel as 
marker for an approximate sizing of the proteins. Separation was performed in a 
discontinuous buffer system with a 0.2M Tris (pH 8.9) solution in the tank and a 
0.3M Tris (pH 8.45), 0.03% SDS solution as running buffer. 
2.1.13 Immunoblotting 
After separation, proteins were transferred from the gel to nitrocellulose 
membranes (Amersham Biosciences, Freiberg, Germany) in a sandwich setting 
(BioRad, Muenchen, Germany) for 1 h at 350 mA following otherwise a standard 
protocol (Ausubel, 1999). After transfer, membranes were blocked with 5% BSA 
in TBST (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween-20), incubated with 
primary antibodies (4°C, overnight), washed with TBST, incubated with HRP 
(Horse Radish Peroxidase)-conjugated secondary antibodies (room temperature; 2 
h), washed and then subjected to ECL (a highly sensitive enhanced 
chemiluminiscent substrate for detecting HRP on immunoblots) detection. The 
activity of HRP-conjugated secondary antibodies (Jackson labs, West Grove, 
USA) was determined using ECL Western Blotting Substrate (Pierce 
Biotechnology, Rockford, USA). Primary antibodies, mouse monoclonal anti-α-
Tubulin antibodies (clone DM1A from Sigma-Aldrich, Munich, Germany) and 
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rabbit polyclonal α-Synuclein antibodies (Anaspec, Fremont, USA) were diluted 
1:2,000- and 1:300-fold, respectively. HRP conjugated secondary antibodies were 
used at the dilution of 1: 3,000. 
2.1.14 Dot blotting  
Purified protein samples of αS wild type and αS variants were spotted on to the 
nitrocellulose membranes for dot blotting as described (Jahn et al., 1984). Dot 
blotting was done using the anti-oligomer antibody/A11 (Invitrogen Corporation, 
Camarillo, USA) antibody as described (Kayed et al., 2003).   
 
2.2 Fly Techniques 
2.2.1 Maintenance of flies 
Flies were kept and propagated on standard fly food used in the Lab, a corn flour-
soya flour-molasses medium that is supplemented with dry yeast (Casteggio 
Lieviti srl, Casteggio, Italy) at 250C and 20-30% humidity. For measuring 
circadian locomotor activity rhythms and sleep assays, flies were kept in a 12h 
light/12h dark (LD) cycle unless mentioned differently in the ‘results’ section.  
2.2.2 Generation of stable transgenic fly lines 
The site-specific PhiC31integrase/φC31integrase recombination system (Bischof 
et al., 2007) was used to generate transgenic flies which contain the transgene in 
the same chromosomal location. PhiC31 site-specific integration system depends 
on the presence of bipartite sequences, the so-called attachment site P (attP) and 
the attachment site B (attB) integrated into the fly genome that contain also a 
PhiC31integrase gene to carry out irreversible integration between attB and attP 
sites (attB + attP + φC31integrase => attR + attL + φC31integrase). For details see 
Bischof et al., 2007. 
 
The DNA constructs used as transgenes were prepared by cloning the cDNAs of 
αS variants into the GAL4-responsive pUAST expression vector (Bischof et al., 
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2007) containing the attachment site B (attB). The resulting plasmids were 
injected into the fly embryos, which were double homozygous for both attP 
(attachment site P) site and germ-line-specific φC31integrase. The genomic 
location of the attP landing site used for integration was mapped to the 3R-86Fb 
position in the genome (ZH-86Fb line) (Bischof et al., 2007). For details see 
http://flyc31.frontiers-in-genetics.org/landing_platforms.php. Site-specific 
insertions of the transgenes were verified by single fly PCR using primer pairs of 
the sequence 5´ACT GAA ATC TGC CAA GAA GTA 3´ and 5`GCA AGA AAG 
TAT ATC TCT ATG ACC 3´, respectively. 
2.2.3 Ectopic gene expression via the UAS/GAL4 system 
The UAS/GAL4 system allows for ectopic induction of genes in a spatially and 
temporally controlled fashion (Brand and Perrimon, 1993). This two-component 
system is borrowed from yeast where the transcription factor GAL4 binds to its 
target Upstream Activating Sequence (UAS) to activate transcription (Brand and 
Perrimon, 1993). A transgenic fly carrying a specific enhancer element upstream 
of the gal4 gene, when mated with a transgenic fly carrying a coding sequence 
fused downstream of the UAS, results in progeny, which expresses the UAS-fused 
coding region in response to GAL4 activity driven by an enhancer element that 
directs the spatio-temporal pattern of gal4 expression. 
2.2.4 Antibody (Ab) staining of adult fly brains 
Whole-mount adult fly brains from the 2day and 30day old animals were prepared 
and immunostained according to the previously published protocol (Wu and Luo, 
2006). Rabbit anti-tyrosine hydroxylase (TH) (dilution 1:150; Chemicon 
International, Temecula, USA) was used to positively stain the Dopaminergic 
(DA) neurons, and Mouse anti-nc82 (dilution 1: 200; Developmental Studies 
Hybridoma Bank, University of Iowa, Iowa City, IA) was used as a counter stain. 
From the confocal sections of fly brains of different genotypes, dorsomedial (DM) 
and dorsolateral (DL) clusters of DA neurons were defined and counted as 
described (Cooper et al., 2006; Sang et al., 2007). ‘Cell counter’ plug-in as 
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provided by the ImageJ64 software was used for counting the DA neurons in the 
stacks of confocal images (http://rsbweb.nih.gov/ij/index.html).  
2.2.5 Dissection of larval NMJs (Neuromuscular Junctions) 
Midstage third-instar larvae were put on a dissection plate with both ends fixed by 
fine pins and then covered by a drop of ice-cold hemolymph-like saline (HL-3) 
(low calcium saline solution containing 0-0.3mM calcium (Broadie, 2000; Stewart 
et al., 1994). Dissection scissors were used to first make a small hole at the dorsal 
midline of the larva near the posterior end, which was then extended along the 
dorsal midline to the anterior end. The epidermis was stretched flat and pinned 
down, and internal organs and CNS were removed carefully with forceps (Qin et 
al., 2005). 
2.2.6 Immunocytochemical staining of NMJs  
After dissection, NMJs were fixed with 4% paraformaldehyde for 5 min. 
Preparations were blocked with 950 µl PBT (0.1M Phosphate Buffer with 0.05% 
Triton X-100) mixed with 50 µl NGS (Normal Goat Serum; 5% solution) for 30 
mins. Primary antibodies  (mouse α-Synuclein at 1:100 dilution and Rabbit-α-Glu 
RIID at 1: 500 dilution in NGS blocking solution) were added and incubated over 
night at 40C. After incubating with primary antibodies, preparations were washed 
three times, 10 min each, with PBT. Secondary antibodies (anti-mouse Alexa 488 
(1:500 dilution), anti-Rabbit Cy3 (1:500 dilution) and anti-HRP (Horse  Radish 
Peroxidase) Cy5 (1:250 dilution) were added in blocking solution and incubated 
for 4h at room temperature. After three washes with PBT (10 min each), 
preparations were mounted with vectashield mounting medium (Vector 
Laboratories, Burlingame, USA).  
2.2.7 Confocal microscopy 
Preparations stained with fluorescently tagged antibodies were used as samples to 
acquire images. Confocal images were taken with a Leica TCS SP5 confocal 
microscope (Leica Microsystems GmbH, Mannheim, Germany) using a 40 X, 1.4 
numerical aperture HCX PL APO objective involving the Leica Application Suite 
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Advanced Fluorescence (LAS AF) 1.5.1 software (Leica Microsystems GmbH, 
Mannheim, Germany).  
     Table 2.1: List of primary antibodies used in this study 
 
Antibody (Ab) 
 
Animal 
 
Source 
 
Epitope 
detected 
 
Dilution 
Tyrosine 
Hydroxylase 
Rabbit Chemicon 
International 
Tyrosine 
Hydroxylase 
1:150 
Monoclonal αS 
(LB509 clone) 
Mouse Zymed 
Laboratories 
α-Synuclein 1:100 
Polyclonal αS Rabbit Anaspec Inc. α-Synuclein 1:300 
A11  Rabbit Invitrogen 
Corporation 
Common 
conformation 
of amyloid 
oligomers 
1:200 
Monoclonal α-
Tubulin 
Mouse Sigma Inc. α-Synuclein 1:2000 
Elav Mouse Iowa Hybridoma 
Bank 
Elav 1:200 
HRP-Cy5 Goat Dianova Horse Radish 
Peroxidase 
1:250 
Drosophila 
PDF 
Mouse Iowa Hybridoma 
Bank 
Pigment 
Dispersion 
Factor 
1:150 
nc82 Mouse Iowa Hybridoma 
Bank 
Bruchpilot 1:200 
 
      Table 2.2: List of secondary antibodies used in this study 
 
Epitope detected 
 
Animal 
 
Source 
 
Label 
 
Dilution 
Mouse IgG Goat Molecular Probes Alexa 488 1:500 
Mouse IgG Goat Molecular Probes Alexa 568 1:500 
Mouse IgG Goat Pierce HRP 1:2000 
Rabbit IgG Goat Molecular Probes Alexa 488 1:500 
Rabbit IgG Goat Molecular Probes Alexa 568 1:500 
Rabbit IgG Goat Pierce HRP 1:2000 
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  Table 2.3:List of fly stocks used and generated in this study 
Name Genotype Reference/Source 
Wildtype lines   
white w1118 Lindsley and Zimm, 
1992 
OreR wildtype Lindsley and Zimm, 
1992 
Gal4 driver and UAS lines 
elav-Gal4 w*P{GawB}elavc155 Bloomington Stock 
number 458 
Ddc-Gal4 w*;;P{Ddc-GAL4.L}4.36 Bloomington Stock 
number 7009 
TH-Gal4 w*;;P{TH-GAL4.F}3 Andretic et al., 2005 
OK6-Gal4 w*;P{GawB}OK6 S.Sigrist’s Lab, FU 
Berlin 
attP-Landing site y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.attP}ZH-86Fb 
Bischof et al., 2007 
 
UAS-lacZ y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-lacZ}ZH-86Fb 
Generated in this  
study 
UAS-EGFP y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-egfp}ZH-86Fb 
Generated in this  
study 
UAS-[WT-αS] y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-[WT-αS]}ZH-
86Fb 
Generated in this  
study 
UAS-[TP-αS] y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-[TP-αS]}ZH-
86Fb 
Generated in this  
study 
UAS-[A56P-αS] y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-[A56P-
αS]}ZH-86Fb 
Generated in this  
study 
UAS-[A53T-αS] y1 M{vas-int.Dm}ZH-2A w*; 
M{3xP3-RFP.UAS-[A53T-αS]}ZH-
86Fb 
Generated in this  
study 
UAS-EKO/Kir2.1 y1w*;E222+[UAS-EKO] Benjamin White  
(NIH, USA) 
UAS-NaChBac y1w*;UAS-NaChBac-GFP Benjamin White 
(NIH,USA) 
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2.3 Behavioral Assays 
2.3.1 Climbing assay 
Flies expressing different αS variants were placed in a newly designed behavior 
assay apparatus containing a bottom vial and an inverted upper vial. They were 
assayed for their ability to climb from the bottom to upper vial in thirty seconds. 
To avoid photic outside effects during the assay period, both vials were encased in 
black boxes. As flies get attracted towards the light, I have also provided a light 
source at the top of the upper vial by two light emitting diodes. This type of set up 
provides a directionality and motivation for the flies to climb from bottom to the 
top. A photograph of the apparatus is shown in Figure 11 A. 
2.3.2 Longevity assay 
Flies expressing αS variants and control animals expressing lacZ were collected 
and maintained under 12h light/12h dark (LD) at 25 °C with constant humidity 
and population density per vial. Flies were transferred to fresh food vials and 
scored for survival in 5-day intervals. Survival curves were calculated and plotted 
using Kaplan-Meier statistics (Fall et al., 2003; Rajput et al., 2009), and 
differences were analysed by using the log-rank method (GraphPad Prism 
software, San Diego, USA). 
2.3.3 Analysis of circadian behaviour 
Flies were crossed to obtain the appropriate offspring genotype, which were 
allowed to develop (pre and post-eclosion stages) at 25°C in the 12h light/12h 
dark (LD) conditions unless mentioned otherwise. To assess the circadian activity, 
flies of different genotypes were loaded into the Drosophila Activity Monitoring 
(DAM) systems (Trikinetics, Waltham, USA) and their activity was recorded. 
Initially, the flies were allowed to continue their entrainment under LD (12:12) 
conditions for the at least three days before they were switched into a ‘free-run’ 
mode under the 12h dark/12h dark (DD) conditions using the Trikinetics data 
collection system. Data were analysed with Clock Lab to extract the circadian 
behaviour (http://www.actimetrics.com/ClockLab/) of the flies. Double-plotted 
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actograms, Chi-squared or Lomb-Scragle periodograms were plotted using 
MATLAB 7.4 (R 2007a) software using the Clock Lab programs. 
2.3.4 Sleep assays 
Flies were grown under LD 12h:12h at 25 °C before and after the eclosion. Males 
were collected from the progeny and aged with equal population density under LD 
12:12 at 25 °C. After 28-30 days, locomotor activity of the aged flies was 
recorded in LD by the Drosophila Activity Monitoring (DAM) system 
(Trikinetics, Waltham, USA) as described (Joiner et al., 2006; Pitman et al., 
2006). “Sleep” was measured as bouts of 5 min of inactivity (Shaw et al., 2000), 
using a moving window of 1 min intervals. Average bout length (ABL) was 
calculated from the sum of sleep bouts of all lengths (in minutes) divided by the 
total number of sleep bouts. Algorithms written for computing these parameters 
are included in the appendix A.  
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     “We see only what we know.”  
 
(Johann Wolfgang von Goethe) 
 
 
 
 
 
3 
Results 
 
3.1 Structure-based rational design of the α-synuclein 
variants  
α-Synuclein (αS) is a natively unstructured protein. It has a high propensity 
to misfold and aggregate into fibrils in the process of amyloidogenesis (Cookson, 
2005). Formation of pre-fibrillar soluble oligomers is one of the earlier steps in 
the aggregation pathway of αS (Cookson, 2005). There is accumulating evidence 
that the small and diffusible pre-fibrillar oligomers of amyloidogenic proteins are 
potential pathogenic species in neurodegenerative processes, e.g. oligomers of 
soluble amyloid-β-protein (Aβ) in Alzheimer’s disease (reviewed in Haass and 
Selkoe, 2007) and oligomers of polyglutamine in the expanded polyglutamine 
disorders (Sanchez et al., 2003).  
αS can not form stable and enriched oligomers like Aβ and other 
amyloidogenic proteins (Lashuel and Lansbury, 2006), and aggregation is a 
dynamic biophysical and biochemical process. Therefore, investigating the role of 
soluble pre-fibrillar αS oligomers in PD pathogenesis and understanding the 
nature of toxic αS species is a challenging problem. To address this problem, we 
have rationally designed different variants of αS that could potentially form more 
pre-fibrillar oligomeric species (in collaboration with P. Karpinar; Christian 
Griesinger’s and Markus Zweckstetter’s Lab). The rational design was based on 
the structural information of αS monomer in solution and the topology of αS 
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fibrils (Bertoncini et al., 2005; Heise et al., 2005; Vilar et al., 2008). Fundamental 
premise in the rational design of αS variants was preventing the fibril formation, 
by impinging for example on the ‘cross-β’ structure and promoting thereby the 
pre-fibrillar oligomer formation. Cross-β structure in fibrils is stabilized by the 
extensive structural interactions of inter and intra-molecular β strands of αS. 
Thus, replacement of Alanine to Proline, which serves as a β strand breaker, was 
performed in the key regions of αS-monomer that would normally become the 
inner core of the ‘cross-β’ structure in the perspective fibrils. Several αS variants 
were generated in this fashion by replacing the Alanines A30, A56 and A76, 
respectively (Figure 8A), and both their in vitro aggregation properties and 
oligomer-forming tendencies were examined by various biophysical methods as 
reported (Karpinar et al., 2009). The following αS variants were generated: A30P, 
A56P, A76P, A30P/A56P, A30P/A76P and A30P/A56P/A76P (TP-αS). 
 
 
(on the next page) 
Figure 8: α-Synuclein variants with reduced fibrillation propensity and impaired β-
structure form more on-pathway pre-fibrillar oligomers  
(A) Domain structure of αS depicting the location of mutations in monomer and their 
relative position in the fibrillar structure derived from solid state NMR. These αS variants 
were rationally designed to promote formation of oligomeric pre-fibrillar species by 
actively impairing the formation of β-structure in the fibrils resulting from aggregation. 
Highly ordered cross-β-structure is a paramount structural feature of the amyloidogenic 
fibrils. (B) Fibril formation kinetics of wildtype-αS/WT-αS (black), A56P-αS (Yellow), 
and TP-αS (red) followed by Thioflavin T fluorescence (ThT); a.u. = arbitrary units. ThT 
fluorescence increases with the rate of fibril formation. (C) Dot blot assay on the 
nitrocellulose membrane using conformation specific A11 antibody. A11 recognizes a 
mixture of oligomers and monomers of TP-αS (O/M) but not monomeric TP-αS (M) on 
membrane, whereas anti-αS antibody recognizes both TP-αS (M) and TP-αS (O/M).  
Results in B & C were obtained in collaboration with Pinar Karpinar (Christian 
Griesinger´s and Markus Zweckstetter’s Lab). 
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3.2 TP-αS and A56P-αS show increased propensity to form 
oligomers and delayed fibril-formation kinetics 
Among the different αS variants generated, A56P-αS and TP-αS 
(A30P/A56P/A76P-αS) variants showed a potential delay in fibril formation and 
an increased propensity to form oligomers (Figure 8B, C; see Karpinar et al., 
2009). Soluble pre-fibrillar oligomers formed by TP-αS and A56P-αS also share 
significant structural and conformational similarity with the ‘on pathway’ 
oligomers formed by the (wild type) WT-αS. For example, liquid-state NMR and 
circular dichroism (CD) spectroscopy indicated that point mutations did not 
markedly alter the structural properties of the αS monomer in solution; and also 
mutations didn’t prohibit the formation of α-helical conformation on the surface 
of SDS micelles (experiments were done in collaboration with the Dept. of NMR 
based structural biology, MPIbpc). Furthermore, conformational specific 
antibody, called A11,  recognizes the TP-αS oligomers (Figure 8C). The A11 
antibody is shown to recognize a common unknown conformation shared by toxic 
amyloid protein oligomers. A11 also recognizes the WT-αS oligomers (Kayed et 
al., 2003) and a variety of other toxic amyloid oligomers (amyloid-β, 
polyglutamine, prion peptide 106-126, islet amyloid polypeptide, lysozyme).  
In addition, biophysical experiments including Electron Microscopy, Atomic 
Force Microscopy, Dynamic Light Scattering, and Ultra Violet absorption 
spectrum were carried out in collaboration with M. Zweckstetter´s the group as 
reported (Karpinar et al., 2009), and they conclusively show that both αS 
structural variants, TP-αS and A56P-αS, not only show delayed aggregation 
kinetics and increased propensity to form oligomers, but that both αS variants also 
have impaired β structures as summarized in the Figure 9. Most importantly, TP-
αS did not form fibrils under the standard conditions used for Thioflavin T (ThT) 
aggregation assay (Figure 8B) and forms highest amount of soluble oligomers 
among the different αS variants generated.  
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Figure 9: Illustration of the summary of results based on in vitro experiments with 
structure based design variants of the αS  
α-synuclein variants with impaired formation of β-structure in the perspective fibrils 
show delayed fibrillation kinetics with increased lag-phase, and form more of pre-fibrillar 
oligomers. As shown above, two important variants, A56P-αS and TP-αS, show delayed 
fibril formation and increased propensity to form oligomers compared to the wildtype-αS 
(WT-αS). Remarkably, TP-αS didn’t show any fibrils even after two weeks of incubation 
in the standard aggregation assay based on ThT fluorescence. Experimental support for 
this scheme derives from experiments conducted by P. Karpinar, N. Rezaei-Ghaleh, and 
A. Kumar of the Griesinger and Zweckstetter labs as published  (Karpinar et al., 2009). 
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3.3 Generating the Drosophila model for Parkinson’s disease 
 
My aim was to correlate the in vitro properties of structure-based αS variants 
to their in vivo neurotoxicity and study its biological relevance to the PD 
pathogenesis. Studying in vivo neurotoxic effects of these structural variants of αS 
helps us to better understand (i) the nature of toxic species in the aggregation 
pathway (intermediate pre-fibrillar oligomers or fibrils), (ii) the correlation 
between soluble oligomer formation and neurotoxicity, and (iii) the possible 
mechanism of toxicity. Therefore, to investigate the neurotoxic effects and the 
biological relevance of different variants of αS, I have generated a new 
Drosophila model for PD by using the PhiC31 based site-specific recombination 
system (Figure 10A). Drosophila lacks the αS gene in its wild type genome and is 
a valid model for Parkinson’s disease and many other neurodegenerative diseases 
(Auluck et al., 2002; Feany and Bender, 2000) when the αS gene is inserted into 
the fly genome. In order to explore the biological consequences of αS, and αS 
mutant genes, transgenic Drosophila individuals carrying the following transgenes 
were generated: wild type-αS/WT-αS; A56P-αS and TP-αS variants (the 
designed αS variants, see Section 3.2); and A53T-αS, a dominant genetic mutant 
of αS found in the human PD patients (Polymeropoulos et al., 1997). Using 
PhiC31 based site-specific recombination system for Drosophila transgenesis 
(Bischof et al., 2007), individual transgenic plasmid constructs, each carrying a 
different variant of αS were precisely targeted to the same location in genome 
(“site-specific integration”) which was verified by PCR using the single fly DNA 
PCR approach (Figure 10B; Section 2.1.10).  
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Figure 10: Generating the Drosophila model for Parkinson’s disease by using φ-C31 
based site-specific recombination method 
(A) Schematic showing the φ-C31 based site-specific recombination. All transgenic 
plasmid constructs carrying attB site along with human α-synuclein (α-syn) DNA 
elements were targeted to the attP landing-site present on the 3rd chromosome. Embryos 
used for the microinjections were double homozygous for attP landing-site and φ-C31 
Integrase expression in germline. (B) Agarose gel picture showing the results from single 
fly PCR to confirm the targeted site-specific insertion of all the transgenic constructs of 
αS to the same location in genome; attP and LacZ lanes are controls with an empty attP 
landing-site and the lacZ insertion respectively. (C) Western blot analysis on fly head 
extracts after expressing different variants of αS shows similar expression levels. Tubulin 
is the loading control and head extract from the LacZ expressing animals was used as a 
“negative control”.  
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Previous results have shown that PD onset and αS aggregation depend on the 
dosage and expression level of αS. The genomic duplication and triplication of αS 
gene cause autosomal dominant familial Parkinson’s disease (Ibanez et al., 2004; 
Singleton et al., 2003). Thus, another inherent advantage offered by Phi-C31 site-
specific integration has circumvented the problem of expression dosage by 
achieving equivalent expression levels of αS among transgenics expressing αS 
variants. To confirm this, western blot analysis done on the fly head extracts 
expressing different αS variants and the results are shown in Figure 10C. 
3.4 Pre-fibrillar oligomer-enriched structural variants of αS 
cause motor deficits  
PD is clinically defined as a movement disorder characterized by resting 
tremor, bradykinesia (slowness of movement), rigidity and postural instability, i.e. 
problems of initiating and stopping the movement (reviewed in Cookson, 2005). 
To assess whether the Drosophila PD model recapitulates the symptoms of human 
disorder, I have tested the motor performance of aged (4 weeks) flies expressing 
different variants of αS in a climbing assay (refer to methods section 2.3.1). For 
their targeted expression, I used the pan-neuronal elav-Gal4 driver employing the 
UAS/GAL4 system (Brand and Perrimon, 1993) (Section 2.2.).  
To subsequently test for fly movements in response to αS and αS mutant 
gene expression, I have designed a special climbing assay apparatus (see Figure 
11A). This specially designed climbing assay apparatus is useful both to assay the 
negative-geotactic locomotor function and the positive-phototactic behavior of 
flies. In this apparatus, a light source (LED box) present at the top of upper 
chamber serves both as an attraction cue to motivate the flies to climb up and it 
provides thereby the directionality of the climbing response of the flies. The 
response of flies was scored as the climbing index (i.e. percentage of flies 
reaching the upper chamber in thirty seconds). The results summarized in Figure 
11B indicate that flies expressing oligomer forming TP-αS, A56P-αS variants, 
and human associated A53T-αS exert significant locomotor dysfunction as 
compared to the wildtype-αS/WT-αS and LacZ expressing control flies. Among 
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the αS variants examined, TP-αS showed more chronic motor deficits as 
compared to the A56P-αS and A53T-αS, respectively. This finding correlates 
with the ability of these αS variants to form more pre-fibrillar oligomers in vitro 
(see Section 3.2). Both types of control flies, i.e. flies expressing WT-αS and 
LacZ flies showed no significant locomotor dysfunction. 
 
 
 
 
 
(on the next page) 
Figure 11: Drosophila expressing pre-fibrillar oligomer enriched α-Synuclein 
variants show motor deficits in the climbing assay 
(A) Newly designed apparatus for the climbing assay that can be used to simultaneously 
assay both negative-geotactic and positive-phototactic behaviour of flies. It has a set of 
glass columns, each separated into lower chamber and upper chamber with a shutter in 
between. All the columns are encased in black vials to avoid photic effects from the 
outside environment. Shutters, both in the bottom and centre of all individual columns, 
can be opened and closed with a single switch. Light Emitting Diodes (LEDs) on the top 
of each column provide the light source of appropriate wavelength to serve as an 
attraction cue to motivate the flies to climb up. Intensity of all LEDs can be controlled 
using a regulator. (B) Climbing Index (percentage of flies reaching the upper chamber in 
a given amount of time) of four week old flies expressing different variants of αS under 
the elav-Gal4 pan-neuronal driver (n= 35-50 for each genotype and values shown 
represent mean ± SEM; ns= non-significant P > 0.05, *P < 0.01, **P < 0.001). 
Significance values were determined by one-way ANOVA followed by the Newman-
Keuls Multiple Comparison post hoc test. 
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3.5 Pre-fibrillar oligomer-enriched αS structural variants 
reduce longevity 
Parkinson’s disease is not fatal, but it can reduce longevity. The disease 
progresses more quickly in older than in younger patients. Patients with PD have 
mortality rates 35% to 65% higher than those of matched controls (Fall et al., 
2003; Rajput et al., 2009). To assess the effects on longevity, survival of flies 
expressing different αS variants was followed over a period of 70 days. The 
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results summarized in Figure 12 A, B show that the rate of survival has 
dramatically decreased after the median survival time in the flies expressing more 
oligomer-forming TP-αS and A56P-αS versions. 
 
Figure 12: Longevity of flies expressing different variants of αS and LacZ  
(A-B) Kaplan-Meier survival curves of the flies expressing WT-αS (black), TP-αS (red), 
A56P-αS (yellow), A53T-αS (green), and LacZ (blue). Survival curve comparison using 
Logrank test shows significant differences in longevity between the WT-αS versus TP-
αS (***P < 0.0001), and WT-αS versus A56P-αS (*P < 0.0217).  In each experiment n= 
350-400 for different genotypes. Note that the rate of survival has dramatically decreased 
after the median survival time in the animals expressing more oligomer-forming versions 
of the αS. 
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3.6 Expression of pre-fibrillar structural αS variants causes 
age-dependent degeneration of dopaminergic (DA) neurons 
The major symptoms of PD in humans result from the profound and 
selective loss of DA neurons in the Substantia Nigra pars Compacta (SNc) (Braak 
et al., 2003).  Studies on Drosophila models of PD have also reported the specific 
loss or dysfunction of DA neurons in the adult fly brain (Chen and Feany, 2005; 
Cooper et al., 2006; Feany and Bender, 2000; Periquet et al., 2007). Particularly, 
the dorsomedial (DM) and dorsolateral (DL) clusters of DA neurons (schematic in 
Figure 13 A), were known to be preferentially sensitive or vulnerable to the αS 
toxicity (Periquet et al., 2007; Sang et al., 2007). In addition, DM and DL clusters 
are easy to identify and count. Therefore, I followed age-dependent degeneration 
of the DA neurons in DM and DL clusters by expressing WT-αS and the different 
variants of αS (TP-αS, A56P-αS, and A53T-αS) using the pan-neuronal elav-
Gal4 driver.  
3.6.1 No degeneration of DA neurons in young flies expressing αS 
variants 
DA neurons were positively stained with the anti tyrosine-hydroxylase 
antibody in two-day old adult whole-mount fly brains that express different 
variants of αS. DM and DL clusters were separately analyzed and the number of 
neurons was counted as described in Section 2.2.4. As shown in the Figure 13B, C 
there were no significant differences in the number of DA neurons in the young 
flies (2 days after hatching) expressing different variants of αS. 
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Figure 13: Dopaminergic (DA) neurons in the young flies expressing different 
variants of αS and LacZ  
(A) Schematic representation of the distribution of DA neurons in dorsolateral (DL) and 
dorsomedial (DM) clusters (black arrows) in the adult Drosophila brain as defined by 
Sang et al., 2007. DM and DL clusters are well-characterized, easy to count, and are 
known to be sensitive to the αS neurotoxicity. (B-C) Quantification of DA neurons in the 
DM and DL clusters in the whole-mount young adult brains (two-day-old) expressing 
different αS variants or lacZ. DA neurons were positively stained with anti-TH (anti-
Tyrosine Hydroxylase) antibody. The values shown represent ± SEM and n > 12 for each 
genotype in all experiments; n.s. = non-significant P > 0.05. Significance values were 
determined by one-way ANOVA followed by the Newman-Keuls Multiple Comparison 
post hoc test. There are no statistically significant differences in the number of DA 
neurons among the 2-day old adult flies expressing different variants of αS and LacZ.  
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3.6.2 Degeneration of DA neurons in old flies expressing αS 
variants 
In contrast to the young flies, the old flies (30 days after hatching) 
expressing different variants of αS showed significant differences in the DA 
numbers of both DL and DM clusters as shown in Figure 14B, C. Flies expressing 
TP-αS version showed more highly degenerated DM and DL clusters (Figure 
14D, E) compared to the A56P-αS, which forms lesser oligomers than TP-αS. 
Neurotoxicity of A53T-αS was in a similar range as observed with A56P-αS, 
whereas the WT-αS and LacZ caused no significant loss of the DA neurons. The 
loss of neurons correlates well with the deficits observed in climbing assay and 
longevity assay, i.e. flies expressing more pre-fibrillar oligomer forming TP-αS 
exhibited highest neurotoxicity.  
 
 
 
 
(on the next page) 
Figure 14: Age dependent degeneration of DA neurons in the flies expressing 
different variants of αS 
(A) Schematic representation of the distribution of DM and DL clusters (black arrows) of 
DA neurons in the adult Drosophila brain as defined by Sang et al., 2007. (B-C) 
Quantification of DA neurons in the DM and DL clusters in whole-mount adult brains of 
the 30-day-old animals expressing αS variants and lacZ control. DA neurons were 
positively stained with anti-TH (anti-Tyrosine Hydroxylase) antibody. The values shown 
represent ± SEM and n ≥12 for each genotype in all experiments; * P < 0.01, ** P < 
0.001. Significance values were determined by one-way ANOVA followed by the 
Newman-Keuls Multiple Comparison post hoc test. (D-E) Representative confocal 
images (maximum z-projections) from the anti-TH stained (green) whole amount brains 
of WT-αS and TP-αS (30-day-old males). Loss of TH immunostaining/degeneration of 
DA neurons in the DM cluster (white arrow) of TP-αS compared to the WT-αS DM 
cluster. 
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3.7 Dopamine dependent behavioral deficits in flies 
expressing αS variants  
Drosophila exhibits cardinal features of circadian rhythms and sleep 
(reviewed in Hendricks and Sehgal, 2004) similar to mammals (Harbison et al., 
2009). In these processes, the DA neuronal circuit and signaling play 
evolutionarily conserved and vital roles in a wide spectrum of behavioral and 
molecular pathways (Shirlee Tan, 2003). In Drosophila, DA neurons were shown 
to have a potential role in circadian control of locomotor activity (Suh and 
Jackson, 2007) and in modulation of sleep-wake states (Andretic et al., 2005; 
Dzirasa et al., 2006; Huber et al., 2004; Kume et al., 2005) in a mammal-like 
manner. These features make the Drosophila PD model an attractive and valuable 
system to understand the etiology of non-motor symptoms of human PD including 
sleep disorders, deterioration of cognition, depression and disturbances of 
autonomic function (Chaudhuri and Schapira, 2009; Poewe, 2008). Therefore, I 
have studied the effect of expression of αS variants on specific DA dependent 
behaviors such as sleep and circadian locomotor activity rhythms. 
3.8 Sleep abnormalities in PD flies expressing αS variants 
Sleep abnormalities are highly prevalent in PD (>76% of patients) (Rye, 
2006; Schapira, 2004). In order to test whether this disorder relates to DA 
neurons, I examined the function of WT-αS and αS expression in DA neurons 
using the Ddc-Gal4 driver. In Drosophila, the DA neurons project to the 
mushroom body (MB) lobes (Zhang et al., 2007) which plays a dynamic role in 
sleep regulation (Joiner et al., 2006; Pitman et al., 2006). In addition, DA neuronal 
signaling is also known to have a direct and critical effect on the regulation of 
sleep/wake cycle in Drosophila (Andretic et al., 2005; Kume et al., 2005). Thus, 
after expressing different αS variants specifically in DA neurons, I studied the 
sleep and assayed various sleep parameters as outlined and detailed in Figure 15.   
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Figure 15: Flow chart depicting the sleep assay and analysis in Drosophila  
Flies with different genotypes were grown at 250C under LD (light 12h: dark 12h) 
conditions. They were loaded into the Drosophila Activity Monitors (DAMs) in the first 
week after eclosion. Each DAM has 32 channels (8x4), and each channel can 
accommodate a tiny transparent glass tube containing a single fly. Glass tube has a ‘food-
cap’ at one end and a stopper at the other end. DAMs monitor the activity of individual 
flies as they move across the glass tube, and the data from each channel resulting from a 
single fly can be stored and analyzed separately. For all the sleep assays, data has been 
collected in one-minute bins. Inactive periods of a fly are displayed as ‘zero’ (0) in the 
DAM data. Sleep is defined as a bout of 5 or more minutes of inactivity (Shaw et al., 
2000). Our algorithm (see appendix A) scans for the five or more consecutive zeroes with 
one-minute sliding window in the DAM data of individual flies and scores different sleep 
parameters (for e.g. total sleep, bout length, and bout number) with defined criteria.  
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In Drosophila, sleep episodes are interrupted both at day and night. Sleep 
parameters like total amount of sleep, bout length (= average length of sleep 
episodes), and the bout number (= average number of sleep episodes) were 
measured for flies expressing αS and different variants of it as outlined in Fig.8 
(Cirelli et al., 2005; Foltenyi et al., 2007; Joiner et al., 2006; Pitman et al., 2006). 
Figure 16A, B show that flies expressing αS variants exert significant differences 
in the quality of sleep as defined by both bout numbers and bout lengths. 
However, the total length of the sleep episodes of flies of the different genotypes 
was not affected (Figure 16C). Most importantly, the severity of the effects on 
sleep quality, as defined by decreased bout numbers and increased bout lengths as 
compared to the WT-αS and lacZ expressing flies, corresponds to pre-fibrillar 
oligomer forming tendencies of the αS variants, i.e. the flies expressing TP-αS 
were stronger affected than flies expressing A56P-αS or the A53T-αS variants. 
The observed effects only on bout numbers and lengths indicate that the quality of 
sleep is significantly affected. Furthermore, changes in both sleep bout numbers 
and bout lengths, without any effect on total sleep, indicate that the mechanisms 
regulating sleep initiation and sleep maintenance are affected by the expression of 
the mutant αS variants. In addition, flies expressing the TP-αS variant showed a 
highly abnormal sleep profile as compared to the WT-αS and lacZ-expressing 
flies (Figure 16D).  
To ensure that the observed sleep phenotypes are not the consequences of the 
indirect abnormal waking time activity, I further characterized the activity index 
(= activity levels during waking time) of wild type, αS and αS mutant flies. 
Activity index gives information about the activity levels of flies are when they 
are not sleeping, thus it helps us to know whether the effects on sleep episodes are 
because of the indirect abnormal wake-time activity or the direct effects on sleep 
behavior. Absence of any significant differences in the activity index indicates 
that the sleep phenotypes of the flies are not due to an abnormal wake time 
activity (Figure 16E).  Taken together, the flies expressing oligomer-forming 
versions of the αS (TP-αS and A56P-αS) have seriously perturbed sleep quality 
Results 
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in a way similar to the sleep problems observed in PD patients (Arnulf et al., 
2008; Factor, 2002; Zimmerman, 2008; Harbison, 2009). The severity of the 
effects on sleep is directly correlated with the tendency of the mutant αS variants 
to form oligomers in vitro. Thus, the effects on Drosophila sleep not only 
consolidate the pattern of toxicity as observed with the above described 
experiments showing that oligomer forming αS mutants are more toxic than wild 
type, but they can also serve as sensitive readout to correlate the degree of in vitro 
oligomer formation with toxic effects in vivo.  
 
 
 
 
 
 
 
 
 
(on the next page) 
Figure 16: Dopamine dependent sleep deficits in the flies expressing different 
variants of αS  
(A) Bout numbers (sleep episodes) are drastically decreased in the flies expressing the 
oligomer-forming versions of the αS compared to the flies expressing WT-αS and lacZ 
controls. (B) Bout length (average length of sleep episodes) in flies expressing different 
variants of αS is altered in a diametrically opposite fashion to the pattern of bout 
numbers. (C) There are no significant differences in the total amount of sleep in the flies 
expressing different variants of αS.  (D) Sleep profile of TP-αS (red) is drastically altered 
compared to the WT-αS and lacZ flies; light and shaded rectangles represent the 
light/dark (12h: 12h) condition respectively. (E) Activity index (activity levels during 
wake period) of the different genotypes expressing variants of αS. For all the genotypes 
n=32 in all experiments, and the values represent ± SEM; n.s. = non significant P > 0.05, 
* P < 0.01, **P < 0.001. Significance values were determined by one-way ANOVA 
followed by the Newman-Keuls Multiple Comparison post hoc test.  
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3.9 Abnormalities in circadian locomotor activity behavior of 
flies expressing an oligomer-forming αS variant 
In Drosophila, mutations and drugs that affect dopamine signaling have been 
shown to have an impact on a broad range of behaviors such as locomotion, 
learning, sleep, sexual performance, decision-making, mechanosensory startle and 
visual tracking (Andretic et al., 2005; Bainton et al., 2000; Kim et al., 2007; Kume 
et al., 2005; Ye et al., 2004). Dopaminergic neuronal signaling in Drosophila is 
also predicted to have a role in translating the circadian molecular oscillations in 
clock cells into the locomotor activity rhythms (Hirsh et al., 2010; Suh and 
Jackson, 2007). I examined, therefore, the circadian locomotor activity rhythms of 
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flies expressing the “more-oligomer-forming variant” of αS using the TP-αS 
mutation.  
Typical experiments to study circadian rhythms were conducted according to 
the scheme and setup depicted in Figure 17.  The rhythms of circadian locomotor 
activity of Drosophila reflect the direct output of the central circadian clock in the 
brain (Rosato and Kyriacou, 2006). Rhythmic locomotor activity profiles of flies 
are comparable to the sinusoidal waves with period (T), phase (φ), and amplitude 
(A) functions. The same parameters can therefore be used to study activity 
rhythms as outlined in Figure 18. In addition, another interesting feature of 
Drosophila circadian locomotor activity is entrainment (Figure 17A), i.e. the 
phenomenon that circadian clocks can ‘learn’ to anticipate and react to predictable 
external cues rather than merely respond to them. This phenomenon describes an 
anticipation of light transition which results in a slow increase in locomotor 
activity already a few hours prior the actual lights-on/off transition. It reflects the 
ability of the “clock” to start a certain behavior as a reaction to predictable 
external cues such as a lights-on/lights-off transition.  
 
(on the next page) 
Figure 17:  Schematic representation of a typical circadian experiment 
Flies with different genotypes (WT-αS, TP-αS, Lac-Z, w1118) were grown at 250C under 
LD (light 12h: dark 12h) conditions. They were loaded into the Drosophila Activity 
Monitors (DAMs) for circadian locomotor activity monitoring. Each DAM has 32 
channels (8x4) and each channel can accommodate a tiny transparent glass tube with a 
single fly. Glass tube has a ‘food-cap’ at one end and a stopper at the other end. DAMs 
monitor the activity of individual flies, and data from each channel resulting from a single 
fly can be stored and analyzed separately (as described in the Section 2.3.3). In 
Drosophila, locomotor activity rhythms reflect the output rhythms of central circadian 
clock in the brain (Rosato and Kyriacou, 2006). Therefore, the locomotor activity 
recorded from DAMs can used to study the circadian rhythmicity. For the sake of 
explanatory simplicity, I’ve divided the circadian activity experiment into two phases: 
Phase A and B. w1118refers to the fly genotype. 
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Phase A experiments reported in this work involve the following steps: 1) flies were 
entrained under LD (12h: 12h) conditions for 2 days after loading into DAMs, 2) 
experiment was continued for 3-4 more days in DAMs under the same LD (12h: 12h) 
conditions, and 3) the resulting data from the experiment was used for generating 
circadian activity profiles and double-plotted actograms (as exemplified by the w1118 
histogram above). Actograms show the activity (Y-axis) as a function of time (X-axis). 
LD bar on the top of each actogram shows the timings of lights-on/off condition with 
light/dark colors at corresponding time points on the X-axis. Steps covered in the Phase A 
are sufficient for some circadian experiments. w1118refers to the fly genotype. 
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Phase B experiments involve an extension to the Phase A with an additional step of 
switching LD (12h: 12h) condition to the continuous dark (DD) condition and thereafter 
recording the DAM data for at least 4 days. This step is also called free-run because there 
won’t be any external light cue given to the internal clock. Clock is allowed to run freely 
after the entrainment in Phase A. Circadian behavior from the DD experiment (Phase B) 
is useful to analyze the real functionality of internal biological clock. Data was analyzed 
by plotting into actograms and periodograms.  
 
Figure 18: Properties of rhythmic data 
Waves are characterized by period (τ or T), amplitude (A) and phase (φ), illustrated in the 
left panel by two sinusoidal waves having a same τ and A but different φ. 
Correspondingly, the same parameters can be used to describe activity profiles, right 
panel. The activity profiles in this figures have the same τ but different A and φ. They 
represent the average of many flies under DD conditions. M and E indicate the subjective 
morning and evening peaks of activity, respectively (Rosato and Kyriacou, 2006).  
 
Since the TP-αS mutation showed the strongest effects of the αS variants in 
the behavioral assays applied, and it exerted also the highest neurotoxicity effects 
on DA neurons, I specifically assessed the circadian locomotor rhythms of flies 
expressing a Ddc-Gal4 driven TP-αS transgene in DA neurons and compared the 
effects of flies expressing αS-WT and lacZ transgenes under otherwise identical 
conditions. As shown in Figure 19, there were no significant differences between 
the circadian profiles of WT-αS and TP-αS. In particular, the anticipatory 
behavior remained unchanged (see the black arrows in Figure 19A, B). 
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Figure 19: Circadian locomotor activity profiles of young Drosophila expressing 
WT-αS and TP-αS 
(A) Time-series circadian activity profile of the young flies (3-day old) expressing WT-
αS in DA neurons. (B) Time-series circadian activity profile (3 days) of the young flies 
(3-day old) expressing TP-αS in DA neurons. Activity profiles were recorded in the first 
week after eclosion. Experiments (Phase A according to the Figure 17) were done under 
the LD (12h: 12h) conditions; n=32 in each experiment. Light and shaded regions inside 
the large rectangles represent alternating light/dark cycles respectively. Before every 
lights-on/off transition, both WT-αS and TP-αS flies anticipate (black arrows) the 
predictable morning and evening transitions (i.e. their locomotor activity starts increasing 
few hours before the actual lights-on/off transition and reaches peak exactly at the time of 
lights-on/off transition due to startle response). Anticipation is because of the learned 
memory of circadian clock during entrainment. Notice that there is no significant 
difference in the anticipatory behavior of young flies expressing the WT-αS or TP-αS. 
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In contrast to the locomotor activity profiles of young flies, the 
corresponding profiles of the 30-day old flies that express WT-αS or lacZ (Figure 
20A, B) were significantly different from those of flies which express TP-αS 
(Figure 20C) in DA neurons as shown in the overlay profiles (Figure 20D,E). On 
the other hand old A53T-αS expressing flies have very subtle effect on circadian 
locomotor activity (see Figure 26 in the Appendix). However, the results 
demonstrate that the TP-αS expressing old animals have lost the anticipatory 
behavior completely (black arrows in Figure 20).  
 
 
 
 
 
 
(on the next page) 
Figure 20: Circadian locomotor activity profiles of old Drosophila expressing WT-
αS and TP-αS   
(A) Time-series circadian activity profile of the 30-day old flies expressing WT-αS in 
DA neurons; n=45. (B) Time-series circadian activity profile of the 30-day old flies 
expressing lacZ in DA neurons; n=28-32. (C) Time-series circadian activity profile of the 
30-day old flies expressing TP-αS in DA neurons; n=44. (D) Overlay of the activity 
profiles of WT-αS (green) and TP-αS (red). (E) Overlay of the activity profiles of WT-
αS (green) and lacZ (blue). Experiments (Phase A according to the Figure 17) were done 
under the LD (12h: 12h) conditions. Black arrows in each rectangle point the anticipatory 
behavior. Thirty-day old TP-αS expressing flies (red profile) fail to anticipate (i.e. the 
loss of learned circadian memory) the predictable lights-on/off transition; they only have 
a startle response to the sudden changes in environment during the transitions. On the 
other hand 30-day old WT-αS flies (green profile) have normal anticipation like lacZ 
expressing (blue profile) control animals. 
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To assess the effects of WT-αS and TP-αS expression on central circadian 
clock, I also monitored circadian locomotor activities under the constant dark 
(DD) condition (Phase B experiment according to Figure 17) of young (3 days 
after hatching) and old (30-day after hatching) flies that express WT-αS and TP-
αS in neurons (schematic presentation in Figure 21A). The circadian activity of 
young flies expressing WT-αS and TP-αS is not perturbed under the continuous 
dark/free run condition, as shown by both the preserved pattern of activity in 
double-plotted actograms (Figure 21B, C) and normal periodicity (roughly 24 
hours) from the chi-square periodograms (Figure 21D, E). In contrast, however, 
the activity pattern of aged 30-day old flies expressing oligomer-forming TP-αS is 
perturbed. Double-plotted actograms (Figure 21F, G) show that the 30-day old 
flies expressing TP-αS have an altered phase as compared to the WT-αS 
expressing animals. Also the chi-square periodograms (Figure 14H, I) show that 
flies expressing TP-αS have highly affected circadian periodicity (T) of 26.7 
hours as compared to the normal 23.7 hours periodicity (T) of WT-αS flies. In 
summary, flies expressing TP-αS in DA neurons show a severe age dependent 
circadian clock activity defect as shown by both an altered circadian activity 
pattern and circadian periodicity.  
(on the next page) 
Figure 21: Age dependent circadian defects in Drosophila expressing TP-αS in the 
DA neurons 
(A) Schematic of the procedure used for circadian experiment. Flies were initially 
entrained in LD conditions before switching to the ‘free run’ under DD conditions (Phase 
B experiment according to the Figure 17). (B-C) Actograms of the young adult flies (one-
week) expressing WT-αS and TP-αS under the DD conditions. (D) Chi-square 
periodogram of the young flies expressing WT-αS; periodicity of circadian rhythms (T) = 
23.8h. (E) Chi-square periodogram of the young flies expressing TP-αS; periodicity of 
circadian rhythms (T)=23.8h. (F-G) Actograms of 30-day old flies expressing WT-αS 
and TP-αS under the DD conditions. (H) Chi-square periodogram of the 30-day old flies 
expressing WT-αS; periodicity of circadian rhythms (T) = 23.7h. (I) Chi-square 
periodogram of the 30-day old flies expressing TP-αS; periodicity of circadian rhythms 
(T) = 26.7h. n = 32-58 flies in each experiment. In the double-plotted actograms, x-axis 
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represents time of the day (in the span 48 hrs) and each stair on the y-axis represents 
activity-histogram on the corresponding day. In the chi-square periodograms, x-axis 
represents the time in hours and y-axis represents the amplitude of locomotor activity 
wave. 
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3.10 Circadian defects in response to TP-αS expression can 
be mimicked by DA neuron inactivation 
To understand and attribute the specificity of circadian defects caused by 
neurotoxic and oligomer-forming TP-αS expression to the dopaminergic system, I 
have genetically reduced the activity of DA neurons (see Figure 22) by expressing 
EKO/Kir 2.1. The corresponding transgene contains a mutant Shaker potassium 
channel that decreases synaptic excitability and output of the DA neurons (Baines 
et al., 2001; White et al., 2001). Conversely, I have also targeted the expression of 
the bacterial sodium channel (NaChBac) in DA neurons, which was shown 
previously to interfere with DA neuronal function by increasing their excitability 
(Luan et al., 2006). For these experiments I used the TH-Gal4 transgene to drive 
the expression of the UAS-bearing EKO/Kir 2.1 and NaChBac transgenes 
specifically in the DA neurons of central nervous system (Friggi-Grelin et al., 
2003).  
 
 
 
Figure 22: Schematic representation of inactivation/attenuation of the Dopaminergic 
(DA) neurons  
Genetically targeting the expression of one copy of EKO/Kir 2.1 (mutant Shaker 
potassium channel) or NaChBac (bacterial sodium channel) specifically to the DA 
neurons inactivates the neurons (Luan et al., 2006; White et al., 2001), and allows us to 
study DA dependent behaviors in Drosophila.  
 
 
DA Neuron
Inactivation by:
1) EKO/Kir 2.1
2) NaChBac
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The pattern of circadian activity shown in double-plotted actograms (Figure 
23B, D and 23C, E) indicates that the inactivation of DA neurons caused a phase 
shift in circadian clock activity (Figure 23D, E) similar to the phase shift caused 
by the expression of TP-αS (Figure 23B, C). Also the period of circadian 
rhythmicity (T) as calculated by chi-square periodograms show that the normal 
24-hrs period (T) is increased in the flies with inactivated/attenuated DA neurons 
(Figure 23 G, H; 27.6 hours in EKO expressing flies, and 27 hours in NaChBac 
expressing flies). Thus, the periodicity in DA inactivated animals is altered as has 
been observed with the flies that express the TP-αS variant in DA neurons (Figure 
23F).  
 
 
 
(on the next page) 
Figure 23: Circadian defects caused by TP-αS mimic the effects of DA neuron 
inactivation by using genetic methods  
(A) Schematic of the procedure used for circadian experiment. Flies were initially 
entrained in LD conditions before switching to the ‘free run’ under DD conditions (Phase 
B experiment according to the Figure 17). (B-C) Actograms of 30-day old flies 
expressing TP-αS under the DD conditions, n=58. (D) Actogram of flies with 
EKO/Kir2.1 (= the mutant Shaker potassium channel) inactivated DA neurons under the 
DD condition, n=32. (E) Actogram of flies with NaChBac (bacterial sodium channel) 
inactivated DA neurons under the DD conditions, n=32. (F) Chi-square periodogram of 
the 30-day old flies (“old”) expressing TP-αS; periodicity of circadian rhythms (T) = 
26.7h. (G) Chi-square periodogram of flies with the inactivated DA neurons by 
EKO/Kir2.1 expression; periodicity of circadian rhythms (T) = 27.6h. (H) Chi-square 
periodogram of flies with the inactivated DA neurons by NaChBac; periodicity of 
circadian rhythms (T) = 27h. In the double-plotted actograms, x-axis represents time of 
the day (in the span 48 hrs) and each stair on the y-axis represents activity-histogram on 
the corresponding day. In the chi-square periodograms, x-axis represents the time in 
hours and y-axis represents the amplitude of locomotor activity wave. 
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3.11 Defective localization of neurotoxic αS variants to the 
synaptic terminals in vivo 
αS is a presynaptic protein that localizes specifically to the axon terminals of 
neurons (Iwai et al., 1995; Maroteaux et al., 1988; Takamori et al., 2006). αS is 
also known to have an important role in the synaptic function (Chandra et al., 
2005) and hence, synucleinopathies are widely deemed as ‘synaptopathies’. In 
addition, small diffusible pre-fibrillar oligomers formed by the aggregating 
proteins which are associated with neurodegeneration (for e.g. amyloid-β-
oligomers) are known to adversely affect synaptic structure and function 
(reviewed in Haass and Selkoe, 2007).  
As a first step towards understanding the possible mechanism of synaptic 
dysfunction caused by the oligomer-forming TP-αS and human PD associated 
A53T-αS, I started to examine the synaptic behavior of neurotoxic αS variants 
along with WT-αS, using Drosophila larval neuromuscular junction (NMJ) as a 
model. NMJ is one of the most popular genetic model to investigate synapse 
physiology, functional and structural plasticity of the synapse (Catalina Ruiz-
canada, 2006). In order to test whether αS variants interfere with any of these 
processes, I expressed the αS variants in larval NMJs using the motor-neuron 
specific driver OK6-Gal4. Expression and localization of the protein was probed 
by fluorescent immunostaining with the anti-αS antibody (in collaboration with S. 
Sigrist’s lab). As summarized in the Figure 24, TP-αS and A53T-αS failed to 
localize to the synaptic terminals, whereas WT-αS localized to the expected site, 
i.e. the synaptic terminals as shown by its co-localization with a synaptic marker 
called Bruchpilot (BRP). Thus, one aspect of the αS variants is that they fail to 
properly localize at the synaptic terminals of the NMJs.  
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Figure 24: Defective localization of αS variants to the synaptic terminals  
Confocal images of the immunostained larval NMJs (neuromuscular junctions) 
expressing WT-αS (left panel), A53T-αS (middle panel), and TP-αS (right panel). NMJ 
preparations were stained with anti-αS/αSyn (red), anti-Horse Radish Peroxidase/HRP 
(blue), and anti-Bruchpilot/BRP (green) antibodies. Synaptic terminals are marked by 
staining with BRP (green) antibody, and NMJs are marked by the HRP (blue) antibody. 
WT-αS (red) is localized to the synapses (arrow) whereas TP-αS and A53T-αS are not 
targeted to the synaptic terminals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!"#$!%&'() *() !"#$!+,-&'() *() !"#$!&)*()'()
Results 
 66 
 
 
 
 
 
“Why are things as they are and not otherwise?” 
 
(Johannes Kepler) 
 
 
 
4 
Discussion 
 
 
Lewy bodies with fibrillar aggregates of αS are one of the hallmark 
pathological features of Parkinson’s disease and other synucleinopathies. The 
clinico-pathological link between PD and the presence of αS aggregates has been 
clearly established (Shults, 2006). The aggregates of αS are formed as a result of 
the dynamic pathway of aggregation involving a step-wise assembly of the soluble 
pre-fibrillar oligomeric species from the misfolded αS (reviewed in Lansbury and 
Lashuel, 2006). Despite recent advances made in understanding PD pathogenesis, 
the nature of potential pathogenic species in the aggregation pathway of αS has 
remained unresolved. Accumulating body of evidence from the studies on 
neurodegenerative diseases such as Alzheimer’s and Huntington’s disease suggest 
that small oligomeric intermediates in the aggregation pathway, rather than the 
aggregates themselves, are the potent pathogenic species (reviewed in Haass and 
Selkoe, 2007).  
4.1 Accumulation of αS has a toxic gain-of function 
Synucleinopathies including PD are the protein conformational 
neurodegenerative disorders caused by misfolding and aggregation of the αS. 
Misfolding and aggregation of αS is influenced and promoted by genetic and 
sporadic factors. Though αS is a presynaptic protein highly enriched in the brain, 
αS knockout mice show either no or subtle (and opposite) effects on the synaptic 
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transmission (Abeliovich et al., 2000; Cabin et al., 2002; Chandra et al., 2004; 
Yavich et al., 2004). However, overexpression of the αS blocks endoplasmic 
reticulum (ER)-to-Golgi vesicular traffic (Cooper et al., 2006; Gitler et al., 2008) 
and reduces neurotransmitter release by inhibiting synaptic vesicle reclustering 
after endocytosis (Cooper et al., 2006; Nemani et al., 2010). Factors that promote 
accumulation of αS by affecting its steady-state levels either by inhibiting cellular 
protein degradation machinery or duplication/triplication of the αS gene locus 
result in the early-onset PD (Ibanez et al., 2004; Singleton et al., 2003). In 
addition, recent genome-wide association studies have unequivocally revealed that 
SNP (single nucleotide polymorphism) variations within the αS and LRRK2 
(leucine-rich repeat kinase 2) gene loci contribute to the etiology of sporadic PD 
(Simon-Sanchez et al., 2009). Together, these studies strongly suggest that αS 
accumulation has a gain-of-toxic-function, but do not provide any specific clue 
regarding the cause of toxic function.  
4.2 Soluble oligomers of α-synuclein are the likely culprits 
in PD pathogenesis 
It is clear that there is a well-known link between αS accumulation and PD. 
But is it possible that mere accumulation of monomeric αS causes the 
neurodegenerative disease? The following facts indicate (but do not prove) that 
monomeric form of αS is non-toxic: (i) αS is highly expressed in the normal 
brain, (ii) mutations that cause human disease don’t significantly alter the native 
structure of the protein, but reduce its stability and hence its steady-state level in 
vivo while accelerating its aggregation in vitro (Conway et al., 1998; Conway et 
al., 2000; El-Agnaf et al., 1998; Greenbaum et al., 2005), and (iii) the cell death in 
neurodegenerative diseases exhibits stochastic behavior and seems to be highly 
dependent on the expression levels of the aggregation-prone proteins like αS – 
that is, small changes in expression levels have a significant effect on the disease 
onset and progression (Perutz and Windle, 2001). Evidence gathered from the 
studies on PD and other neurodegenerative diseases also supports that monomeric 
forms of the αS and other aggregation-prone proteins are most-likely non-toxic. 
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However, post-translational modifications on monomeric αS may play an 
important role in the modulation of neurotoxicity, as exemplified by the opposing 
effects of Y215 and S129 phosphorylation in the C-terminal region (Chen and 
Feany, 2005; Chen et al., 2009).  
Having discussed the possibility of monomeric αS being non-toxic, I will 
now briefly examine the pathogenicity of insoluble fibrillar aggregates of αS. 
Presence of insoluble fibrillar aggregates of αS in the brains of patients is linked 
to the PD and other synucleinopathies. Considering the propensity of αS to 
aggregate, though it was hypothesized and shown that aggregation of proteins 
apparently triggers a cascade of events that would finally result in the 
neurodegeneration and disease (reviewed in Hardy and Selkoe, 2002; Lansbury 
and Lashuel, 2006), recent studies suggest that fibrils may not be the potent 
pathogenic species (Arrasate et al., 2004; Ross and Poirier, 2004). In addition, 
lack of correlation between the rate of fibril and inclusion body formation with 
neurotoxicity (Chen and Feany, 2005; Outeiro and Lindquist, 2003; Volles and 
Lansbury, 2007), and the presence of amyloid plaques containing αS in the cortex 
of many cognitively normal 70-year-olds indicates that apparently fibrils are not 
the pathogenic species in the aggregation pathway of αS (Dickson et al., 1992). 
Though it is apparently clear that fibrils or inclusion bodies are not the principal 
pathogenic agents, one should not exclude the possibility that they may physically 
obstruct or interfere with normal cellular traffic to some extent. Conversely, 
strong support for the non-toxic nature of fibrils comes from a circumstantial 
evidence which indicates that inclusion bodies/fibrils can indeed act as protective 
repositories in the brain by sequestering pathogenic misfolded and abnormal 
proteins (Caughey and Lansbury, 2003; Tompkins and Hill, 1997). 
Seemingly innocuous nature of αS monomers and fibrils or inclusion bodies 
raises the high possibility of soluble pre-fibrillar oligomers being principal 
pathogenic agents in the neurodegeneration of PD and other synucleinopathies. 
Indeed, experimental evidence from the studies on aggregation-prone proteins like 
Amyloid-β, Huntingtin, and Ataxin-I, which play a key role in prominent 
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neurodegenerative disorders, shows that soluble pre-fibrillar oligomeric forms are 
the potential pathogenic species responsible for neurotoxicity (Arrasate et al., 
2004; Cummings et al., 1999; Haass and Selkoe, 2007; Schaffar et al., 2004). 
Taking it further, soluble amyloid oligomers of Aβ are even known to interfere 
with the synaptic functions and alter electrical properties of the neuronal 
membranes (Cirrito et al., 2005; Snyder et al., 2005; Walsh et al., 2002). In 
addition, the early-onset Parkinson’s disease associated αS mutants, A30P, A53T, 
and E46K, accelerate/promote oligomerization but not the rate of fibril formation 
by αS (Conway et al., 2000). This common property of increased oligomerization 
of the different human PD-causing αS mutants suggests that in fact pre-fibrillar 
oligomers of αS in the aggregation pathway might play a vital pathogenic role in 
conferring toxicity to neuronal systems in the brain. It is also well-known that 
aggregation-prone proteins including αS involved in various neurodegenerative 
diseases form annular pore-like pre-fibrillar oligomeric structures which share 
some morphological features both in vitro and in vivo (Lansbury and Brice, 2002; 
Lashuel and Lansbury, 2006; Pountney et al., 2004). These diffusible annular 
amyloid pore-like oligomers can impair presynaptic functions, neuronal and 
mitochondrial membranes; in addition, they can promote their own accumulation 
by inhibiting proteasome (Kitada et al., 1998; Lansbury and Brice, 2002; Leroy et 
al., 1998). However, the role of pre-fibrillar oligomers of αS in PD pathogenesis 
is still unclear. It needs to be further studied and established systematically by 
linking in vitro and in vivo studies.  
Precisely ascertaining the pathogenic nature of soluble-oligomers of αS in vivo is 
confronted by three potential problems: (i) dynamic nature of αS aggregation, (ii) 
transient and labile nature of pre-fibrillar oligomers, and (iii) lack of αS variants 
with native-like structural properties that can form more pre-fibrillar oligomers 
with less/no fibrils. Since the metastable oligomeric species of αS are very 
difficult to assess and too unstable to characterize (Kim et al., 2009) relative 
importance of these oligomers in PD pathogenesis is still unknown (Lansbury and 
Lashuel, 2006). In this conflicting background of uncertainties, my study is aimed 
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at addressing the key pathogenic role of soluble-oligomers of αS. Towards this 
aim, I adopted a systematic approach to correlate in vitro oligomer formation with 
the in vivo pathogenicity of different rationally designed αS mutations in 
Drosophila. 
4.3 Formation of more pre-fibrillar oligomers by the TP-αS 
and A56P-αS variants  
New αS variants were rationally designed based on the structural 
information of αS (Section 3.1, Figure 8) in order to circumvent the problems 
outlined above for ascertaining the potential pathogenic nature of soluble pre-
fibrillar oligomers of αS (Section 4.2). The goal of rational design was to enrich 
the oligomers of αS or lock the αS in metastable oligomeric state by impinging on 
the cross-β structure to destabilize the formation of αS fibrils. Therefore, 
considering the flexibility of αS backbone in monomeric state and the location of 
β strands in amyloid fibrils (Bertoncini et al., 2005; Heise et al., 2005a; Vilar et 
al., 2008), selective replacement of the Alanine residues with Proline (β strand 
breaker) was done in the key N-terminal regions of αS. The amino acid residues 
A30, A56, and A76 present in the N-terminal region were chosen not only with 
respect to the structural reasons (see, Section 3.1; Figure 8) but also because of the 
lately discovered crucial functional role of N-terminal region in mediating the 
synaptic toxicity caused by αS overexpression (Nemani et al., 2010). In 
compliance with the rational-design principle, TP-αS and A56P-αS variants 
formed high amounts of pre-fibrillar oligomers and showed delayed fibrillation 
kinetics in vitro (Section 3.2; Figure 8 B, C; Karpinar et al., 2009). Strikingly, TP-
αS didn’t form any fibrils under the experimental conditions used for ThT 
aggregation assay, and A56P-αS formed only small amounts of fibrils towards the 
end of assay albeit rather with delayed lag phase (Figure 8 B).  
Though TP-αS and A56P-αS variants have the properties that are 
quintessential to test the hypothesis of whether pre-fibrillar oligomers of αS are 
potential pathogenic species in the neurodegeneration of PD, it is also desirable 
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that the chosen point mutations do not alter the native structural properties of αS. 
As natively unfolded WT-αS is stabilized by the long-range interactions and 
pseudo-secondary structures, we studied the overall secondary and tertiary 
structural changes in the TP-αS and A56P-αS variants by using Circular 
Dichroism (CD) spectroscopy and liquid-state NMR spectroscopy.  Fortuitously, 
we found no marked changes in the structures of αS variants in comparison with 
the WT-αS as reported in my published work (Karpinar et al., 2009). In addition, 
TP-αS and A56P-αS both adopt helical conformation when bound to small 
unilamellar vesicles (SUVs), which is a well-studied property of the WT-αS (see 
details in Karpinar et al., 2009). Adoption of helical conformation when bound to 
SUVs indicates that the mutations introduced in αS variants do not compromise 
the intrinsic conformational flexibility or structural plasticity of the protein that 
may be required to play a functional role in binding to the neuronal or synaptic 
vesicle membranes. Taken together, the αS variants TP-αS and A56P-αS show 
very close structural, and possibly functional, kinship with the native WT-αS in 
their soluble monomeric form.  
Given a high structural resemblance of the TP-αS and A56P-αS to the WT-
αS in their monomeric form but significant differences in soluble pre-fibrillar 
oligomer formation and delayed fibrillation kinetics (summarized in Figure 9), do 
they also share structurally similar aggregation intermediates and follow normal 
(on-pathway) aggregation pathway as WT-αS? The pre-fibrillar oligomeric 
intermediates formed by TP-αS and A56P-αS variants can seed the fibrillation of 
WT-αS. This finding indicates that they are the normal ‘on-pathway’ aggregation 
intermediates (Karpinar et al., 2009). In contrast to the on-pathway aggregation 
intermediates, off-pathway pre-fibrillar intermediates are not the products of 
normal aggregation pathway and are known to be non-toxic (Ehrnhoefer et al., 
2008). Moreover, oligomeric intermediates formed by the new αS variants were 
recognized by conformation-specific A11 antibody (Figure 7 C) – an idiosyncratic 
feature of several pathogenic amyloid oligomers (Kayed et al., 2003). The A11 
antibody recognizes some unknown common structural conformation present in 
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the amyloid oligomers formed by different amyloid forming proteins (for e.g. Aβ, 
αS) involved in the neurodegenerative diseases (Kayed et al., 2003). Together, 
these results indicate that TP-αS and A56P-αS follow a normal aggregation 
pathway and their aggregation intermediates share similar structural properties as 
WT-αS.  
By designing αS variants that share similar properties with the WT-αS in 
their monomeric form, but have different propensities of increased 
oligomerization and decreased fibrillation, we created a platform to precisely test 
and correlate the tendency of in vitro oligomer formation to the in vivo 
neurotoxicity in different animal model systems such as C.elegans, Drosophila, 
and rat mid brain DA neurons. In this study, I specifically generated a new 
Drosophila PD model to test the in vivo neurotoxicity of more-oligomer-forming 
αS variants in an organism that does not contain an αS gen in its genome. 
4.4 An improved Drosophila PD model to study the 
pathogenicity of oligomer-forming αS variants  
Drosophila has no αS or αS-like genes in its wild type genome (Auluck and 
Bonini, 2002; Feany and Bender, 2000). Since PD is caused by the toxic-gain-of 
αS function, lack of endogenous αS in the genome of Drosophila offers a unique 
advantage of testing the pathogenicity αS variants having different in vitro 
properties after introducing them into its genome. Moreover, human αS undergoes 
similar processing events and post-translational modifications in the Drosophila 
(Chen et al., 2009). Though architecture of fly brain is different from the 
mammalian brain, to some extent they share considerable functional similarity 
both in the biological processes and, in the pathways that govern these biological 
processes (reviewed in Colwell, 2007; Hendricks and Sehgal, 2004; Lessing and 
Bonini, 2009). Hence, together with the canonical advantages offered by 
Drosophila as an experimental system, it has become a commendable animal 
model to study various human neurodegenerative disorders including PD.  
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I have used the Phi-C31 based site-specific recombination system (Bischof et 
al., 2007) that allowed precise targeting of different αS variants, TP-αS, A56P-
αS, A53T-αS, and wild type/WT-αS to the identical genomic location (Figure 10; 
Section 3.3; Section 2.2.2). The αS variants, TP-αS and A56P-αS form more 
oligomers in vitro, whereas A53T-αS accelerates or promotes oligomer formation 
in vitro and causes also early-onset PD in humans (Conway et al., 2000). As 
mentioned before, the expression levels of certain disease-associated proteins and 
neurodegeneration are clearly related. For example, triplication or duplication of 
αS gene causes PD (Ibanez et al., 2004; Singleton et al., 2003), and 
overexpression to a lesser extent due to a promoter polymorphism increases an 
individual’s risk of PD (Mueller et al., 2005; Myhre et al., 2008). In light of this 
sensitive connection between neurodegeneration and expression levels of αS, 
advantages offered by the Phi-C31 based site-specific integration system, that is 
similar expression-dosage (see, Figure 10 C for the similar αS expression levels) 
and avoidance of possible ‘position effects’, make it the best Drosophila PD 
model ever developed for the precise comparison of pathogenicity of different αS 
variants in vivo.  
In contrast, all the Drosophila PD models generated heretofore (see, Feany 
and Bender, 2000; Liu et al., 2008) were based on introducing human αS gene 
into the Drosophila genome randomly with the help of P-element mediated 
transgenesis (Rubin and Spradling, 1982; Spradling and Rubin, 1982). A major 
caveat associated with the P-element based approach is the variability of αS 
expression caused by ‘position effects’, i.e. the expression level of the transgene 
varies in dependence of its site of genomic localization. As mentioned above, 
having a precise control over the expression levels of different αS variants is of 
paramount importance in this type of study to allow for accurate qualitative and 
quantitative functional comparisons.  
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4.5 Motor deficits and reduced longevity: human PD-like 
features in the flies expressing pre-fibrillar oligomer-forming 
αS variants 
Climbing ability and longevity are the two straightforward preliminary 
assays to follow neurodegeneration in the Drosophila models of 
neurodegenerative diseases (reviewed in Lessing and Bonini, 2009). It is also 
known from the previous studies that 3-4 week-old flies expressing human PD-
causing αS mutant (A30P-αS), and  LRRK2 (leucine-rich repeat kinase)-linked  
PD mutant (LRRK2-G2019S) show motor deficits in the climbing assay (Feany 
and Bender, 2000; Liu et al., 2008). Climbing assay measures the motor 
performance as a read-out of the normal ability of flies to climb up (negative-
geotactic behavior). In the specially designed climbing apparatus (Figure 11 A), 
light source on top served as an attraction cue for the flies to motivate them to 
climb up. As dopamine (DA) is a ‘pleasure molecule’ involved in the reward 
behavior in response to positive attraction/reward cues (Ebstein et al., 2010; 
Johnson and Kenny, 2010), flies with reduced levels of DA might also show 
affected phototactic behavior. In the climbing assay that measures both motor 
performance (negative-geotactic) and positive-phototactic behavior of the flies, 
more-oligomer-forming TP-αS and A56P-αS expressing flies show severe motor 
deficits (Figure 11 B; Section 3.4). Interestingly, the TP-αS flies show highly 
impaired motor performance compared to the A56P-αS, which corresponds to 
their ability to form more oligomers of αS in in-vitro. Motor deficits in A53T-αS 
flies are comparable to the deficits in A56P-αS flies (Figure 11 B; Section 3.4).  
It seems advantages offered by the accurate control of expression levels of 
different αS variants, and a new set-up that allows to simultaneously assay both 
negative-geotactic and positive-phototactic behavior of the flies have already 
manifested by detecting the sensitive differences in motor deficits caused by the 
overexpression of WT-αS and human PD-linked A53T-αS. In contrast to this 
observation, A53T-αS didn’t show enhanced toxicity in the climbing assay 
compared to WT-αS in the Drosophila PD model generated by Feany and Bender 
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(2000) by randomly introducing the αS gene into the fly genome with the help of 
P-element mediated transgenesis. 
Like in the climbing assay decribed above, the more oligomer-forming TP-
αS flies also show dramatically reduced longevity in comparison with the WT-αS 
and Lac-Z expressing animals (Figure 12; Section 3.5). Though WT-αS 
expression doesn’t show any significant effects on the climbing ability, it results 
in slightly reduced longevity compared to the Lac-Z expressing animals. This is 
consistent with the ability of WT-αS to cause toxicity when overexpressed for a 
very longtime. Absence of any motor deficits in the 30-day old post-eclosion flies 
expressing WT-αS animals suggests that at similar expression levels ‘more 
oligomer-forming’ αS variants cause early-onset of motor deficits in the flies. 
Furthermore, highest oligomer-forming version TP-αS showed highest toxicity in 
both climbing and longevity assays whereas the A56P-αS and A53T-αS showed 
comparably similar levels of toxicity, giving a direct firsthand correlation between 
the soluble-oligomer formation and toxicity in the preliminary assays of 
neurodegeneration. 
4.6 Degeneration of DA neurons in the flies expressing pre-
fibrillar oligomer-forming αS variants 
Since age dependent loss of dopaminergic neurons (DA neurons) is the 
hallmark feature of PD, I followed degeneration of DA neurons in the adult 
Drosophila brain. The DA neuronal numbers in the DL (dorso-lateral) and DM 
(dorso-medial) clusters of the young flies (2 days after hatching) expressing 
different variants of αS are normal and show no sign for degeneration (Figure 13 
B, C; Section 3.6.1), whereas the old flies (30 days after hatching) show 
significant differences in the numbers of neurons (Figure 14 B, C; Section 3.6.2). I 
observed that flies expressing the oligomer-forming αS-TP have lost highest 
number of DA neurons in both DM and DL clusters.  As noted in previous assays 
(Section 3.4, 3.5), the neurotoxicity exhibited in response to the expression of the 
A56P-αS and A53T-αS mutants was similar but clearly less pronounced than in 
response to TP-αS expression (Figure14 B, C). In all cases, the toxic effect was 
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more pronounced than that observed with WT-αS expression, which does not 
cause a significant neuronal loss when compared to control animals expressing the 
Lac-Z marker under otherwise identical conditions (Figure 14 B, C).  
Although progressive neuronal loss is an important feature of PD and other 
neurodegenerative diseases, some neurological impairment may reflect 
dysfunction rather than loss of neurons. Moreover, neuronal systems have 
absolutely high levels of plasticity and complex compensatory mechanisms that 
come into play before they finally resort to degeneration. While observed 
neuronal loss definitely gives a measure of the neurotoxicity exhibited by different 
αS variants, it does not give any clue regarding the neuronal dysfunction caused 
by αS variants. For example, though neuronal loss is comparably similar in the 
flies expressing A56P-αS and A53T-αS, it is still possible that A56P-αS causes 
more neuronal dysfunction than A53T-αS as reflected in the stronger motor 
deficits that were observed in the climbing assay applied. Interestingly, as 
expected from the effects on climbing and longevity, TP-αS expressing flies have 
lost highest number of DA neurons. This finding provides support for the 
argument that soluble pre-fibrillar oligomers are the cause, and possibly the 
principal pathogenic agents causing neurodegeneration associated with PD. 
However, though DA neurons are most vulnerable to the αS toxicity, neuronal 
degeneration in PD patients is not limited to the DA neurons but rather extends to 
other neural regions as the disease progresses (Farrer, 2006).  
4.7 Non-motor deficits in PD flies expressing pre-fibrillar 
oligomer forming αS variants  
The clinical presentation of PD with motor symptoms has partly 
overshadowed the focus on the study of non-motor symptoms of PD. However, 
non-motor symptoms such as sleep abnormalities and compromised circadian 
function (Factor, 2002; Whitehead et al., 2008) highly affect the quality of life in 
human PD patients as much as clinical motor symptoms. Research on the 
pathophysiology of non-motor symptoms has been hindered, in part, by the lack 
of an appropriate animal model that can reproduce the non-motor symptoms of 
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PD (Sheila M. Fleming, 2009). Therefore, I’ve studied sleep abnormalities and 
circadian locomotor activity rhythms in the Drosophila PD model, both to 
elucidate the pathogenicity of pre-fibrillar oligomer forming variants, and to 
eventually develop a simple animal model for studying the pathophysiology of 
non-motor symptoms in Parkinson’s disease.  
4.8 Sleep abnormalities in the PD flies  
Cardinal features of mammalian sleep are conserved in Drosophila 
(reviewed in Colwell, 2007; Hendricks and Sehgal, 2004). In the past few years, 
Drosophila has emerged as a commendable non-mammalian model to understand 
the neurogenetics of sleep (Harbison et al., 2009; Ho and Sehgal, 2005) after it 
was demonstrated that the quiescence in Drosophila represents a sleep-like state 
in flies. In addition, flies show canonical features of the vertebrate sleep: (i) 
increased arousal threshold or reduced responsiveness to mechanical stimuli,  (ii) 
homeostatic drive to recover from the lost sleep, (iii) fragmented sleep in older 
flies, (iv) response to the drugs like caffeine and methamphetamine, (v) conserved 
sleep/wake signaling (cAMP and EGFR), and (vi) conserved molecular response 
to sleep deprivation such as up-regulation of BiP/GRP78 gene expression 
(Zimmerman et al., 2008).   
Since sleep abnormalities are one of the prominently reported non-motor 
symptoms in PD patients, I have examined the sleeping behavior of flies 
expressing different αS variants by analyzing various sleep parameters such as 
bout numbers, bout lengths, total sleep, sleep profiles, and activity index as 
outlined in Section 3.8 (see also Figure 15). The flies expressing ‘more-oligomer-
forming’ variants of αS, TP-αS and A56P-αS show sleep abnormalities. They 
have a decreased number of sleep-bouts and an increased length of sleep-bouts. 
However, the total length of the sleep period is not altered. These findings suggest 
that sleep abnormalities are most likely due to the effects on the mechanisms 
regulating sleep initiation and maintenance (Section 3.8; Figure 16 A-C). 
Moreover, the effects on Drosophila sleep not only consolidate the pattern of 
toxicity observed in previous assays (i.e. the climbing and longevity assays as 
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well as DA neuronal death), but also show that oligomer-forming αS mutants are 
more efficient to cause the PD-associated effects than the wild type αS protein. 
Thus, sleep abnormalities in flies expressing αS variants can serve as a sensitive 
readout to correlate the degree of in vitro pre-fibrillar oligomer formation with 
PD-related effects in vivo (Figure 16). Among the different αS variants tested, the 
TP-αS variant stands out by causing highest intensity of sleep abnormalities 
(Figure 16 D). The effects are less pronounced in response to the expression of the 
A56P-αS variant, a finding that parallels the pre-fibrillar oligomer-formation 
tendencies of the two αS variants in vitro.  
Can sheer DA neuronal dysfunction that is not associated with degeneration 
cause sleep abnormalities? Since sleep was studied in the flies during their first-
week after eclosion and as there is no DA neurodegeneration observed in the first-
week (Section 3.6.1; Figure 13), sleep abnormalities observed in this assay is 
likely to be caused by DA neuronal dysfunction rather than by their degeneration. 
Though DA plays a similar role in sleep/wake control in both mammals and 
Drosophila (reviewed in Zimmerman et al., 2008), effect of the DA neuronal 
dysfunction on Drosophila sleep can be mechanistically explained by the fact that 
DA neurons send their projections to the lobes of mushroom-body (MB) (Zhang 
et al., 2007), a brain site shown to play a dynamic role in sleep regulation (Joiner 
et al., 2006; Pitman et al., 2006). In addition, a very recent study focused on 
elucidating a link between memory deficits and abnormal sleep in PD flies also 
emphasizes the pathological relevance of sleep in neurodegeneration of PD 
(Seugnet et al., 2009). The results shown here do not allow to distinguish between 
DA dysfunction and degeneration as the cause of the sleep abnormalities flies, but 
they suggest that the neuronal degeneration is less likely to be the cause of the 
sleep effects observed. In fact, my results show that flies expressing toxic variants 
of αS show sleep abnormalities in a similar way like human PD patients, and the 
sleep deficits in Drosophila can be used a sensitive readout to correlate the pre-
fibrillar oligomer-forming tendency of αS in vitro to the neurotoxicity in vivo. It 
has been shown that pharmacological imposition of sleep can improve cognitive 
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functions in a mouse model of Huntington’s disease (Whalley, 2007), in light of 
this protective role of sleep in neurodegenerative diseases, the newly introduced 
Drosophila PD model provides now a valuable organism tool for possible screens 
in order to identify therapeutic chemical lead compounds to eventually treat the 
sleep abnormalities in PD patients. 
4.9 Circadian dysfunction in the flies expressing most toxic 
oligomer-forming TP-αS  
Disturbances in the circadian activity pattern are common among patients 
with severe PD and related neurodegenerative disorders (Factor, 2002; Whitehead 
et al., 2008). Based on the conserved features of the Drosophila circadian clock 
and DA neuronal signaling, it was interesting to ask whether flies with severe PD-
like phenotypes also show circadian activity deficits. Moreover, dopaminergic 
neuronal signaling in Drosophila is predicted to have a role in translating the 
circadian molecular oscillations in clock cells into the locomotor activity rhythms 
(Hirsh et al., 2010; Suh and Jackson, 2007), and like in mammals it is implicated 
to have a role in the regulation of arousal or sleep/wake cycle (Dzirasa et al., 
2006; Ebstein et al., 2010).  
Since TP-αS showed strongest neurotoxic effects among the αS variants in 
all the behavioral assays tests applied, and led to a severe degeneration of DA 
neurons in the DM and DL clusters in adult fly brain, I have also examined the 
effects on circadian locomotor activity rhythms in the flies expressing TP-αS. As 
in the human PD, flies expressing TP-αS also caused circadian deficits in an age-
dependent manner. The circadian locomotor activity profiles of young flies (3-day 
old) was not significantly affected in response to TP-αS as compared to αS 
expression, whereas the circadian locomotor activity profiles of old (30-day old) 
WT-αS and TP-αS flies (compare Figure 19 A,B and 20 B, C) differ significantly, 
i.e. the activity profile of the 30-day old TP-αS expressing flies was aberrant 
when compared to the activity profiles of the WT-αS and Lac-Z flies that served 
as controls. Most notably, the old TP-αS expressing flies have lost their 
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‘anticipatory behavior’ in response to circadian changes in the external 
environment (Section 3.9; Figure 20).  
Furthermore, young flies expressing WT-αS and TP-αS have normal 
circadian activity pattern (Section 3.9; Figure 21 B, C) and circadian periodicity 
(T = 23.8 h) (Figure 21 D, E) under the constant dark conditions (DD/free-run; see 
Figure 17 for the general scheme), In contrast, the old TP-αS expressing flies 
show an abnormal phase-delayed activity pattern (Figure 21 G) associated with an 
increased circadian periodicity (T = 26.7 h) (Figure 21 I) when compared to the 
αS-WT expressing animals (Figure 21 F, H).  
In summary, these results show that the observed dysfunction and 
degeneration of DA neurons in response to the TP-αS expression result in an 
altered circadian locomotor activity. This observation further strengthens the 
proposed role of DA neurons in the regulation of circadian locomotor activity 
(Hirsh et al., 2010; Suh and Jackson, 2007). However, the effects observed on 
circadian locomotor activity rhythms might be the result of indirect perturbations 
caused by the neuronal dysfunction or degeneration of the DAs, rather than a 
direct consequence of the dysfunctional or degenerated DA neurons. Despite 
prevailing mechanisms of ‘degeneracy’ and ‘compensatory effects’ for a 
malfunction in the brain, impairment of a single neuronal circuit can influence the 
functions of an entire network of inter-connected neuronal circuits. Therefore, 
dysfunction and degeneration of one element in response to TP-αS expression, 
such as the DA neurons as shown here, can also affect a behavior that is under the 
control of a neural circuit and thus, we cannot decide whether TP-αS expression 
lead to circadian deficits even if the DA neurons have a role down-stream of the 
clock neurons as predicted by Suh and Jackson, 2007, or whether they have a 
direct function in the process. However, the close vicinity of the DL clusters and 
the so-called PDF-neurons, a group of clock neurons that express a neuropeptide 
called Pigment Dispersion Factor, and the spatial overlap of the PDF neuronal 
arborizations and DA neuronal cell bodies in the fly brain (own observation) 
imply that the effects on circadian locomotor activity rhythms caused by TP-αS 
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expression are more likely indirect effects. Such effects could result from an 
improper translation of circadian molecular oscillations in PDF neurons into the 
activity rhythms.  
I have inactivated the DA neurons directly by using genetic methods 
(Section 3.10; Figure 22), and I have examined the circadian locomotor activity 
rhythms in the flies where DA neurons were inactivated by the targeted 
expression of the shaker mutant EKO/Kir 2.1 or the bacterial sodium channel 
NaChBac (Luan et al., 2006; White et al., 2001) in DA neurons using UAS/GAL4 
system (Brand and Perrimon, 1993). The abnormal circadian activity patterns of 
flies expressing EKO/Kir 2.1 and NaChBac in the DA neurons mimic the 
abnormal pattern of circadian activity after TP-αS-expressing in old flies (Section 
3.10; Figure 23 B-E) both with respect to the observed phase-delay and the 
abnormal circadian periodicity of about 27 hrs instead of 24 hrs (Section 3.10; 
Figure 23 F-H). These results show that the abnormal effects on circadian 
locomotor activities observed after the expression of pre-fibrillar oligomer 
forming TP-αS are indeed specific effects due to the loss of DA neuronal 
functions. The results shown here, therefore, provide strong evidence for the 
possible role of DA neurons in translating circadian molecular oscillations into the 
locomotor activity rhythms. In addition, these results also indicate that we can use 
Drosophila as an experimental system to address the mechanism of the circadian 
activity deficits associated with the PD. 
4.10 Synucleinopathies are synaptopathies: defective 
localization of the neurotoxic αS variants at the synaptic 
terminals of larval NMJs 
Because of the presynaptic localization (George et al., 1995; Iwai et al., 
1995) and predicted role of αS in the synaptic function (Cabin et al., 2002; 
Chandra et al., 2004), synucleinopathies are widely deemed as ‘synaptopathies’. 
As an initial step towards understanding of the mechanism of pathogenesis at 
synapse level, I have examined the localization of the different αS variants at the 
synaptic terminals of larval Neuromuscular Junctions (NMJs) after their targeted 
Discussion 
 83 
expression in motor-neurons (Section 3.11; Figure 24). As shown in the Figure 24, 
the pathogenic αS variants TP-αS and A53T-αS fail to properly localize at the 
synaptic terminals of NMJs, whereas the WT-αS shows a normal localization 
pattern as observed in mammals.  Although it is clearly premature to extrapolate 
and envisage a mechanism of neurotoxicity merely from the improper localization 
of pathogenic αS variants at the motor-neuron NMJs, it is likely that the lack of 
proper folding and formation of pre-fibrillar oligomers of the mutant αS variants 
can elicit an ‘unfolded protein response’ (UPR) and block the ER-to-Golgi traffic 
(Cooper et al., 2006), consequently affecting the endocytosis and other synaptic 
functions in neurons. In addition, the neuronal loss observed in the flies 
expressing the pathogenic oligomer-forming αS variants can be attributed to the 
fact that an UPR leads to the programmed cell death in nervous system (Bredesen 
et al., 2006). In both cases, NMJ function would be severely impaired. This 
conclusion is consistent with the results of recent electrophysiological studies on 
hippocampal slices and rat midbrain dopamine neurons which overexpress αS, 
showing reduced neurotransmitter release that resulted from the inhibition of 
synaptic vesicle reclustering at the nerve synapse (Nemani et al., 2010) without 
having any obvious effects on ER-to-Golgi traffic. In fly larvae, however, the 
mislocalized pathogenic αS variants had no effects on excitatory junctional 
currents (EJCs), paired-pulse ratios and miniature EJCs (unpublished data 
obtained in collaboration with S. Sigrist´s Lab, FU Berlin). These results suggest 
that expression of αS, which is normally not present in flies, and the different pre-
fibrillar oligomer-forming αS variants in motor-neurons do not interfere with the 
process of synaptic transmission at the NMJ as observed in mammals. It is 
therefore unlikely, that the overexpression of αS and αS variants interferes with 
cell trafficking as proposed above or with synaptic transmission per se but rather 
than with a cellular function not directly involved in synaptic transmission at the 
NMJs. Alternatively or in addition, αS overexpression may not interfere with the 
synaptic transmission system at larval Drosophila NMJ which involves the 
glutamatergic system only. Moreover, it is possible that pathogenic synaptic 
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deficits in response to αS and αS variant expression can only be observed in adult 
Drosophila NMJs, since aging is considered as one of the risk factor associated 
with the PD pathogenesis. Confirmation of this proposal has to await further 
studies on the adult NMJs of the fly. 
4.11 Conclusion 
Studies on PD are limited to material of human patients. This limitation 
requires model organisms in which conclusions derived from patient studies can 
be critically tested and the proposed factors and the mechanisms leading to the 
disease can be unraveled. My results show that many aspects of PD, including 
sleep behavior and altered circadian rhythms can be observed in αS-expressing 
Drosophila, an organism that normally lacks αS or αS-like genes in its genome. 
Rationally designed αS mutants, which form more αS pre-fibrillar oligomers in 
vitro (Karpinar et al., 2009) show an inextricable direct correlation between the 
propensity to form more αS pre-fibrillar oligomers in vitro and corresponding 
neurotoxicity in vivo (see caricatured summary in Figure 25). The results obtained 
with Drosophila were corroborated by results concurrently obtained with 
established PD models such as C.elegans (collaboration with S. Eimer’s lab) and 
rat midbrain dopamine neurons (collaboration with S. Kuegler’s lab) conclusively 
demonstrating that pre-fibrillar oligomers are the most toxic pathogenic species in 
the neurodegeneration of PD (see results in the Karpinar et al., 2009). In addition, 
these findings demonstrate that these model organisms can be used to assess the 
toxicity and biological significance of any kind of αS mutants, even though it is 
technically impossible to directly visualize and quantify the pre-fibrillar oligomers 
in vivo (Kim et al., 2009).  
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Figure 25:  Caricatured representation of the conclusive summary  
Representation of experimental summary of the correlation between in vitro behavior of 
the αS variants (black cones) and pathogenicity in vivo (red cones) in different model 
systems including the Drosophila. Blunt-end (maximum) to tapered-end (minimum) of 
the cone represents an arbitrary quantitative range.  
 
Drosophila has the major advantage that transgenes containing αS or any kind of 
αS mutations can be placed exactly into the same chromosomal location and thus, 
their expression is not affected by “position effects” that may lead to different 
expression levels of the transgenes. In addition to this technical improvement, my 
results also show that the Drosophila PD model not only be used to understand 
the pathophysiology of both motor symptoms and cellular aspects of the 
degeneration but also to examine the non-motor PD symptoms such as sleep 
behavior and the effects on the circadian rhythm of PD patients, possibly also 
including other synucleinopathies. Most importantly, this study on elucidating the 
role of soluble pre-fibrillar oligomers of αS in PD sheds a new light on the nature 
of pathogenic species by showing that the αS variants which form more pre-
fibrillar oligomers exhibit highest neurotoxicity. It is therefore possible, to assess 
the biogenesis of aggregopathies and to unveil the pathology of the process 
mechanistically. Furthermore, organism-based assays for drug screening using the 
Drosophila systems come within reach. 
 
Fibril
Formation
Neurotoxicity
Impairment of 
DA-Dependent
Behaviour
Reduced
Survival
WT-!S
TP-!S
A53T-!S
A56P-!S
 Oligomers
Pre-"brillar
Discussion 
 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Science… never solves a problem without creating ten more.”  
 
(George Bernard Shaw) 
 
 
 
 
 
5 
Summary and Outlook 
 
αS is an abundantly expressed, natively unfolded pre-synaptic protein in the 
central nervous system of human brain. Although details about its function are 
still unknown, its aggregation in brain cells leads to neurodegeneration in the 
Parkinson’s disease (PD) as well as other diseases collectively referred to as 
“synucleinopathies”. Synucleinopathies are clinicopathologically characterized by 
the loss of DA neurons and the presence Lewy bodies enriched with αS 
aggregates. It is well established that the aggregation process of αS is the 
harbinger of pathogenic events that finally leads to neurodegeneration in PD and 
synucleinopathies. However, the nature and identity of pathogenic species in the 
aggregation pathway of αS is still a matter of controversial debates. It is for 
example undecided whether αS fibrils, which are the end products of the αS 
aggregation, or the pre-fibrillar oligomers, representing the intermediates in the 
αS aggregation, are the effective pathogenic species. Accumulating evidence 
suggests that pre-fibrillar oligomers of the aggregation-prone proteins such as 
Amyloid-β and Huntingtin are the potential pathogenic species, which cause the 
neurodegeneration of the respective diseases. Since it is believed that 
neurodegenerative diseases caused by or resulting in protein aggregation might 
have common pathogenic mechanisms, I have investigated whether the emerging 
paradigm of potential pathogenesis vested in pre-fibrillar oligomers holds also 
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true for the αS soluble oligomers in the pathogenesis of PD. The systematic 
reverse-genetics approach taken to critically address this problem involved the 
following steps:  
• Generating αS variants that can form more pre-fibrillar oligomers by using 
a structure-based rational design.  
• Testing the in vitro pre-fibrillar oligomer formation of different αS 
variants, and attempting to characterize them. 
• Generating different animal models to test the pathogenicity of αS 
variants. 
• Translating the experimental observations made on the in vitro behavior of 
αS variants into animal models (C.elegans, Drosophila and rat mid brain 
DA neurons) by asking whether the tendency of formation of pre-fibrillar 
oligomers in vitro can be correlated with neurotoxicity in vivo. 
In this context, I have generated an improved experimental system using 
Drosophila melanogaster as a model organism in which questions concerning the 
toxicity and biological significance of αS and pre-fibrillar αS mutants can be 
addressed. αS variants were generated, by a structure-based rational design, which 
remain longer in the pre-fibrillar oligomer-forming stage than wild type αS. They 
include TP-αS and A56P-αS which showed a very close structural resemblance 
and similar conformational flexibility in their native monomeric form to the WT-
αS but exhibited remarkable differences in their fibrillation propensities. Both TP-
αS and A56P-αS had an increased propensity to form more pre-fibrillar oligomers 
and decreased propensity to form fibrils in vitro. Among the different αS variants, 
TP-αS formed highest amount of pre-fibrillar oligomers followed by the A56P-
αS. We critically tested the pathogenicity of these ‘more-oligomer-forming’ 
variants of αS in comparison with the effects of the WT-αS and the A53T-αS 
mutation that is known to cause human PD using in the above-mentioned different 
PD model organisms.  
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I have generated a new and improved Drosophila PD model by introducing 
αS variants with different oligomer-forming tendencies into the fly genome, 
which normally lacks αS and αS-like genes. For generating the transgene-bearing 
flies, I have used the Phi-C31 based site-specific recombination technique to 
circumvent possible problems associated with different expression levels of the 
inserted transgenes due to so-called ‘position effects’ that derive from different 
genome integration sites. This system, therefore, allows an unbiased functional 
comparison of the pathogenicity of different αS variants when expressed in the 
same cells of the fly. 
After generating the Drosophila PD model by introducing different αS 
variants into the fly genome, I have examined both motor symptoms and non-
motor symptoms that are known from PD patients. This pioneering approach 
allowed me to accurately compare and correlate the propensity of pre-fibrillar 
oligomer formation by the αS variants to their in vivo pathogenicity. The results 
show that this comprehensive yet easily manageable experimental system could 
be useful for both to assess the mechanisms of PD pathogenesis and to screen for 
chemicals serving as lead compounds to develop therapeutic tools in order to 
intervene with PD symptoms.  
In assays designed to assess neurodegeneration, climbing (= negative 
geotaxis and positive phototaxis) and longevity, the ‘more-oligomer-forming’ αS 
variants showed more severe effects than αS expression in the corresponding 
cells. Consistent with its ability to form the highest amount of pre-fibrillar 
oligomers among the αS variants tested, TP-αS also showed most severe effects 
in both the climbing and longevity assay. With respect to its strongest effects in 
vivo, TP-αS was followed by the A56P-αS mutation and the A53T-αS variant 
known to cause PD in human. In addition, flies expressing the more-oligomer-
forming αS variants had lost a higher number of DA neurons in the DL and DM 
clusters of the adult brain, an effect that was found to be age-dependent. In 
contrast, WT-αS expressing flies or flies expressing Lac-Z showed no 
degeneration compared to the expressing control flies. The results indicate that the 
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fly system can be used to assess the capacity to form pre-fibrillar oligomers of αS 
variants by the extent to which they cause neurodegenerative effects in the 
organism.  
Most importantly, however, I have established the first animal PD model that 
can be used to study not only neurodegenerative processes but also non-motor 
symptoms known from PD patients. The available evidence suggests that the 
Drosophila PD model recapitulates sleep abnormalities and circadian deficits that 
are also observed with humans suffering from PD. I found that the circadian 
deficits observed in flies that express the most toxic TP-αS variant are DA 
neuron-dependent effects as the genetic inactivation of DA neurons caused the 
same circadian deficits as observed after expression of the αS mutation. Although 
we do not know whether the abnormal sleep behavior of the TP-αS expressing 
flies is due to direct or indirect effects of the dysfunctional DA neurons, the 
sensitive and clearly graded effects on sleep correlates again with the more-
oligomer-forming tendencies of the αS variants used in the experiments. 
Therefore, not only neurodegeneration but also sleep abnormalities can be used as 
a sensitive readout to correlate the oligomer-forming tendency of αS in vitro to 
the neurotoxicity in vivo. Given the conserved role of DA neuronal signaling in 
mammals and Drosophila, and protective effects of sleep on neurodegeneration, 
we can use the Drosophila model to even screen for therapeutic compounds for 
alleviating the sleep abnormalities in the human PD. I also found that the more-
oligomer-forming αS variants failed to localize to the synaptic terminals of the 
Drosophila larval NMJs whereas the WT-αS localized properly to the synaptic 
terminals as observed in mammals. Whether the mislocalization of TP-αS has any 
effect on synaptic function, which do not involve the glutamatergic system during 
the larval stage, and whether a possible effect is age-dependent remains to be 
shown.  
 
Taken together, this work has shown that more-oligomer-forming αS 
variants are highly pathogenic. This observation strengthens the hypothesis that 
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pre-fibrillar oligomers are a potent pathogenic αS species in PD and possibly also 
in other synucleinopathies. The severe pathogenic effects caused by the more-
oligomer-forming αS variants are also corroborated by the results from other 
animal models that were concurrently used to address the same question. Whether 
the pre-fibrillar oligomers are the primary cause of neurodegeneration or whether 
this process eventually requires αS aggregation in addition to the toxic oligomers 
remains to be shown. However, in addition to supporting the hypothesis that the 
pre-fibrillar status of αS is at least toxic for neurons, my results establish a novel 
experimental system in which the non-motor aspects of PD, the mechanism of 
cellular action and likely even the efficacy of lead compounds leading to 
therapeutic drugs can be addressed in the future.  
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A 
Appendix 
 
Algorithms used for the sleep analysis in Drosophila 
The following ‘source code’ (SleepAnalysis.scr) was used for the sleep analyses 
carried out in this study. Running “SleepAnalysis.scr” (Script 1) elicits and runs 
three AWK programmes subsequently: sleepAnalysis.awk (Script 2), 
sleep30minRed.awk (Script 3), and outlierFly.awk (Script 4). Data collected from 
the Drosophila Activity Monitors (DAMs) in one-minute bins was used as an 
input for the programme. Output of this procedure gives a sleep-data matrix 
containing the defined sleep parameters in (see Figure 15, Section 3.8) for all the 
flies. All the comments used to explain the programming steps are preceded by 
the symbol ‘#’.  
 
Script 1 
 
SleepAnalysis.scr 
 
#!/bin/ksh 
 
##################################################################
###### 
# program for analysis of Drosophila sleep data 
# 
# required awk programmes: 'outlierFly.awk' 'sleepAnalysis.awk' and 
'sleep30minRed.awk' 
# 
##################################################################
##### 
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### user input 
 
# bad data sets (that will not be included into analysis) 
set -A badData  Madhu11M002C09 Madhu11M002C17  
 
startDate="20070720 0600"  # starting date 
#startDate="20070718 0000"  # starting date 
nHour=24    # number of hours to be analyzed 
 
sleepFile="dSleep_M005-MO06_aSyn-A53T-6.txt"   # major output 
file for sleep 
dataFile30minRaw="dSleep30min_M005-MO06_aSyn-A53T-6.txt" # sleep 
per 30 minutes ==> last column contains average value for all flies 
 
 
# reformatted data files 
dataFile="dataMatrixRaw_M005-MO06_aSyn-A53T-6.txt" # data matrix with all 
data reformated 
dataFileSel="dataMatrix_M005-MO06_aSyn-A53T-6.txt" # data matrix with data 
selected for analysis 
 
 
 
#### 
# temporary files created during analysis 
tempFile="temp.txt" 
tempFileB="temp2.txt" 
tempFileC="temp3.txt" 
 
 
##################################################################
## 
###  main 
##################################################################
## 
 
 
echo "REMARK: $# files were supplied." 
echo "REMARK: $@" 
echo 
"=========================================================
===" 
echo "" 
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### 
### Cleaning up 
### 
 
if [ -s $tempFile ] 
then 
   rm $tempFile 
fi 
if [ -s $tempFileB ] 
then 
   rm $tempFileB 
fi 
if [ -s $tempFileC ] 
then 
   rm $tempFileC 
fi 
 
 
### 
### Conversion and merging of data files 
### 
 
for m in "$@"  
do 
  echo "REMARK: Conversion of $m ..." 
  ((flagBad=0)) 
 
  for n in ${badData[*]} 
  do 
    if [ "$m" = "$n" ] 
    then 
       ((flagBad=1)) 
        echo "WARNING: $n excluded." 
    fi 
  done 
 
 
  if [ $flagBad -eq 0 ] 
  then 
       if [ "$m" = "$1" ] 
       then 
 
          tr '\015' '\012' < $m | sed '/^$/d' > $tempFile 
          wc -l $tempFile | read nLine dummy 
 
          echo "REMARK: # of data points in input files: $nLine." 
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          echo "REMARK: Conversion of first data file $m successful." 
          echo "" 
       else 
 
          tr '\015' '\012' < $m | sed '/^$/d' > $tempFileB 
          wc -l $tempFileB | read nLineB dummy 
 
          if [ $nLine -eq $nLineB ] 
          then 
            paste $tempFile $tempFileB > $tempFileC 
            mv $tempFileC $tempFile 
 
            echo "REMARK: Conversion of $m conversion successful." 
          else 
             echo "WARNING: $m does not have the same # of lines." 
             echo "WARNING: $m excluded from analysis." 
             exit 
          fi 
 
       fi  
  fi 
 
  echo "" 
 
done 
 
mv $tempFile $dataFile 
 
 
### 
### Selection of data points for analysis 
### 
 
fgrep -n "$startDate" $dataFile | sed -e s/':'/' '/g | cut -d" " -f1 | read stLine 
tailLine=$(echo "$nLine - $stLine + 1" | bc -l) 
headLine=$(echo "$nHour * 60" | bc -l) 
echo "REMARK: $headLine data points selected. Starting date: $startDate. 
Duration: $nHour hours." 
echo "nLine=$nLine stLine=$stLine  tailLine=$tailLine headLine=$headLine" 
 
#tail -$tailLine $dataFile | head -$headLine > $dataFileSel 
 
#nawk -v nL=$headLine stL=$stLine 'BEGIN{i=0;ok=0}; $1 == "20080121" && 
$2 == "0000"{ok=1;i++}; ok==1 && i <= nL {print $0;i++}' $dataFile > 
$dataFileSel 
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nawk -v nL=$headLine -v stL=$stLine 'BEGIN{i=0;ok=0}; NR==stL 
{ok=1;i++}; ok==1 && i <= nL {print $0;i++}' $dataFile > $dataFileSel 
 
 
 
### 
### Sleep analysis for each day 
### 
 
nawk -f sleepAnalysis.awk $dataFileSel > $sleepFile 
 
 
### 
### Sleep analysis per 30 min 
### 
 
echo "REMARK: Analyzing sleep per 30 min ..." 
 
if [ -s $dataFile30minRaw ] 
then 
   rm $dataFile30minRaw 
fi 
 
l=-1 
while (( l=l+1)); (( l < 30 )) 
do 
#  nSel=$(echo "$headLine - $l" | bc -l) 
#  echo "l= $l, headLine=$headLine, nSel=$nSel"  
#  tail -$nSel $dataFileSel | nawk -v off=$l -f sleep30minRed.awk >> 
$dataFile30minRaw 
 
#  nawk -v off=$l 'NR > l+1 {print $0}' $dataFileSel | nawk -v off=$l -f 
sleep30minRed.awk >> $dataFile30minRaw 
 
 
 
nawk -v off=$l 'NR > off {print $0}' $dataFileSel > ttt 
wc -l ttt | read nLine dummy 
echo "l=$l, nLine=$nLine, headLine=$headLine" 
cat ttt | nawk -v off=$l -f sleep30minRed.awk >> $dataFile30minRaw 
 
done 
 
sort -n $dataFile30minRaw > $tempFile 
mv $tempFile $dataFile30minRaw 
echo "REMARK: Done." 
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### 
### Identification of outliers 
### 
nawk -f outlierFly.awk $dataFile30minRaw 
 
 
 
### 
### Cleaning up temporary files 
### 
 
if [ -s $tempFile ] 
then 
   rm $tempFile 
fi 
if [ -s $tempFileB ] 
then 
   rm $tempFileB 
fi 
if [ -s $tempFileC ] 
then 
   rm $tempFileC 
fi 
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Script 2 
 
 
SleepAnalysis.awk 
 
BEGIN{ 
 maxcol = 300 
 for(i=1;i<=maxcol;i++){ 
 
                nSleep[i] = 0 
                fBout[i] = 0 
                nBout[i] = 0 
                sumSleep[i] = 0 
                sumActivity[i] = 0 
                nMinutes = 0 
       } 
 
     } 
 
NR == 1 {nocol=NF; printf "#REMARK: # of data columns = %d\n\n", nocol - 2} 
{         
 
        nMinutes++ 
 
#        printf "%s %s   ",$1, $2 
 for(i=3;i<=nocol;i++){ 
 
              sumActivity[i] = sumActivity[i] + $i 
 
 
              if ( $i == 0 ) { 
 
#                  printf "   sleep = %d",$i 
 
 
                  nSleep[i]++ 
                    
                  if ( nSleep[i] == 5 )  fBout[i] = 1 
                   
                } 
 
                else { 
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                   if(nSleep[i] >= 5 && fBout[i] == 1){ 
                      printf "nSleep[%d] = %d\n", i-2, nSleep[i] 
                      sumSleep[i] += nSleep[i] 
                      nBout[i]++ 
                     } 
 
#                   printf "no sleep = %d", $i 
                   fBout[i] = 0 
                   nSleep[i] = 0 
                } 
 
#          printf "   " 
 } 
 
#    printf "\n" 
} 
 
END{ 
      printf "\n\nREMARK: %d minutes in total analyzed.\n", nMinutes 
 
      printf "\n" 
      for(i=3;i<=nocol;i++){ 
          if(nSleep[i] >= 5 && fBout[i] == 1) { 
             printf "nSleep[%d] = %d    ", i-2, nSleep[i] 
             nBout[i]++ 
            } 
       } 
      printf "\n\n" 
 
 
      printf "REMARK: # of bouts:  " 
      nBoutAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%d  ", nBout[i] 
         nBoutAve += nBout[i] 
      } 
      printf "\n" 
 
 
     printf "REMARK: Average bout length:  " 
      lengthBoutAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%d  ", sumSleep[i] / nBout[i] 
         lengthBoutAve += sumSleep[i] / nBout[i] 
      } 
      printf "\n\n" 
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      printf "REMARK: Total amount of sleep:  " 
      sumSleepAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%d  ", sumSleep[i] 
         sumSleepAve += sumSleep[i] 
      } 
      printf "\n" 
 
 
      printf "REMARK: Total wake period:  " 
      wakeAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%d  ", nMinutes - sumSleep[i] 
         wakeAve += (nMinutes - sumSleep[i]) 
      } 
      printf "\n" 
 
 
      printf "REMARK: Total activity:  " 
      sumActivityAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%d  ", sumActivity[i] 
         sumActivityAve += sumActivity[i] 
      } 
      printf "\n" 
 
 
      printf "REMARK: Normalized total activity:  " 
      normSumActivityAve=0 
      for(i=3;i<=nocol;i++){ 
         printf "%.3f  ", sumActivity[i] / (nMinutes - sumSleep[i]) 
         normSumActivityAve += sumActivity[i] / (nMinutes - sumSleep[i]) 
      } 
      printf "\n\n" 
 
 
      printf "REMARK: Average number of bouts for all flies = %.3f\n", nBoutAve 
/ (nocol-2) 
      printf "REMARK: Average bout length for all flies = %.3f\n", lengthBoutAve 
/ (nocol-2) 
      printf "REMARK: Average of total amount of sleep for all flies = %.3f\n", 
sumSleepAve / (nocol-2) 
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      printf "REMARK: Average of total wake period for all flies = %.3f\n", 
wakeAve / (nocol-2) 
      printf "REMARK: Average of total activity for all flies = %.3f\n", 
sumActivityAve / (nocol-2) 
      printf "REMARK: Average of normalized total activity for all flies = %.3f\n", 
normSumActivityAve / (nocol-2) 
     } 
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Script 3 
 
sleep30minRed.awk  
 
 
BEGIN{ 
 maxcol = 300 
 for(i=1;i<=maxcol;i++){ 
                nSleep[i] = 0 
                fBout[i] = 0 
                nBout[i] = 0 
                sumSleep[i] = 0 
        } 
       sumSleepAve = 0 
       sumSleepMin = 0 
       sumSleepMax = 0 
       sumSleepVar = 0 
       sumSleepAve2 = 0 
     } 
 
NR == 1 {nocol=NF} 
 
{         
#        printf "%s %s   ",$1, $2 
 for(i=3;i<=nocol;i++){ 
 
              if ( $i == 0 ) { 
#                  printf "   sleep = %d",$i 
 
                  nSleep[i]++ 
                  if ( nSleep[i] == 5 )  fBout[i] = 1 
                } 
                else { 
                   if(nSleep[i] >= 5 && fBout[i] == 1){ 
#                      printf "nSleep[%d] = %d\n", i-2, nSleep[i] 
                      sumSleep[i] += nSleep[i] 
                      nBout[i]++ 
                     } 
 
#                   printf "no sleep = %d", $i 
                   fBout[i] = 0 
                   nSleep[i] = 0 
                } 
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#          printf "   " 
 } 
#    printf "\n" 
 
     if (NR % 30 == 0) { 
         sumSleepAve = 0 
         sumSleepAve2 = 0 
         sumSleepMin = 99 
         sumSleepMax = 0 
         sumSleepVar = 0 
 
         for(i=3;i<=nocol;i++){  
             if(fBout[i] == 1)  sumSleep[i] += nSleep[i] 
             sumSleepAve += sumSleep[i] 
             sumSleepAve2 += sumSleep[i]*sumSleep[i] 
 
             if (sumSleep[i] < sumSleepMin)  sumSleepMin = sumSleep[i] 
             if (sumSleep[i] > sumSleepMax)  sumSleepMax = sumSleep[i] 
         } 
 
          
         sumSleepVar = (sumSleepAve2 - sumSleepAve * sumSleepAve /(nocol-2)) 
/ (nocol-2) 
          
 
         printf "%d  ", NR-15+off 
         for(i=3;i<=nocol;i++)  printf "%d   ",sumSleep[i] 
         printf "     %.3f  %.3f  %.1f  %.1f\n",sumSleepAve / (nocol-2), 
sqrt(sumSleepVar), sumSleepMin, sumSleepMax 
 
 
         for(i=3;i<=nocol;i++){ 
            nSleep[i] = 0 
            fBout[i] = 0 
            nBout[i] = 0 
            sumSleep[i] = 0 
         } 
         sumSleepAve = 0 
    } 
 
    nLine = NR 
} 
 
BEGIN{ 
 maxcol = 300 
 for(i=1;i<=maxcol;i++){ 
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                nSleep[i] = 0 
                fBout[i] = 0 
                nBout[i] = 0 
                sumSleep[i] = 0 
        } 
       sumSleepAve = 0 
       sumSleepMin = 0 
       sumSleepMax = 0 
       sumSleepVar = 0 
       sumSleepAve2 = 0 
     } 
 
NR == 1 {nocol=NF} 
 
{         
#        printf "%s %s   ",$1, $2 
 for(i=3;i<=nocol;i++){ 
 
              if ( $i == 0 ) { 
#                  printf "   sleep = %d",$i 
 
                  nSleep[i]++ 
                  if ( nSleep[i] == 5 )  fBout[i] = 1 
                } 
                else { 
                   if(nSleep[i] >= 5 && fBout[i] == 1){ 
#                      printf "nSleep[%d] = %d\n", i-2, nSleep[i] 
                      sumSleep[i] += nSleep[i] 
                      nBout[i]++ 
                     } 
 
#                   printf "no sleep = %d", $i 
                   fBout[i] = 0 
                   nSleep[i] = 0 
                } 
#          printf "   " 
 } 
#    printf "\n" 
 
     if (NR % 30 == 0) { 
         sumSleepAve = 0 
         sumSleepAve2 = 0 
         sumSleepMin = 99 
         sumSleepMax = 0 
         sumSleepVar = 0 
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         for(i=3;i<=nocol;i++){  
             if(fBout[i] == 1)  sumSleep[i] += nSleep[i] 
             sumSleepAve += sumSleep[i] 
             sumSleepAve2 += sumSleep[i]*sumSleep[i] 
 
             if (sumSleep[i] < sumSleepMin)  sumSleepMin = sumSleep[i] 
             if (sumSleep[i] > sumSleepMax)  sumSleepMax = sumSleep[i] 
         } 
 
          
         sumSleepVar = (sumSleepAve2 - sumSleepAve * sumSleepAve /(nocol-2)) 
/ (nocol-2) 
          
 
         printf "%d  ", NR-15+off 
         for(i=3;i<=nocol;i++)  printf "%d   ",sumSleep[i] 
         printf "     %.3f  %.3f  %.1f  %.1f\n",sumSleepAve / (nocol-2), 
sqrt(sumSleepVar), sumSleepMin, sumSleepMax 
 
 
         for(i=3;i<=nocol;i++){ 
            nSleep[i] = 0 
            fBout[i] = 0 
            nBout[i] = 0 
            sumSleep[i] = 0 
         } 
         sumSleepAve = 0 
    } 
 
    nLine = NR 
} 
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Script 4 
outlierFly.awk  
 
 
NR == 1 { 
   nocol=NF 
   print $(NF-3), $(NF-2), $(NF-3) - 2 * $(NF-2) 
   
   for(i=1;i<=nocol;i++) outlierFly[i] = 0 
} 
 
{         
   for(i=2;i<=nocol-4;i++)  
            if ( $i < ($(NF-3) - 2 * $(NF-2)) )  outlierFly[i]++ 
} 
 
END{ 
      printf "\n\n# Outlier   " 
      for(i=2;i<=nocol-4;i++)  printf "%d   ",outlierFly[i] 
      printf "\n" 
   } 
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Figure 26: Circadian locomotor activity profiles of old Drosophila expressing WT-
αS and A53T-αS 
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(A) Time-series circadian activity profile of the 30-day old flies expressing WT-αS in 
DA neurons; n=45. (B) Time-series circadian activity profile of the 30-day old flies 
expressing lacZ in DA neurons; n=28-32. (C) Time-series circadian activity profile of the 
30-day old flies expressing A53T-αS in DA neurons; n=32. (D) Overlay of the activity 
profiles of WT-αS (green) and A53T-αS (grey). (E) Overlay of the activity profiles of 
WT-αS (green) and lacZ (blue). Experiments (Phase A according to the Figure 17) were 
done under the LD (12h: 12h) conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, 
P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., et al. (2000). Mice 
lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine 
system. Neuron 25, 239-252. 
Abou-Sleiman, P.M., Muqit, M.M., and Wood, N.W. (2006). Expanding insights 
of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7, 207-
219. 
Andretic, R., van Swinderen, B., and Greenspan, R.J. (2005). Dopaminergic 
modulation of arousal in Drosophila. Curr Biol 15, 1165-1175. 
Antzutkin, O.N., Balbach, J.J., Leapman, R.D., Rizzo, N.W., Reed, J., and Tycko, 
R. (2000). Multiple quantum solid-state NMR indicates a parallel, not antiparallel, 
organization of beta-sheets in Alzheimer's beta-amyloid fibrils. Proc Natl Acad 
Sci U S A 97, 13045-13050. 
Arnulf, I., Leu, S., and Oudiette, D. (2008). Abnormal sleep and sleepiness in 
Parkinson's disease. Curr Opin Neurol 21, 472-477. 
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S. (2004). 
Inclusion body formation reduces levels of mutant huntingtin and the risk of 
neuronal death. Nature 431, 805-810. 
Auluck, P.K., and Bonini, N.M. (2002). Pharmacological prevention of Parkinson 
disease in Drosophila. Nat Med 8, 1185-1186. 
Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., and Bonini, N.M. 
(2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model 
for Parkinson's disease. Science 295, 865-868. 
Ausubel, F.M. (1999). Current Protocols in Molecular Biology. John Wiley & 
Sons, Inc. 
Bibliography 
 112 
Baines, R.A., Uhler, J.P., Thompson, A., Sweeney, S.T., and Bate, M. (2001). 
Altered electrical properties in Drosophila neurons developing without synaptic 
transmission. J Neurosci 21, 1523-1531. 
Bainton, R.J., Tsai, L.T., Singh, C.M., Moore, M.S., Neckameyer, W.S., and 
Heberlein, U. (2000). Dopamine modulates acute responses to cocaine, nicotine 
and ethanol in Drosophila. Curr Biol 10, 187-194. 
Balbach, J.J., Petkova, A.T., Oyler, N.A., Antzutkin, O.N., Gordon, D.J., 
Meredith, S.C., and Tycko, R. (2002). Supramolecular structure in full-length 
Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization 
from solid-state nuclear magnetic resonance. Biophys J 83, 1205-1216. 
Barrachina, M., Castano, E., Dalfo, E., Maes, T., Buesa, C., and Ferrer, I. (2006). 
Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with 
Lewy bodies. Neurobiol Dis 22, 265-273. 
Bernado, P., Bertoncini, C.W., Griesinger, C., Zweckstetter, M., and Blackledge, 
M. (2005). Defining long-range order and local disorder in native alpha-synuclein 
using residual dipolar couplings. J Am Chem Soc 127, 17968-17969. 
Bertoncini, C.W., Jung, Y.-S., Fernandez, C.O., Hoyer, W., Griesinger, C., Jovin, 
T.M., and Zweckstetter, M. (2005). From The Cover: Release of long-range 
tertiary interactions potentiates aggregation of natively unstructured {alpha}-
synuclein. Proceedings of the National Academy of Sciences 102, 1430-1435. 
Bischof, J., Maeda, R.K., Hediger, M., Karch, F., and Basler, K. (2007). An 
optimized transgenesis system for Drosophila using germ-line-specific phiC31 
integrases. Proc Natl Acad Sci U S A 104, 3312-3317. 
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., and Braak, 
E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. 
Neurobiol Aging 24, 197-211. 
Brand, A.H., and Perrimon, N. (1993). Targeted gene expression as a means of 
altering cell fates and generating dominant phenotypes. Development 118, 401-
415. 
Bredesen, D.E., Rao, R.V., and Mehlen, P. (2006). Cell death in the nervous 
system. Nature 443, 796-802. 
Broadie, K.S. (2000). In "Drosophila protocols" Cold Spring Harbor Laboratory 
Press 273-295. 
Bibliography 
 113 
Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, 
K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R., et al. (2002). Synaptic vesicle 
depletion correlates with attenuated synaptic responses to prolonged repetitive 
stimulation in mice lacking alpha-synuclein. J Neurosci 22, 8797-8807. 
Catalina Ruiz-canada, V.B. (2006). The Fly Neuromuscular Junction: Structure 
and Function, Vol 75. 
Caughey, B., and Lansbury, P.T. (2003). Protofibrils, pores, fibrils, and 
neurodegeneration: separating the responsible protein aggregates from the 
innocent bystanders. Annu Rev Neurosci 26, 267-298. 
Chandra, S., Fornai, F., Kwon, H.B., Yazdani, U., Atasoy, D., Liu, X., Hammer, 
R.E., Battaglia, G., German, D.C., Castillo, P.E., et al. (2004). Double-knockout 
mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad 
Sci U S A 101, 14966-14971. 
Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M., and Sudhof, 
T.C. (2005). Alpha-synuclein cooperates with CSPalpha in preventing 
neurodegeneration. Cell 123, 383-396. 
Chaudhuri, K.R., and Schapira, A.H. (2009). Non-motor symptoms of Parkinson's 
disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8, 464-474. 
Chen, L., and Feany, M.B. (2005). Alpha-synuclein phosphorylation controls 
neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. 
Nat Neurosci 8, 657-663. 
Chen, L., Periquet, M., Wang, X., Negro, A., McLean, P.J., Hyman, B.T., and 
Feany, M.B. (2009). Tyrosine and serine phosphorylation of alpha-synuclein have 
opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 
119, 3257-3265. 
Chien, S., Reiter, L.T., Bier, E., and Gribskov, M. (2002). Homophila: human 
disease gene cognates in Drosophila. Nucleic Acids Res 30, 149-151. 
Chiti, F., and Dobson, C.M. (2006). Protein misfolding, functional amyloid, and 
human disease. Annu Rev Biochem 75, 333-366. 
Cirelli, C., Bushey, D., Hill, S., Huber, R., Kreber, R., Ganetzky, B., and Tononi, 
G. (2005). Reduced sleep in Drosophila Shaker mutants. Nature 434, 1087-1092. 
Bibliography 
 114 
Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C., 
Schoepp, D.D., Paul, S.M., Mennerick, S., and Holtzman, D.M. (2005). Synaptic 
activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-
922. 
Clayton, D.F., and George, J.M. (1998). The synucleins: a family of proteins 
involved in synaptic function, plasticity, neurodegeneration and disease. Trends 
Neurosci 21, 249-254. 
Colwell, C.S. (2007). Soporific signaling: how flies sleep through the night. Nat 
Neurosci 10, 1079-1080. 
Conway, K.A., Harper, J.D., and Lansbury, P.T. (1998). Accelerated in vitro fibril 
formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. 
Nat Med 4, 1318-1320. 
Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., and 
Lansbury, P.T., Jr. (2000). Acceleration of oligomerization, not fibrillization, is a 
shared property of both alpha-synuclein mutations linked to early-onset 
Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad 
Sci U S A 97, 571-576. 
Cookson, M.R. (2005). The biochemistry of Parkinson's disease. Annu Rev 
Biochem 74, 29-52. 
Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., 
Liu, K., Xu, K., Strathearn, K.E., Liu, F., et al. (2006). Alpha-synuclein blocks 
ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 
313, 324-328. 
Cummings, C.J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y., Ciechanover, A., 
Orr, H.T., Beaudet, A.L., and Zoghbi, H.Y. (1999). Mutation of the E6-AP 
ubiquitin ligase reduces nuclear inclusion frequency while accelerating 
polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892. 
Dedmon, M. M., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M. and 
Dobson, C. M (2005). Mapping Long-Range Interactions in α-Synuclein using 
Spin-Label NMR and Ensemble Molecular Dynamics Simulations J. Am. Chem. 
Soc., 127, 476– 7. 
Dickson, D.W., Crystal, H.A., Mattiace, L.A., Masur, D.M., Blau, A.D., Davies, 
P., Yen, S.H., and Aronson, M.K. (1992). Identification of normal and 
Bibliography 
 115 
pathological aging in prospectively studied nondemented elderly humans. 
Neurobiol Aging 13, 179-189. 
Ding, T.T., Lee, S.J., Rochet, J.C., and Lansbury, P.T., Jr. (2002). Annular alpha-
synuclein protofibrils are produced when spherical protofibrils are incubated in 
solution or bound to brain-derived membranes. Biochemistry 41, 10209-10217. 
Dobson, C.M. (2003). Protein folding and misfolding. Nature 426, 884-890. 
Dzirasa, K., Ribeiro, S., Costa, R., Santos, L.M., Lin, S.C., Grosmark, A., 
Sotnikova, T.D., Gainetdinov, R.R., Caron, M.G., and Nicolelis, M.A. (2006). 
Dopaminergic control of sleep-wake states. J Neurosci 26, 10577-10589. 
Ebstein, R.P., Israel, S., Chew, S.H., Zhong, S., and Knafo, A. (2010). Genetics of 
human social behavior. Neuron 65, 831-844. 
Ehrnhoefer, D.E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., 
Engemann, S., Pastore, A., and Wanker, E.E. (2008). EGCG redirects 
amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct 
Mol Biol 15, 558-566. 
El-Agnaf, O.M., Jakes, R., Curran, M.D., Middleton, D., Ingenito, R., Bianchi, E., 
Pessi, A., Neill, D., and Wallace, A. (1998). Aggregates from mutant and wild-
type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in 
human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. 
FEBS Lett 440, 71-75. 
Factor, S.A. (2002). Parkinson's Disease: Diagnosis and Clinical Management. 
Fall, P.A., Saleh, A., Fredrickson, M., Olsson, J.E., and Granerus, A.K. (2003). 
Survival time, mortality, and cause of death in elderly patients with Parkinson's 
disease: a 9-year follow-up. Mov Disord 18, 1312-1316. 
Farrer, M.J. (2006). Genetics of Parkinson disease: paradigm shifts and future 
prospects. Nat Rev Genet 7, 306-318. 
Feany, M.B., and Bender, W.W. (2000). A Drosophila model of Parkinson's 
disease. Nature 404, 394-398. 
Foltenyi, K., Greenspan, R.J., and Newport, J.W. (2007). Activation of EGFR and 
ERK by rhomboid signaling regulates the consolidation and maintenance of sleep 
in Drosophila. Nat Neurosci 10, 1160-1167. 
Bibliography 
 116 
Forman, M.S., Trojanowski, J.Q., and Lee, V.M. (2004). Neurodegenerative 
diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat 
Med 10, 1055-1063. 
Friggi-Grelin, F., Coulom, H., Meller, M., Gomez, D., Hirsh, J., and Birman, S. 
(2003). Targeted gene expression in Drosophila dopaminergic cells using 
regulatory sequences from tyrosine hydroxylase. J Neurobiol 54, 618-627. 
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, 
M.S., Shen, J., Takio, K., and Iwatsubo, T. (2002). alpha-Synuclein is 
phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160-164. 
George, J.M., Jin, H., Woods, W.S., and Clayton, D.F. (1995). Characterization of 
a novel protein regulated during the critical period for song learning in the zebra 
finch. Neuron 15, 361-372. 
Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., 
Caldwell, K.A., Caldwell, G.A., Rochet, J.C., McCaffery, J.M., et al. (2008). The 
Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. 
Proc Natl Acad Sci U S A 105, 145-150. 
Goedert, M. (2001). Alpha-synuclein and neurodegenerative diseases. Nat Rev 
Neurosci 2, 492-501. 
Gosavi, N., Lee, H.J., Lee, J.S., Patel, S., and Lee, S.J. (2002). Golgi 
fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and 
precedes the formation of fibrillar inclusion. J Biol Chem 277, 48984-48992. 
Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R., 
Englander, S.W., Axelsen, P.H., and Giasson, B.I. (2005). The E46K mutation in 
alpha-synuclein increases amyloid fibril formation. J Biol Chem 280, 7800-7807. 
Haass, C., and Selkoe, D.J. (2007). Soluble protein oligomers in 
neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev 
Mol Cell Biol 8, 101-112. 
Harbison, S.T., Mackay, T.F., and Anholt, R.R. (2009). Understanding the 
neurogenetics of sleep: progress from Drosophila. Trends Genet 25, 262-269. 
Hardy, J., and Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer's 
disease: progress and problems on the road to therapeutics. Science 297, 353-356. 
Bibliography 
 117 
Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., 
Teplow, D.B., and Selkoe, D.J. (1999). Protofibrillar intermediates of amyloid 
beta-protein induce acute electrophysiological changes and progressive 
neurotoxicity in cortical neurons. J Neurosci 19, 8876-8884. 
Heise, H., Hoyer, W., Becker, S., Andronesi, O.C., Riedel, D., and Baldus, M. 
(2005a). Molecular-level secondary structure, polymorphism, and dynamics of 
full-length {alpha}-synuclein fibrils studied by solid-state NMR. Proceedings of 
the National Academy of Sciences 102, 15871-15876. 
Heise, H., Hoyer, W., Becker, S., Andronesi, O.C., Riedel, D., and Baldus, M. 
(2005b). Molecular-level secondary structure, polymorphism, and dynamics of 
full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci 
U S A 102, 15871-15876. 
Hendricks, J.C., and Sehgal, A. (2004). Why a fly? Using Drosophila to 
understand the genetics of circadian rhythms and sleep. Sleep 27, 334-342. 
Hirsh, J., Riemensperger, T., Coulom, H., Iche, M., Coupar, J., and Birman, S. 
(2010). Roles of dopamine in circadian rhythmicity and extreme light sensitivity 
of circadian entrainment. Curr Biol 20, 209-214. 
Ho, K.S., and Sehgal, A. (2005). Drosophila melanogaster: An Insect Model for 
Fundamental Studies of Sleep. Methods Enzymol 393, 772-793. 
Hsiao, K., and Prusiner, S.B. (1991). Molecular genetics and transgenic model of 
Gertsmann-Straussler-Scheinker disease. Alzheimer Dis Assoc Disord 5, 155-162. 
Huber, R., Hill, S.L., Holladay, C., Biesiadecki, M., Tononi, G., and Cirelli, C. 
(2004). Sleep homeostasis in Drosophila melanogaster. Sleep 27, 628-639. 
Ibanez, P., Bonnet, A.M., Debarges, B., Lohmann, E., Tison, F., Pollak, P., Agid, 
Y., Durr, A., and Brice, A. (2004). Causal relation between alpha-synuclein gene 
duplication and familial Parkinson's disease. Lancet 364, 1169-1171. 
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, 
A., and Saitoh, T. (1995). The precursor protein of non-A beta component of 
Alzheimer's disease amyloid is a presynaptic protein of the central nervous 
system. Neuron 14, 467-475. 
Jahn, R., Schiebler, W., and Greengard, P. (1984). A quantitative dot-
immunobinding assay for proteins using nitrocellulose membrane filters. Proc 
Natl Acad Sci U S A 81, 1684-1687. 
Bibliography 
 118 
Johnson, P.M., and Kenny, P.J. (2010). Dopamine D2 receptors in addiction-like 
reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 
Joiner, W.J., Crocker, A., White, B.H., and Sehgal, A. (2006). Sleep in Drosophila 
is regulated by adult mushroom bodies. Nature 441, 757-760. 
Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, 
A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A., et al. (2000). 
Subcellular localization of wild-type and Parkinson's disease-associated mutant 
alpha -synuclein in human and transgenic mouse brain. J Neurosci 20, 6365-6373. 
Karpinar, D.P., Balija, M.B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, 
N., Kim, H.Y., Taschenberger, G., Falkenburger, B.H., Heise, H., et al. (2009). 
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase 
neurotoxicity in Parkinson's disease models. EMBO J 28, 3256-3268. 
Katzenschlager, R., Evans, A., Manson, A., Patsalos, P.N., Ratnaraj, N., Watt, H., 
Timmermann, L., Van der Giessen, R., and Lees, A.J. (2004). Mucuna pruriens in 
Parkinson's disease: a double blind clinical and pharmacological study. J Neurol 
Neurosurg Psychiatry 75, 1672-1677. 
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, 
C.W., and Glabe, C.G. (2003). Common structure of soluble amyloid oligomers 
implies common mechanism of pathogenesis. Science 300, 486-489. 
Kim, H.Y., Cho, M.K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., 
Fernandez, C.O., Lashuel, H.A., Benz, R., Lange, A., et al. (2009). Structural 
properties of pore-forming oligomers of alpha-synuclein. J Am Chem Soc 131, 
17482-17489. 
Kim, Y.C., Lee, H.G., and Han, K.A. (2007). D1 dopamine receptor dDA1 is 
required in the mushroom body neurons for aversive and appetitive learning in 
Drosophila. J Neurosci 27, 7640-7647. 
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, 
S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998). Mutations in the parkin 
gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608. 
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, 
H., Epplen, J.T., Schols, L., and Riess, O. (1998). Ala30Pro mutation in the gene 
encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106-108. 
Bibliography 
 119 
Kume, K., Kume, S., Park, S.K., Hirsh, J., and Jackson, F.R. (2005). Dopamine is 
a regulator of arousal in the fruit fly. J Neurosci 25, 7377-7384. 
Lansbury, P.T., Jr., and Brice, A. (2002). Genetics of Parkinson's disease and 
biochemical studies of implicated gene products. Curr Opin Cell Biol 14, 653-
660. 
Lansbury, P.T., and Lashuel, H.A. (2006). A century-old debate on protein 
aggregation and neurodegeneration enters the clinic. Nature 443, 774-779. 
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. and Lansbury, P. T., Jr. (2002). 
NACP, a protein implicated in Alzheimer's disease and learning, is natively 
unfolded. Nature 418, 291. 
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T. and 
Lansbury, P. T., Jr. J. Mol. Biol. 2002 
Lashuel, H.A., and Lansbury, P.T., Jr. (2006). Are amyloid diseases caused by 
protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39, 
167-201. 
Lee, V.M., and Trojanowski, J.Q. (2006). Mechanisms of Parkinson's disease 
linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 
33-38. 
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., 
Brownstein, M.J., Jonnalagada, S., Chernova, T., et al. (1998). The ubiquitin 
pathway in Parkinson's disease. Nature 395, 451-452. 
Lessing, D., and Bonini, N.M. (2009). Maintaining the brain: insight into human 
neurodegeneration from Drosophila melanogaster mutants. Nat Rev Genet 10, 
359-370. 
Lindsley, D.L., and Zimm, G.G. (1992). The Genome of Drosophila 
melanogaster. Academic Press. 
Liu, Z., Wang, X., Li X, Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., 
Moran,T., Ross, C.A., Montell, C., Smith, W.W. (2008). A Drosophila model for 
LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105, 2693-8.  
Luan, H., Lemon, W.C., Peabody, N.C., Pohl, J.B., Zelensky, P.K., Wang, D., 
Nitabach, M.N., Holmes, T.C., and White, B.H. (2006). Functional dissection of a 
Bibliography 
 120 
neuronal network required for cuticle tanning and wing expansion in Drosophila. J 
Neurosci 26, 573-584. 
Manyam, B.V. (1990). Paralysis agitans and levodopa in "Ayurveda": ancient 
Indian medical treatise. Mov Disord 5, 47-48. 
Maries, E., Dass, B., Collier, T.J., Kordower, J.H., and Steece-Collier, K. (2003). 
The role of alpha-synuclein in Parkinson's disease: insights from animal models. 
Nat Rev Neurosci 4, 727-738. 
Maroteaux, L., Campanelli, J.T., and Scheller, R.H. (1988). Synuclein: a neuron-
specific protein localized to the nucleus and presynaptic nerve terminal. J 
Neurosci 8, 2804-2815. 
Moore, D.J., West, A.B., Dawson, V.L., and Dawson, T.M. (2005). Molecular 
pathophysiology of Parkinson's disease. Annu Rev Neurosci 28, 57-87. 
Mueller, J.C., Fuchs, J., Hofer, A., Zimprich, A., Lichtner, P., Illig, T., Berg, D., 
Wullner, U., Meitinger, T., and Gasser, T. (2005). Multiple regions of alpha-
synuclein are associated with Parkinson's disease. Ann Neurol 57, 535-541. 
Myhre, R., Toft, M., Kachergus, J., Hulihan, M.M., Aasly, J.O., Klungland, H., 
and Farrer, M.J. (2008). Multiple alpha-synuclein gene polymorphisms are 
associated with Parkinson's disease in a Norwegian population. Acta Neurol 
Scand 118, 320-327. 
Nawathean, P., and Rosbash, M. (2004). The doubletime and CKII kinases 
collaborate to potentiate Drosophila PER transcriptional repressor activity. Mol 
Cell 13, 213-223. 
Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, 
F.A., Nicoll, R.A., and Edwards, R.H. (2010). Increased expression of alpha-
synuclein reduces neurotransmitter release by inhibiting synaptic vesicle 
reclustering after endocytosis. Neuron 65, 66-79. 
Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., 
Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., et al. 
(2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of 
Parkinson's disease. Science 317, 516-519. 
Outeiro, T.F., and Lindquist, S. (2003). Yeast cells provide insight into alpha-
synuclein biology and pathobiology. Science 302, 1772-1775. 
Bibliography 
 121 
Pallier, P.N., Maywood, E.S., Zheng, Z., Chesham, J.E., Inyushkin, A.N., Dyball, 
R., Hastings, M.H., and Morton, A.J. (2007). Pharmacological imposition of sleep 
slows cognitive decline and reverses dysregulation of circadian gene expression in 
a transgenic mouse model of Huntington's disease. J Neurosci 27, 7869-7878. 
Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M.G., and Feany, M.B. 
(2007). Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. 
J Neurosci 27, 3338-3346. 
Perutz, M.F., and Windle, A.H. (2001). Cause of neural death in 
neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 
412, 143-144. 
Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, 
F., and Tycko, R. (2002). A structural model for Alzheimer's beta -amyloid fibrils 
based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S 
A 99, 16742-16747. 
Pitman, J.L., McGill, J.J., Keegan, K.P., and Allada, R. (2006). A dynamic role 
for the mushroom bodies in promoting sleep in Drosophila. Nature 441, 753-756. 
Poewe, W. (2008). Non-motor symptoms in Parkinson's disease. Eur J Neurol 15 
Suppl 1, 14-20. 
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., 
Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997). Mutation in the alpha-
synuclein gene identified in families with Parkinson's disease. Science 276, 2045-
2047. 
Pountney, D.L., Lowe, R., Quilty, M., Vickers, J.C., Voelcker, N.H., and Gai, 
W.P. (2004). Annular alpha-synuclein species from purified multiple system 
atrophy inclusions. J Neurochem 90, 502-512. 
Qin, G., Schwarz, T., Kittel, R.J., Schmid, A., Rasse, T.M., Kappei, D., 
Ponimaskin, E., Heckmann, M., and Sigrist, S.J. (2005). Four different subunits 
are essential for expressing the synaptic glutamate receptor at neuromuscular 
junctions of Drosophila. J Neurosci 25, 3209-3218. 
Rajput, A.H., Uitti, R.J., Rajput, A., and Offord, K.P. (2009). Mortality in 
Parkinson's disease. Mov Disord. 
Reddy, A.B., and O'Neill, J.S. (2010). Healthy clocks, healthy body, healthy 
mind. Trends Cell Biol 20, 36-44. 
Bibliography 
 122 
Rochet, J.C., Conway, K.A., and Lansbury, P.T., Jr. (2000). Inhibition of 
fibrillization and accumulation of prefibrillar oligomers in mixtures of human and 
mouse alpha-synuclein. Biochemistry 39, 10619-10626. 
Rosato, E., and Kyriacou, C.P. (2006). Analysis of locomotor activity rhythms in 
Drosophila. Nat Protoc 1, 559-568. 
Rosen, A.D. (1978). Amyotrophic lateral sclerosis. Clinical features and 
prognosis. Arch Neurol 35, 638-642. 
Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegenerative 
disease. Nat Med 10 Suppl, S10-17. 
Rubin, G.M., and Spradling, A.C. (1982). Genetic transformation of Drosophila 
with transposable element vectors. Science 218, 348-353. 
Rubinsztein, D.C. (2006). The roles of intracellular protein-degradation pathways 
in neurodegeneration. Nature 443, 780-786. 
Rye, D.B. (2006). Excessive daytime sleepiness and unintended sleep in 
Parkinson's disease. Curr Neurol Neurosci Rep 6, 169-176. 
Sanchez, I., Mahlke, C., and Yuan, J. (2003). Pivotal role of oligomerization in 
expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379. 
Sang, T.K., Chang, H.Y., Lawless, G.M., Ratnaparkhi, A., Mee, L., Ackerson, 
L.C., Maidment, N.T., Krantz, D.E., and Jackson, G.R. (2007). A Drosophila 
model of mutant human parkin-induced toxicity demonstrates selective loss of 
dopaminergic neurons and dependence on cellular dopamine. J Neurosci 27, 981-
992. 
Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., 
Sakahira, H., Siegers, K., Hayer-Hartl, M., and Hartl, F.U. (2004). Cellular 
toxicity of polyglutamine expansion proteins: mechanism of transcription factor 
deactivation. Mol Cell 15, 95-105. 
Schagger, H., and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in the range from 
1 to 100 kDa. Anal Biochem 166, 368-379. 
Schapira, A.H. (2004). Excessive daytime sleepiness in Parkinson's disease. 
Neurology 63, S24-27. 
Bibliography 
 123 
Selkoe, D.J. (2003). Folding proteins in fatal ways. Nature 426, 900-904. 
Seugnet, L., Galvin, J.E., Suzuki, Y., Gottschalk, L., and Shaw, P.J. (2009). 
Persistent short-term memory defects following sleep deprivation in a drosophila 
model of Parkinson disease. Sleep 32, 984-992. 
Sharon, R., Bar-Joseph, I., Frosch, M.P., Walsh, D.M., Hamilton, J.A., and 
Selkoe, D.J. (2003a). The formation of highly soluble oligomers of alpha-
synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 
37, 583-595. 
Sharon, R., Bar-Joseph, I., Mirick, G.E., Serhan, C.N., and Selkoe, D.J. (2003b). 
Altered fatty acid composition of dopaminergic neurons expressing alpha-
synuclein and human brains with alpha-synucleinopathies. J Biol Chem 278, 
49874-49881. 
Shaw, P.J., Cirelli, C., Greenspan, R.J., and Tononi, G. (2000). Correlates of sleep 
and waking in Drosophila melanogaster. Science 287, 1834-1837. 
Sheila M. Fleming, M.-F.C. (2009). Modeling Nonmotor Symptoms of 
Parkinson’s Disease in Genetic Mouse Models. Advances in Behavioral Biology 
Volume 58 
, 483-491. 
Shirlee Tan, B.H., and Emiliana Borreli (2003). Dopaminergic mouse mutants: 
Investigating the roles of different Dopamine receptor subtypes  and the 
Dopamine transporter. International Review of Neurobiology 54, 145-197. 
Shults, C.W. (2006). Lewy bodies. Proc Natl Acad Sci U S A 103, 1661-1668. 
Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., 
Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., et al. (2009). 
Genome-wide association study reveals genetic risk underlying Parkinson's 
disease. Nat Genet 41, 1308-1312. 
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., 
Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003). alpha-
Synuclein locus triplication causes Parkinson's disease. Science 302, 841. 
Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson, V.L., 
Dawson, T.M., Iwatsubo, T., and Ross, C.A. (2005). Alpha-synuclein 
phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-
SY5Y cells. J Neurosci 25, 5544-5552. 
Bibliography 
 124 
Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, 
A.C., Salter, M.W., Lombroso, P.J., Gouras, G.K., et al. (2005). Regulation of 
NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058. 
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative 
diseases. Nat Rev Neurosci 4, 49-60. 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and 
Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. 
Spradling, A.C., and Rubin, G.M. (1982). Transposition of cloned P elements into 
Drosophila germ line chromosomes. Science 218, 341-347. 
Stewart, B.A., Atwood, H.L., Renger, J.J., Wang, J., and Wu, C.F. (1994). 
Improved stability of Drosophila larval neuromuscular preparations in 
haemolymph-like physiological solutions. J Comp Physiol A 175, 179-191. 
Suh, J., and Jackson, F.R. (2007). Drosophila ebony activity is required in glia for 
the circadian regulation of locomotor activity. Neuron 55, 435-447. 
Takamori, S., Holt, M., Stenius, K., Lemke, E.A., Gronborg, M., Riedel, D., 
Urlaub, H., Schenck, S., Brugger, B., Ringler, P., et al. (2006). Molecular 
anatomy of a trafficking organelle. Cell 127, 831-846. 
Tompkins, M.M., and Hill, W.D. (1997). Contribution of somal Lewy bodies to 
neuronal death. Brain Res 775, 24-29. 
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, 
D.A., Kondo, J., Ihara, Y., and Saitoh, T. (1993). Molecular cloning of cDNA 
encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl 
Acad Sci U S A 90, 11282-11286. 
Ulmer, T.S., Bax, A., Cole, N.B., and Nussbaum, R.L. (2005). Structure and 
dynamics of micelle-bound human alpha-synuclein. J Biol Chem 280, 9595-9603. 
Vilar, M., Chou, H.T., Luhrs, T., Maji, S.K., Riek-Loher, D., Verel, R., Manning, 
G., Stahlberg, H., and Riek, R. (2008). The fold of alpha-synuclein fibrils. Proc 
Natl Acad Sci U S A 105, 8637-8642. 
Volles, M.J., and Lansbury, P.T., Jr. (2002). Vesicle permeabilization by 
protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations 
and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602. 
Bibliography 
 125 
Volles, M.J., and Lansbury, P.T., Jr. (2007). Relationships between the sequence 
of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast 
toxicity. J Mol Biol 366, 1510-1522. 
Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., 
Rowan, M.J., and Selkoe, D.J. (2002). Naturally secreted oligomers of amyloid 
beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 
416, 535-539. 
Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. and Lansbury, P. T., Jr. 
Biochemistry 1996, 35, 13709– 15 
Whalley, K. (2007). Neurodegenerative disease: A good night's sleep 
. Nature Reviews Neuroscience 8. 
White, B.H., Osterwalder, T.P., Yoon, K.S., Joiner, W.J., Whim, M.D., 
Kaczmarek, L.K., and Keshishian, H. (2001). Targeted attenuation of electrical 
activity in Drosophila using a genetically modified K(+) channel. Neuron 31, 699-
711. 
Whitehead, D.L., Davies, A.D., Playfer, J.R., and Turnbull, C.J. (2008). Circadian 
rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. 
Mov Disord 23, 1137-1145. 
Wu, J.S., and Luo, L. (2006). A protocol for dissecting Drosophila melanogaster 
brains for live imaging or immunostaining. Nat Protoc 1, 2110-2115. 
Yavich, L., Tanila, H., Vepsalainen, S., and Jakala, P. (2004). Role of alpha-
synuclein in presynaptic dopamine recruitment. J Neurosci 24, 11165-11170. 
Ye, Y., Xi, W., Peng, Y., Wang, Y., and Guo, A. (2004). Long-term but not short-
term blockade of dopamine release in Drosophila impairs orientation during flight 
in a visual attention paradigm. Eur J Neurosci 20, 1001-1007. 
Zhang, K., Guo, J.Z., Peng, Y., Xi, W., and Guo, A. (2007). Dopamine-mushroom 
body circuit regulates saliency-based decision-making in Drosophila. Science 316, 
1901-1904. 
Zimmerman, J.E., Naidoo, N., Raizen, D.M., and Pack, A.I. (2008). Conservation 
of sleep: insights from non-mammalian model systems. Trends Neurosci 31, 371-
376. 
 
 
Bibliography 
 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Curriculum Vitae 
 
 
M A D H U  B A B U  G A J U L A  B A L I J A  
 
First Name          : Madhu Babu 
Last Name          : Gajula Balija 
Date of Birth          : 20th August1982 
Age           : 27 years  
Gender                   : Male 
Nationality          : Indian 
Languages Known     : English, Hindi, Telugu, Kannada, and basic German 
 
 
P R O F I L E  
A c a d e m i c   
 Strategic, independent and innovative thinker. Manifested leadership by 
proficiently seizing opportunities, establishing collaborations, setting direction and 
managing scientific projects. Mainly driven by curiosity, novelty, and impact. Worked 
with teams of diverse academic and cultural backgrounds. Specialized in Molecular 
Biology, Developmental Biology, and Genetics. 
N o n - A c a d e m i c  
 Penchant for public service, demonstrated leadership and organizational skills, 
adept fund-raiser,  and an ardent lover of liberal arts—business, history, politics and 
innovation. Firmly believes in social entrepreneurship and ‘creative capitalism’ for 
creating social impact.  
C A R E E R  G O A L S  &  V I S I O N  
S h o r t - t e r m   
• To work towards international development, or to work at the interface of the 
corporate sector and government, or to work as a consultant in a multi-national 
company. 
 
• To get admission into the MPP/MBA (Public Policy and Business Administration) 
program offered jointly by the Harvard Business School and Harvard Kennedy 
School of Government. 
L o n g - t e r m   
• Aspire to deliver improved public services by influencing public policy, specifically 
for creating more opportunities in the developing countries by promoting innovation, 
research and development in science and technology. 
Curriculum Vitae 
 128 
 
E D U C AT I O N   
• Ph.D. Molecular Biology (2006-Present)  
International Max Planck Research School for Molecular Biology, Germany 
Max Planck Institute for Biophysical Chemistry, Goettingen, Germany 
• M.Sc. Molecular Biology (2005-2006) 
International Max Planck Research School for Molecular Biology, Germany 
• M.Sc. Biochemistry (2002-2004) 
University of Hyderabad, Hyderabad, India 
• B.Sc. Biochemistry, Chemistry, Zoology (1999-2002) 
Osmania College, S.K. University, Anantapur, India 
S C H O L A R S H I P S  &  AW A R D S   
• Internship at the WHO (World Health Organization) in Bonn, Germany (Oct – Dec, 
2009)  
• Stipend from the Max Planck Society, Germany (2006-Present) 
• Stipend from the Swiss National Science Foundation, Switzerland (2005-2006) 
• Stipend of the Excellence Foundation for the Promotion of the Max Planck Society, 
Germany (2004-2005) 
• Merit Scholarship from the University of Hyderabad, India (2002-2004) 
• Secured 2nd rank in the overall performance in M.Sc. Biochemistry at University of 
Hyderabad, India (2004) 
• Summer Research Fellowship from the Indian Academy of Science, India (2003) 
• Secured 4th rank in all India examination conducted by ICAR (Indian Council of 
Agricultural Research) for Junior Research Fellowships, India (2002) 
L E A D E R S H I P  &  O R G A N I Z AT I O N A L  S K I L L S   
M o t t o :  Making a difference by creating shared opportunities by building shared 
responsibilities through common interests and collective action.  
• F o u n d e d  the organization called SPARC (Society Promoters for Advancement, 
Redemption and Change) to bring awareness, to provide career guidance, and to 
encourage leadership among the youth of rural India (this project is still under the 
state development). 
• R e p r e s e n t a t i v e  of PhD students (PhD Committee) at the Max Planck Institute for 
Biophysical Chemistry.  
• O r g a n i z e d  an international scientific conference Horizons in Molecular Biology 
2008 and a career fair for scientists Horizons Career Fair 2008 with the support from 
the International Max Planck Research School for Molecular Biology. 
• O r g a n i z e d  career seminars and get-togethers/retreats (social and scientific) for the 
PhD students and Postdoctoral fellows at the Max Planck Institute for Biophysical 
Chemistry. 
• O r g a n i z e d  massive literacy campaigns in the small villages to spread the light of 
education as a member of the Students Union at University of Hyderabad (India).  
• F u n d - r a i s i n g  a n d  M e d i a t i o n :  Raised nearly INR 3,00,000 (USD 6,200) to save 
Curriculum Vitae 
 129 
the life of a patient suffering from the kidney failure due to Alport’s Syndrome (read 
the story published in national daily The Hindu) by starting a donation drive 
(Navodayan Helpline) for his kidney transplantation and post-transplantation medical 
expenses.  
Raised INR 40,000 (USD 850) for helping the tsunami victims in 2005.  
Played an instrumental role in convincing our state’s (Andhra Pradesh, India) medical 
ethics committee to allow banned kidney transplantation from a third party kidney 
donor in a special case.  
 
R E S E A R C H  E X P E R I E N C E  
• Uncovering the role of pre-fibrillar oligomers of α-synuclein in the pathogenesis of 
Parkinson’s disease (2006-Present) 
• Investigating the role of BRP85KDa (Bruchpilot) in peptidergic transmission 
Prof. Dr. Herbert Jäckle, MPI for Biophysical Chemistry, Goettingen, Germany. 
Prof. Dr. Christian Griesinger, MPI for Biophysical Chemistry, Goettingen, Germany. 
Dr. Stefan Eimer, European Neuroscience Institute, Goettingen, Germany. 
Prof. Dr. Stephan Sigrist, Freie University, Berlin, Germany. 
 
• Generation of ‘sev-wg’ transgenic Drosophila for a genetic screen to identify new 
components of the Wnt signaling pathway 
Developing an effective strategy to study cell-cell competition in mammals 
Prof. Dr. Konrad Basler, Institute of Molecular Biology, University of Zürich, Zürich, 
Switzerland. 
 
• Measuring the single exocytotic events by using patch-clamp technique 
From 01-05-05 to 01-07-05 (Lab rotation 3) 
Prof. Dr. Erwin Neher, MPI for Biophysical Chemistry, Goettingen, Germany. 
• Elucidating the presence and role of maternally provided Dnd and Nanos in 
primordial germcell migration in Zebra fish embryos   
From 01-03-2005 to 30-04-05 (Lab rotation 2) 
Prof. Dr. Erez Raz, MPI for Biophysical Chemistry, Goettingen. 
• Characterization of Upd (Drosophila JAK/STAT pathway ligand) secretion modifiers 
by RNAi  
From 01-01-2005 to 28-02-05 (Lab rotation 1) 
Prof. Dr. Martin Zeidler, MPI for Biophysical Chemistry, Goettingen. 
• Elucidation of activities of lysosomal glycosidases from Xiphophorous fish embryonic 
cell line (A 2) 
From 01-01-2004 to 30-04-2004. 
Prof. Dr. N. Siva Kumar, Dept. of Biochemistry, University of Hyderabad, Hyderabad, India.  
• Generation of point mutants of Eco.P15I.Mod (modification subunit of Eco.P15I type 
III restriction enzyme) by PCR based site directed mutagenesis 
From 29-04-2003 to 30-07-2003 (Summer Research Fellow) 
Prof. Dr. D. Narasimha Rao, Dept. of Biochemistry, Indian Institute of Science, Bangalore, 
India. 
Curriculum Vitae 
 130 
 
C O N F E R E N C E S   
2009  50th Annual Drosophila Research Conference, Chicago, IL, USA.  
2008  49th Annual Drosophila Research Conference, San Diego, CA, USA. 
2007  48th Annual Drosophila Research Conference, Philadelphia, PA, USA. 
2007 EMBO Conference on Chromatin and Epigenetics, Heidelberg, 
Germany. 
2006 International Conference on Magnetic Resonance in Biological Systems 
(ICMRBS), Goettingen, Germany. 
 
P O S T E R  P R E S E N TAT I O N S  
Madhu Babu GB, Karpinar DP, Opazo F, Falkenburger B, Riedel D, Herzig A, Jaeckle H, 
Eimer S, Schulz JB, Griesinger C, Zweckstetter M. 
Soluble pre-fibrillar oligomers of α-synuclein in the neurodegeneration of Parkinson’s 
disease. 49th Annual Drosophila Research Conference, San Diego, USA (2008). 
Madhu Babu GB, Karpinar DP, Opazo F, Falkenburger B, Riedel D, Herzig A, Jaeckle H, 
Eimer S, Schulz JB, Griesinger C, Zweckstetter M.  
Soluble pre-fibrillar oligomers of α-synuclein in the neurodegeneration of Parkinson’s 
disease. 50th Annual Drosophila Research Conference, Chicago, USA (2009). 
 
P U B L I C AT I O N   
Karpinar DP*, Balija MB*, Kügler S*, Opazo F*, Rezaei-Ghaleh N, Wender N, Kim HY, 
Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, 
Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jäckle H, Eimer S, Schulz JB, 
Griesinger C, Zweckstetter M. 
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity 
in Parkinson’s disease models. EMBO J. 28 (20): 3256-68, 2009.  
*equal contribution of authors 
 
 
 
 
 
 
 
 
Curriculum Vitae 
 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
